{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:08:35Z","timestamp":1793927315001,"version":"4.8.0"},"reference-count":1831,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DK123384"],"award-info":[{"award-number":["K23DK123384"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK111024"],"award-info":[{"award-number":["P30DK111024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004364","name":"BP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eprac.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T23:33:12Z","timestamp":1660174392000},"page":"923-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":479,"title":["American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan\u20142022 Update"],"prefix":"10.1016","volume":"28","author":[{"given":"Lawrence","family":"Blonde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Sethu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Berga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Izuora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana R.","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William V.","family":"Tamborlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Twining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyathama","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4158\/EP171866.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists - 2017 update","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/M18-0091","article-title":"Prognostic implications of single-sample confirmatory testing for undiagnosed diabetes: A prospective cohort study","volume":"169","author":"Selvin","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/dc10-1546","article-title":"A1c vs glucose testing: A comparison","volume":"34","author":"Sacks","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib5","article-title":"Comparison of the current diagnostic criterion of HbA1c with fasting and 2-hour plasma glucose concentration","volume":"2016","author":"Karnchanasorn","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1210\/clinem\/dgaa710","article-title":"Approach to the patient with mody-monogenic diabetes","volume":"106","author":"Broome","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib7","article-title":"Glycated haemoglobin A1C as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: A systematic review and meta-analysis","volume":"7","author":"Cavero-Redondo","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/dc09-1524","article-title":"Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006","volume":"33","author":"Cowie","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib9","first-page":"S17","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib10","first-page":"197","article-title":"International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care","volume":"30","author":"Gillett","year":"2009","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171315","article-title":"Effect of ethnicity on HbA1c levels in individuals without diabetes: systematic review and meta-analysis","volume":"12","author":"Cavagnolli","year":"2017","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/met.2013.0128","article-title":"Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age","volume":"12","author":"Guo","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.2337\/dc15-2686","article-title":"Are there clinical implications of racial differences in HbA1c? Yes, to not consider can do great harm","volume":"39","author":"Herman","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2016.21035","article-title":"Association of sickle cell trait with hemoglobin A1c in African Americans","volume":"317","author":"Lacy","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002384","article-title":"HbA1c for type 2 diabetes diagnosis in Africans and African Americans: personalized medicine now","volume":"14","author":"Paterson","year":"2017","journal-title":"PLOS Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002383","article-title":"Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis","volume":"14","author":"Wheeler","year":"2017","journal-title":"PLOS Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/M16-2596","article-title":"Racial differences in the relationship of glucose concentrations and hemoglobin A1C levels","volume":"167","author":"Bergenstal","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib18","first-page":"22","article-title":"Course of HbA1c in non-diabetic pregnancy related to birth weight","volume":"71","author":"Versantvoort","year":"2013","journal-title":"Neth J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011059","article-title":"Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus","volume":"6","author":"Khalafallah","year":"2016","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib20","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.2337\/diacare.26.11.3160","article-title":"Follow-up report on the diagnosis of diabetes mellitus","volume":"26","author":"Genuth","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1464-5491.2012.03750.x","article-title":"Long-term effects of the diabetes prevention program interventions on cardiovascular risk factors: A report from the DPP Outcomes Study","volume":"30","author":"Orchard","year":"2013","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrendo.2017.99","article-title":"Adult-onset autoimmune diabetes:\u00a0current knowledge and implications for management","volume":"13","author":"Buzzetti","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120877","article-title":"\u0392 cell dysfunction exists more than 5 years before type 1 diabetes diagnosis","volume":"3","author":"Evans-Molina","year":"2018","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib24","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1507\/endocrj.EJ16-0328","article-title":"Slowly progressive insulin-dependent (type 1) diabetes positive for anti-GAD antibody ELISA test may be strongly associated with a future insulin-dependent state","volume":"64","author":"Oikawa","year":"2017","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/dc14-1813","article-title":"A\u00a0new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history","volume":"38","author":"Sosenko","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc14-2426","article-title":"Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the young (TEDDY)","volume":"38","author":"Steck","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diab.43.6.741","article-title":"GAD antibody negative NIDDM in adult Black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes","volume":"43","author":"Banerji","year":"1994","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4158\/EP161679.RA","article-title":"Diabetic ketoacidosis: A common debut of diabetes among African Americans with type 2 diabetes","volume":"23","author":"Vellanki","year":"2017","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib31","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/dc16-0406","article-title":"Randomized controlled study of metformin and sitagliptin on long-term normoglycemia remission in African American patients with hyperglycemic crises","volume":"39","author":"Vellanki","year":"2016","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J\u00a0Clin Invest"},{"issue":"27","key":"10.1016\/j.eprac.2022.08.002_bib35","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1056\/NEJM199312303292703","article-title":"Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of pima indians","volume":"329","author":"Lillioja","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11892-018-1075-4","article-title":"Ketosis-prone diabetes (Flatbush diabetes): an emerging worldwide clinically important entity","volume":"18","author":"Lebovitz","year":"2018","journal-title":"Curr Diabetes Rep"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.amjms.2020.03.005","article-title":"Five-year glycemic trajectories among healthy African-American and European-American offspring of parents with type 2 diabetes","volume":"359","author":"Razavi","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.eprac.2022.08.002_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154263","article-title":"Multi-year reproducibility of hyperinsulinemic euglycemic clamp-derived insulin sensitivity in free-living adults: association with incident prediabetes in the pop-abc study","volume":"109","author":"James","year":"2020","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib40","first-page":"877","article-title":"VIII. Study design, progress and performance","volume":"34","year":"1991","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib41","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMe0807625","article-title":"UKPDS and the legacy effect","volume":"359","author":"Chalmers","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib42","series-title":"Endotext. South. MDText.com, Inc. 2020","article-title":"Diagnosis and clinical management of monogenic diabetes","author":"Naylor","year":"2021"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.beem.2018.06.008","article-title":"Genetic causes and treatment of neonatal diabetes and early childhood diabetes","volume":"32","author":"Barbetti","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ymgme.2014.12.304","article-title":"Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism","volume":"114","author":"Bennett","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/pedi.12289","article-title":"Characteristics of maturity onset diabetes of the young in a large diabetes center","volume":"17","author":"Chambers","year":"2016","journal-title":"Pediatr Diabetes"},{"issue":"9997","key":"10.1016\/j.eprac.2022.08.002_bib46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)60098-8","article-title":"The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study","volume":"386","author":"De Franco","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/pedi.12766","article-title":"Comprehensive genetic screening: the prevalence of maturity-onset diabetes of the young gene variants in a population-based childhood diabetes cohort","volume":"20","author":"Johnson","year":"2019","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib48","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s00125-018-4728-6","article-title":"A\u00a0UK nationwide prospective study of treatment change in mody: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin","volume":"61","author":"Shepherd","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1210\/jc.2018-01696","article-title":"Frequency and characteristics of MODY 1 (HNF4A mutation) and MODY 5 (HNF1B mutation): analysis from the dpv database","volume":"104","author":"Warncke","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.08.002_bib50","author":"Nankervis"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib51","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2337\/dc12-1157","article-title":"Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in china","volume":"36","author":"Zhu","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejogrb.2016.04.003","article-title":"Survey by the European Board and College of Obstetrics and Gynaecology on screening for gestational diabetes in Europe","volume":"201","author":"Benhalima","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.eprac.2022.08.002_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejogrb.2015.05.003","article-title":"Selective rather than universal screening for gestational diabetes mellitus?","volume":"191","author":"Miailhe","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diabres.2013.10.012","article-title":"Diagnostic criteria and classification of hyperglycaemia first\u00a0detected in pregnancy: A World Health Organization guideline","volume":"103","author":"World Health Organization","year":"2014","journal-title":"Diabetes\u00a0Res Clin Pract"},{"issue":"suppl 3","key":"10.1016\/j.eprac.2022.08.002_bib55","first-page":"131","article-title":"The Interntational Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care","volume":"S173-211","author":"Hod","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc18-1646","article-title":"Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose metabolism","volume":"42","author":"Lowe","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib57","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00125-018-4809-6","article-title":"Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study","volume":"62","author":"Lowe","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2022.08.002_bib58","first-page":"278","article-title":"Criteria for the oral glucose tolerance test in pregnancy","volume":"13","author":"O'Sullivan","year":"1964","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2337\/dc09-1848","article-title":"International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy","volume":"33","author":"Metzger","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib60","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/AOG.0000000000002501","article-title":"ACOG practice bulletin no. 190: Gestational diabetes mellitus ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus","volume":"131","author":"American College of Obstetricians and Gynecologists","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib61","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0002-9378(82)90349-0","article-title":"Criteria for screening tests for gestational diabetes","volume":"144","author":"Carpenter","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11892-017-0922-z","article-title":"Application of one-step IADPSG vs two-step diagnostic criteria for gestational diabetes in the real world: impact on health services, clinical care, and outcomes","volume":"17","author":"Brown","year":"2017","journal-title":"Curr Diabetes Rep"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib63","article-title":"Different strategies for diagnosing gestational diabetes to improve maternal and infant health","volume":"8","author":"Farrar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib64","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0707943","article-title":"Hyperglycemia and adverse pregnancy outcomes","volume":"358","author":"Metzger","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib65","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa2026028","article-title":"A\u00a0pragmatic, randomized clinical trial of gestational diabetes screening","volume":"384","author":"Hillier","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib66","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2337\/dc11-1641","article-title":"Frequency of gestational diabetes mellitus at collaborating centers based on iadpsg consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study","volume":"35","author":"Sacks","year":"2012","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib67","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc07-s225","article-title":"Summary and recommendations of the Fifth International Workshop-Conference on gestational diabetes mellitus","volume":"30","author":"Metzger","year":"2007","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib68","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.mayocp.2020.02.019","article-title":"A\u00a0review of the pathophysiology and management of diabetes in pregnancy","volume":"95","author":"Egan","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"9739","key":"10.1016\/j.eprac.2022.08.002_bib69","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib70","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib71","doi-asserted-by":"crossref","first-page":"l5887","DOI":"10.1136\/bmj.l5887","article-title":"Benefits and harms of intensive glycemic control in patients with type 2 diabetes","volume":"367","author":"Rodriguez-Gutierrez","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","article-title":"Association of hemoglobin A1c with\u00a0cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk","volume":"141","author":"Khaw","year":"2004","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib75","first-page":"S39","article-title":"3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of Medical Care in Diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib76","first-page":"2545","article-title":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et\u00a0al. Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib78","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM200002103420603","article-title":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, et\u00a0al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy","volume":"342","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib81","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib82","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/dc09-1278","article-title":"Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial","volume":"33","author":"Riddle","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib83","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2013-2824","article-title":"Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB Prospective Complications Study","volume":"99","author":"Schoenaker","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9713","key":"10.1016\/j.eprac.2022.08.002_bib84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib86","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-011-2404-1","article-title":"Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds","volume":"55","author":"Zoungas","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2022.08.002_bib87","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ (Clin Res Ed)"},{"issue":"9179","key":"10.1016\/j.eprac.2022.08.002_bib88","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of who and American Diabetes Association diagnostic criteria. The decode study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.08.002_bib89","first-page":"l4894","article-title":"HbA(1c) level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study","volume":"366","author":"Lind","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib91","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib92","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib93","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/CCM.0000000000001650","article-title":"Admission hyperglycemia in critically ill sepsis patients: Association with outcome and host response","volume":"44","author":"van Vught","year":"2016","journal-title":"Crit Care Med"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib94","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in critically ill patients","volume":"345","author":"van den Berghe","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib95","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive vs conventional glucose control in critically ill patients","volume":"360","author":"Finfer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib96","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s00134-009-1585-2","article-title":"A\u00a0prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study","volume":"35","author":"Preiser","year":"2009","journal-title":"Intensive Care Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib97","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1204942","article-title":"Hypoglycemia and risk of death in critically ill patients","volume":"367","author":"Finfer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2021.05.035","article-title":"Impact of preoperative glycometabolic status on outcomes in cardiac surgery: systematic review and meta-analysis","author":"Corazzari","year":"2021","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib99","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an\u00a0Endocrine Society clinical practice guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2337\/dc15-0303","article-title":"Randomized controlled trial of intensive vs conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial","volume":"38","author":"Umpierrez","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib101","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1067\/mtc.2003.181","article-title":"Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting","volume":"125","author":"Furnary","year":"2003","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib103","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.2337\/dc15-1835","article-title":"Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes","volume":"38","author":"Pasquel","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa070716","article-title":"Intensive insulin therapy and pentastarch resuscitation in severe sepsis","volume":"358","author":"Brunkhorst","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib106","series-title":"The Glycemic Control Implementation Guide: Improving Glycemic Control, Preventing Hypoglycemia and Optimizing Care of the Inpatient with Hyperglycemia and Diabetes","year":"2015"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib107","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib108","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc12-1988","article-title":"Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s41669-017-0020-9","article-title":"A\u00a0comparison of inpatient cost per day in general surgery patients with type 2 diabetes treated with basal-bolus vs sliding scale insulin regimens","volume":"1","author":"Phillips","year":"2017","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib110","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2337\/dc07-0278","article-title":"Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes","volume":"30","author":"Guerin","year":"2007","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib111","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2337\/diacare.27.12.2819","article-title":"Outcomes in type 1 diabetic pregnancies: A nationwide, population-based study","volume":"27","author":"Jensen","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2393-10-63","article-title":"Esmaeil SA Preconception care for diabetic women for improving maternal and fetal outcomes: A systematic review and meta-analysis","volume":"10","author":"Wahabi","year":"2010","journal-title":"BMC Preg Childbirth"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11892-016-0765-z","article-title":"Management of type 1 diabetes in pregnancy","volume":"16","author":"Feldman","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.eprac.2022.08.002_bib114","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/1471-2458-12-792","article-title":"Esmaeil SA Pre-pregnancy care for women with pre-gestational diabetes mellitus: A systematic review and meta-analysis","volume":"12","author":"Wahabi","year":"2012","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/dme.13799","article-title":"Impact of different glycaemic treatment targets on pregnancy outcomes in gestational diabetes","volume":"36","author":"Abell","year":"2019","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12884-018-2060-2","article-title":"TARGET Study Group Tight or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity? (TARGET): study protocol for a stepped wedge randomised trial","volume":"18","author":"Crowther","year":"2018","journal-title":"BMC Preg Childbirth"},{"issue":"1 Pt 1","key":"10.1016\/j.eprac.2022.08.002_bib117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0002-9378(91)90637-7","article-title":"Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study","volume":"164","author":"Jovanovic-Peterson","year":"1991","journal-title":"Am J Obstet Gynecol"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib118","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/14767058.2018.1449203","article-title":"Which criteria should be used for starting pharmacologic therapy for management of gestational diabetes in pregnancy? Evidence from randomized controlled trials","volume":"32","author":"Caissutti","year":"2019","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"issue":"36","key":"10.1016\/j.eprac.2022.08.002_bib119","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004712","article-title":"The association between maternal hyperglycemia and\u00a0perinatal outcomes in gestational diabetes mellitus patients: A retrospective cohort study","volume":"95","author":"Cho","year":"2016","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/dc14-1755","article-title":"Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes","volume":"38","author":"Maresh","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib121","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2337\/diacare.27.5.1200","article-title":"HbA1c levels are significantly lower in early and late pregnancy","volume":"27","author":"Nielsen","year":"2004","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib122","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM199511093331901","article-title":"Postprandial vs preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy","volume":"333","author":"de Veciana","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"10110","key":"10.1016\/j.eprac.2022.08.002_bib123","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0140-6736(17)32400-5","article-title":"Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): A multicentre international randomised controlled trial","volume":"390","author":"Feig","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib124","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/dom.13310","article-title":"Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial","volume":"20","author":"Voormolen","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib125","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2337\/dc12-2360","article-title":"The effect of real-time continuous glucose monitoring in pregnant women with diabetes: A randomized controlled trial","volume":"36","author":"Secher","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib126","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00125-019-4850-0","article-title":"Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies","volume":"62","author":"Kristensen","year":"2019","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib127","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/dia.2019.0319","article-title":"Continuous glucose monitoring and glycemic patterns in pregnant women with gestational diabetes mellitus","volume":"22","author":"M\u00e1rquez-Pardo","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"7258","key":"10.1016\/j.eprac.2022.08.002_bib128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib129","first-page":"S97","article-title":"7. Diabetes technology: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1373\/clinchem.2010.148841","article-title":"National Glycohemoglobin Standardization Program (NGSP) Steering Committee Status of hemoglobin A1c measurement and goals for improvement: From chaos to order for improving diabetes care","volume":"57","author":"Little","year":"2011","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib131","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","article-title":"Translating the A1c assay into estimated average glucose values","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib132","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrendo.2010.126","article-title":"Dagogo-Jack S Pitfalls in the use of HbA\u2081(c) as a diagnostic test: the ethnic conundrum","volume":"6","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib133","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/dc16-0042","article-title":"Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference","volume":"39","author":"Selvin","year":"2016","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib134","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1001\/jama.2017.4643","article-title":"Measurement of hemoglobin A1c in patients with sickle cell trait","volume":"317","author":"Rohlfing","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2022.08.002_bib135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2012.12.022","article-title":"Measurement of HbA(1c) in patients with chronic renal failure","volume":"418","author":"Little","year":"2013","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib136","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/193229680900300406","article-title":"Herman WH Do race and ethnicity impact hemoglobin A1c independent of glycemia?","volume":"3","year":"2009","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.eprac.2022.08.002_bib137","first-page":"CD005060","article-title":"Self-monitoring of blood glucose\u00a0in patients with type 2 diabetes mellitus who are not using insulin","volume":"1","author":"Malanda","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib138","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1932296815580160","article-title":"Analytical performance requirements for systems for self-monitoring of blood glucose with focus on system accuracy: relevant differences among ISO 15197:2003, ISO 15197:2013, and current FDA recommendations","volume":"9","author":"Freckmann","year":"2015","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib139","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/1932296820905581","article-title":"Accuracy of blood glucose measurement and blood glucose targets","volume":"14","author":"Eerdekens","year":"2020","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1932296818812062","article-title":"Levy B Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices","volume":"13","author":"Freckmann","year":"2019","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1399-5448.2010.00650.x","article-title":"Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes","volume":"12","author":"Ziegler","year":"2011","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib143","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/193229680700100608","article-title":"Hebblewhite HR A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for statistical correlations","volume":"1","author":"Davidson","year":"2007","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib144","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc12-1770","article-title":"Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants","volume":"36","author":"Miller","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diabres.2012.12.024","article-title":"Frequency of blood glucose testing in well educated patients with diabetes mellitus type 1: how often is enough?","volume":"101","author":"Minder","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib146","first-page":"57","article-title":"Gagliardino JJ Frequency of self-monitoring blood glucose and attainment of HbA1c target values","volume":"53","author":"Elgart","year":"2016","journal-title":"Acta\u00a0diabetol"},{"issue":"7654","key":"10.1016\/j.eprac.2022.08.002_bib147","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/bmj.39534.571644.BE","article-title":"ESMON study group Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial","volume":"336","author":"O'Kane","year":"2008","journal-title":"BMJ (Clin Res Ed)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib148","doi-asserted-by":"crossref","first-page":"JC6","DOI":"10.7326\/0003-4819-156-12-201206190-02012","article-title":"Meta-analysis: self-monitoring in non-insulin-treated\u00a0type 2 diabetes improved HbA1c by 0.25","volume":"156","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7611","key":"10.1016\/j.eprac.2022.08.002_bib149","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.39247.447431.BE","article-title":"Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial","volume":"335","author":"Farmer","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13104-018-3138-7","article-title":"Effects of three frequencies of self-monitored blood glucose on HbA1c and quality of life in patients with type 2 diabetes with once daily insulin and stable control: A randomized trial","volume":"11","author":"Hortensius","year":"2018","journal-title":"BMC Res Notes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib151","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1932296817719290","article-title":"Scavini M Effects of structured vs unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"12","author":"Mannucci","year":"2018","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.eprac.2022.08.002_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109070","article-title":"Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: A novel analysis of data from the prisma trial","volume":"181","author":"Di Molfetta","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib153","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","article-title":"American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus","volume":"27","author":"Grunberger","year":"2021","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib154","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1c to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib156","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2016.19976","article-title":"Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the gold randomized clinical trial","volume":"317","author":"Lind","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib157","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc16-2482","article-title":"REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes","volume":"40","author":"Aleppo","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib158","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib159","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring vs usual care in patients with type 2 diabetes receiving multiple daily insulin injections: A randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/dc19-0888","article-title":"Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study","volume":"43","author":"\u0160oupal","year":"2020","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib161","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.2020.6940","article-title":"Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: A randomized clinical trial","volume":"323","author":"Laffel","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.23","article-title":"The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real-life conditions over a period of one year","volume":"1","author":"Paris","year":"2018","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib163","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13300-019-00741-9","article-title":"Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes","volume":"11","author":"Kr\u00f6ger","year":"2020","journal-title":"Diabetes Ther"},{"issue":"10057","key":"10.1016\/j.eprac.2022.08.002_bib164","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","article-title":"Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial","volume":"388","author":"Bolinder","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib165","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S2213-8587(16)30193-0","article-title":"Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): A randomised, open-label, crossover trial","volume":"4","author":"van Beers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib166","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc19-1610","article-title":"Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): A prospective observational real-world cohort study","volume":"43","author":"Charleer","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000809","article-title":"Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)","volume":"7","author":"Fokkert","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib168","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1210\/jc.2017-02498","article-title":"Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: A real-world study","volume":"103","author":"Charleer","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib169","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12979","article-title":"Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study","volume":"33","author":"Manski-Nankervis","year":"2016","journal-title":"Diabet Med"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib170","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: A randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib171","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","article-title":"Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: A multicenter, open-label randomized controlled trial","volume":"8","author":"Haak","year":"2017","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib172","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13300-017-0255-6","article-title":"Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes","volume":"8","author":"Haak","year":"2017","journal-title":"Diabetes Ther"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib173","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2020.6928","article-title":"Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial","volume":"323","author":"Pratley","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib174","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1464-5491.2009.02867.x","article-title":"Rokne B Fear of hypoglycaemia in mothers and fathers of children with type 1 diabetes is associated with poor glycaemic control and parental emotional distress: A population-based study","volume":"27","author":"Haugstvedt","year":"2010","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2019.0331","article-title":"Davis WA Efficacy of intermittently scanned continuous glucose monitoring in the prevention of recurrent severe hypoglycemia","volume":"22","author":"Davis","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib176","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/dia.2009.0145","article-title":"STAR 3 Randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects","volume":"12","author":"Davis","year":"2010","journal-title":"Star. Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib177","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ajcn\/87.3.638","article-title":"Clifton PM Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes","volume":"87","author":"Pearce","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib178","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/193229681100500320","article-title":"Vigersky RA The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus","volume":"5","author":"Ehrhardt","year":"2011","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib179","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib180","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/HJH.0b013e32832d4aee","article-title":"Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004","volume":"27","author":"Suh","year":"2009","journal-title":"J\u00a0Hypertens"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib181","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Brancati FL Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study","volume":"342","author":"Gress","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib182","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3810\/pgm.2000.04.990","article-title":"Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications","volume":"107","author":"Sowers","year":"2000","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib183","first-page":"i717","article-title":"Carlberg B Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib184","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2215\/CJN.02850315","article-title":"BP and renal outcomes in diabetic kidney disease: the Veterans Affairs Nephropathy in Diabetes trial","volume":"10","author":"Leehey","year":"2015","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"7160","key":"10.1016\/j.eprac.2022.08.002_bib185","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ (Clin Res Ed)"},{"issue":"7258","key":"10.1016\/j.eprac.2022.08.002_bib186","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ (Clin Res Ed)"},{"issue":"9118","key":"10.1016\/j.eprac.2022.08.002_bib187","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"issue":"9200","key":"10.1016\/j.eprac.2022.08.002_bib188","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"9311","key":"10.1016\/j.eprac.2022.08.002_bib189","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib190","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib191","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/HYPERTENSIONAHA.118.12414","article-title":"Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus","volume":"73","author":"Rahman","year":"2019","journal-title":"Hypertens (Dallas. TX"},{"key":"10.1016\/j.eprac.2022.08.002_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107834","article-title":"How to perform better intervention to prevent and control diabetic retinopathy among patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"156","author":"Yusufu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2022.08.002_bib193","article-title":"Blood pressure control for diabetic retinopathy","volume":"1","author":"Do","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib194","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","article-title":"Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: A multicenter, randomized clinical trial","volume":"19","author":"Kato","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib195","first-page":"503","article-title":"Joint National Committee JNC8 guidelines for the management of hypertension in adults","volume":"90","author":"Armstrong","year":"2014","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib196","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"1979","journal-title":"Hypertens (Dallas. TX"},{"issue":"suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib197","first-page":"S12","article-title":"KDOQI\u2122 clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib198","first-page":"193","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension","volume":"12","author":"Torre","year":"2006","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib199","first-page":"S144","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib200","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.287.19.2563","article-title":"Writing Team for the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus","volume":"287","year":"2002","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib201","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib202","article-title":"Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT","volume":"7","author":"Beddhu","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.eprac.2022.08.002_bib203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","article-title":"Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus","author":"Ohkuma","year":"2019","journal-title":"Hypertension. TX"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib204","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/HYPERTENSIONAHA.118.11408","article-title":"Benefits of intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control","author":"Tsujimoto","year":"2018","journal-title":"Hypertension. TX"},{"key":"10.1016\/j.eprac.2022.08.002_bib206","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","article-title":"Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials","volume":"208","author":"Xie","year":"2016","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib207","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","article-title":"Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials","volume":"6","author":"Beddhu","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib208","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215362","article-title":"Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis","volume":"14","author":"Wang","year":"2019","journal-title":"PLOS ONE"},{"issue":"3s","key":"10.1016\/j.eprac.2022.08.002_bib209","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the\u00a0management of high blood pressure in adults: report from the panel\u00a0members appointed to the eighth joint national committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib211","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.eprac.2022.08.002_bib212","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/HYP.0000000000000003","article-title":"An effective approach to high blood pressure control: A science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention","author":"Go","year":"2014","journal-title":"Hypertension. TX"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib213","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension","volume":"16","author":"Weber","year":"2014","journal-title":"J\u00a0Clin Hypertens (Greenwich Conn)"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib214","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3945\/ajcn.116.146803","article-title":"A\u00a0Mediterranean diet lowers blood pressure and improves endothelial function: results from the MedLey randomized intervention trial","volume":"105","author":"Davis","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib215","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/advances\/nmaa041","article-title":"Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: A systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Filippou","year":"2020","journal-title":"Adv Nutr."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib216","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.kint.2018.12.027","article-title":"Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension","volume":"95","author":"Banerjee","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib217","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0042-104935","article-title":"Low-volume high-intensity interval training as a therapy for type 2 diabetes","volume":"37","author":"Alvarez","year":"2016","journal-title":"Int J Sports Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib218","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40292-018-0281-0","article-title":"Effects on cardiovascular risk scores and vascular age after aerobic exercise and nutritional intervention in sedentary and overweight\/obese adults with primary hypertension: the EXERDIET-HTA randomized trial study","volume":"25","author":"Gorostegi-Anduaga","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib219","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12316","article-title":"Obesity in older adults: effect of degree of weight loss on cardiovascular markers and medications","volume":"9","author":"Haywood","year":"2019","journal-title":"Clin Obes"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib220","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/2047487318774419","article-title":"Association of baseline level of physical activity and its temporal changes with incident hypertension and diabetes mellitus","volume":"25","author":"Lee","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib221","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000445504","article-title":"Effect of a modest weight loss in\u00a0normalizing blood pressure in obese subjects on antihypertensive drugs","volume":"9","author":"Gilardini","year":"2016","journal-title":"Obes Facts"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib222","first-page":"549","article-title":"A\u00a0motivational interviewing intervention by pharmacy students to improve medication adherence","volume":"23","author":"Abughosh","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib223","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004691","article-title":"Cluster randomized clinical trial of FAITH (Faith-Based Approaches in the Treatment of Hypertension) in blacks","volume":"11","author":"Schoenthaler","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib224","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jch.12736","article-title":"Effect of expectation of care on adherence to antihypertensive medications among hypertensive blacks: analysis of the counseling African Americans to control hypertension (CAATCH) trial","volume":"18","author":"Grant","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich Conn)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib225","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc16-0941","article-title":"Effect of DECIDE (Decision-Making Education for Choices In Diabetes Everyday) program delivery modalities on clinical and behavioral outcomes in urban African Americans with type 2 diabetes: A randomized trial","volume":"39","author":"Fitzpatrick","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib226","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.12697","article-title":"Mortality outcomes with intensive blood\u00a0pressure targets in chronic kidney disease patients","volume":"73","author":"Aggarwal","year":"2019","journal-title":"Hypertens (Dallas. TX"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib227","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.117.10713","article-title":"Intensive blood pressure targets for diabetic and other high-risk populations: A pooled individual patient data analysis","volume":"71","author":"Aggarwal","year":"2018","journal-title":"Hypertension. TX"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib228","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib229","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.HYP.35.3.844","article-title":"Prognostic value of ambulatory blood pressure: current evidence and clinical implications","volume":"35","author":"Verdecchia","year":"2000","journal-title":"Hypertens (Dallas. TX"},{"issue":"33","key":"10.1016\/j.eprac.2022.08.002_bib230","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007807","article-title":"Comparison of ambulatory blood pressure and clinic blood pressure in relation to cardiovascular diseases in diabetic patients","volume":"96","author":"Shen","year":"2017","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib231","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/dom.13248","article-title":"Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants","volume":"20","author":"Buckley","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib232","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.clinthera.2016.08.007","article-title":"Rodgers A More vs less blood pressure lowering: an update","volume":"38","author":"Atkins","year":"2016","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib233","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/dc17-1722","article-title":"Intensive blood pressure lowering in patients with and patients without type 2 diabetes: A pooled analysis from two randomized trials","volume":"41","author":"Brouwer","year":"2018","journal-title":"Diabetes Care"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib234","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehz149","article-title":"Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk","volume":"40","author":"B\u00f6hm","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/HJH.0000000000001515","article-title":"Okin PM Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus","volume":"36","author":"\u00d3 Hartaigh","year":"2018","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib236","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/HYPERTENSIONAHA.116.07474","article-title":"Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance","volume":"68","author":"Fleg","year":"2016","journal-title":"Hypertens (Dallas. TX"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib237","article-title":"Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMIN trial","volume":"7","author":"White","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib238","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4103\/0366-6999.181959","article-title":"Benefits of fixed dose combination of ramipril\/amlodipine in hypertensive diabetic patients: A subgroup analysis of RAMONA trial","volume":"129","author":"Simonyi","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib239","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib240","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib241","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib242","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib243","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/dom.14079","article-title":"The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib244","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertens (Dallas. TX"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib245","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib246","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41440-019-0234-6","article-title":"The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Kunimura","year":"2019","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib247","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0145721716666680","article-title":"Alam N A comparison of the use of clinical-guideline-recommended antihypertensive regimens in Mexican American, non-Hispanic black, and non-Hispanic white adults with type 2 diabetes and hypertension in the United States: Nhanes 2003-2012","volume":"42","author":"Perez","year":"2016","journal-title":"Diabetes Educ"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib248","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/HJH.0000000000000890","article-title":"LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial","volume":"34","author":"Petrie","year":"2016","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib249","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/HYPERTENSIONAHA.117.09482","article-title":"Hypertension control in adults with diabetes mellitus and recurrent cardiovascular events: global results from the trial evaluating cardiovascular outcomes with sitagliptin","volume":"70","author":"Navar","year":"2017","journal-title":"Hypertens (Dallas. TX"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib250","first-page":"565","article-title":"Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus","volume":"38","author":"Karashima","year":"2016","journal-title":"Clin Exp Hypertens. New York, NY"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib251","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00380-018-1286-2","article-title":"Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the academie study","volume":"34","author":"Imaizumi","year":"2019","journal-title":"Heart Vessels"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib252","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164936","article-title":"Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial","volume":"11","author":"Uzu","year":"2016","journal-title":"PLOS ONE"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib253","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1681\/ASN.2018040443","article-title":"The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): A randomized, controlled trial","volume":"29","author":"Saglimbene","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib254","article-title":"Parving HH Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review","volume":"17","author":"Persson","year":"2016","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib255","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jch.13598","article-title":"Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A bayesian network meta-analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"J\u00a0Clin Hypertens (Greenwich Conn)"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib256","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jch.13053","article-title":"Boully C Blood pressure-lowering efficacy of indapamide sr\/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix sr vs Enalapril in Hypertensive Type 2 Diabetics with Microalbuminuria)","volume":"19","author":"Hanon","year":"2017","journal-title":"J\u00a0Clin Hypertens (Greenwich Conn)"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib257","first-page":"2926","article-title":"Chen HY Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: A meta-analysis of parallel-design RCTs","volume":"20","author":"Lin","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib258","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40256-018-00321-5","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system in diabetic kidney disease: A meta-analysis","volume":"19","author":"Feng","year":"2019","journal-title":"Am J Cardiovasc Drugs Drugs Devices Other Interv"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib259","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","article-title":"Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib260","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/2047487317721644","article-title":"Factors associated with global longitudinal strain decline in hypertensive patients with normal left ventricular ejection fraction","volume":"24","author":"Soufi Taleb Bendiab","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib261","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.3390\/ijerph18126553","article-title":"Impact of diabetes on cardiac function in patients with high blood pressure","volume":"18","author":"Soufi Taleb Bendiab","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib262","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib263","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib264","first-page":"e53","article-title":"Resistant hypertension: detection, evaluation, and management: A scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertens (Dallas. TX"},{"issue":"10008","key":"10.1016\/j.eprac.2022.08.002_bib265","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone vs placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib266","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3390\/nu11081858","article-title":"Association between dietary intake and lipid-lowering therapy: prospective analysis of data from Australian diabetes, obesity, and lifestyle study (AUSDIAB) using a quantile regression approach","volume":"11","author":"Gadowski","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2022.08.002_bib267","first-page":"h3978","article-title":"Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies","volume":"351","author":"de Souza","year":"2015","journal-title":"BMJ (Clin Res Ed)"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib268","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2337\/dc16-0509","article-title":"Association of weight loss maintenance and weight regain on 4-year changes in cvd risk factors: the action for health in diabetes (Look AHEAD) clinical trial","volume":"39","author":"Wing","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib269","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1370\/afm.1924","article-title":"What happens after health coaching? Observational study 1 year following a randomized controlled trial","volume":"14","author":"Sharma","year":"2016","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12933-019-0934-x","article-title":"Effects of 1 year of exercise training vs combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: A randomized trial","volume":"18","author":"Pedersen","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib271","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/nu8110687","article-title":"Clifton PM Differential effects of red meat\/refined grain diet and dairy\/chicken\/nuts\/whole grain diet on glucose, insulin and triglyceride in a randomized crossover study","volume":"8","author":"Kim","year":"2016","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib272","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ajcn\/nqy144","article-title":"Long-term consumption of a Mediterranean diet improves postprandial lipemia in patients with type 2 diabetes: the Cordioprev randomized trial","volume":"108","author":"Gomez-Marin","year":"2018","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib273","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019214","article-title":"Ridderstr\u00e5le M Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: A retrospective cohort study from a specialised diabetes centre in Denmark","volume":"8","author":"Safai","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib274","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-018-0769-x","article-title":"The role of physical activity in the development of first cardiovascular disease event: A tree-structured survival analysis of the Danish ADDITION-PRO cohort","volume":"17","author":"Amadid","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib275","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jamainternmed.2019.0392","article-title":"Association of nonfasting vs fasting\u00a0lipid levels with risk of major coronary events in the Anglo-Scandinavian Cardiac Outcomes Trial-lipid lowering arm","volume":"179","author":"Mora","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib276","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.117.032463","article-title":"Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-c and apolipoprotein B targets in selected worldwide dyslipidemia guidelines","volume":"138","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib277","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9149(03)00262-5","article-title":"Concordance\/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk","volume":"91","author":"Sniderman","year":"2003","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib278","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2016.08.067","article-title":"Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention","volume":"118","author":"Konishi","year":"2016","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib279","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.atherosclerosis.2015.06.002","article-title":"Traditional cardiovascular disease risk factors associated with one-year all-cause mortality among those with coronary artery calcium scores \u2265400","volume":"241","author":"Al Rifai","year":"2015","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib280","first-page":"2356","article-title":"B\u00a0Warranty period of zero coronary artery calcium score for predicting all-cause mortality according to cardiac risk burden in asymptomatic Korean adults","volume":"80","author":"Lee","year":"2016","journal-title":"Circ J Off J Jpn Circ Soc"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib281","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.amjcard.2015.04.046","article-title":"Comparison of coronary computed tomographic angiographic findings in asymptomatic subjects with vs without diabetes mellitus","volume":"116","author":"Park","year":"2015","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib282","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/clc.22539","article-title":"Age, gender, and race-based coronary artery calcium score percentiles in the Brazilian longitudinal study of adult health (ELSA-Brasil)","volume":"39","author":"Pereira","year":"2016","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib283","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10554-014-0542-5","article-title":"Difference of coronary artery disease severity, extent and plaque characteristics between patients with hypertension, diabetes mellitus or dyslipidemia","volume":"31","author":"Tomizawa","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib284","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030234","article-title":"Can risk be predicted? An umbrella systematic review of current risk prediction models for cardiovascular diseases, diabetes and hypertension","volume":"9","author":"Lucaroni","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.eprac.2022.08.002_bib285","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108723","article-title":"X\u00a0Predictive value of abnormal ankle-brachial index in patients with diabetes: A meta-analysis","volume":"174","author":"Nie","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib286","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib287","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib288","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.600497","article-title":"Coronary artery calcification under statin therapy and its effect on cardiovascular outcomes: A systematic review and meta-analysis","volume":"7","author":"Lai","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"10057","key":"10.1016\/j.eprac.2022.08.002_bib289","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib290","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Cook NR Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib291","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"Cook NR C-reactive protein and\u00a0parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib292","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham heart study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib293","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","article-title":"Vasan RS Predicting the\u00a030-year risk of cardiovascular disease: the Framingham Heart Study","volume":"119","author":"Pencina","year":"2009","journal-title":"Circulation"},{"issue":"25 suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib294","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"25 B","key":"10.1016\/j.eprac.2022.08.002_bib295","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib296","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","volume":"66","author":"McClelland","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib298","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pec.2009.10.008","article-title":"The statin choice decision aid in primary care: A randomized trial","volume":"80","author":"Mann","year":"2010","journal-title":"Patient Educ Couns. patient ed"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib299","article-title":"An informatics approach to implement support\u00a0for shared decision making for primary prevention statin therapy","volume":"3","author":"Ye","year":"2018","journal-title":"MDM Policy Pract"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib300","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc13-1870","article-title":"Molitch M Microalbuminuria as a risk predictor in diabetes: the continuing saga","volume":"37","author":"Bakris","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib301","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.111.077487","volume":"127","author":"Purnell","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib302","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2337\/dc18-1446","article-title":"BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox","volume":"42","author":"Edqvist","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib303","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2840-10-39","article-title":"Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study","volume":"10","author":"Flores-Le Roux","year":"2011","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib304","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ahj.2013.01.005","article-title":"Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome","volume":"165","author":"Giraldez","year":"2013","journal-title":"Am Heart J"},{"issue":"9324","key":"10.1016\/j.eprac.2022.08.002_bib305","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib306","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib307","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000787","article-title":"Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht study","volume":"7","author":"de Ritter","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib308","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12872-020-01390-8","article-title":"Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study","volume":"20","author":"Hashemi Madani","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib309","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Taskinen MR Diabetic dyslipidaemia: From basic research to clinical practice","volume":"46","year":"2003","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib310","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","article-title":"Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study","volume":"17","author":"Halcox","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib311","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-020-01015-6","article-title":"Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: A prospective, observational cohort study","volume":"19","author":"Jin","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib312","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib313","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-019-0851-z","article-title":"Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: A systematic review and meta-analysis of prospective studies","volume":"18","author":"Ye","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib314","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Nordestgaard BG Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib315","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/2047487319871733","article-title":"Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib316","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLOS Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib317","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib318","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib319","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: A narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib320","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A\u00a0meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib321","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Jacobson TA Meta-analysis of comparison of effectiveness of lowering apolipoprotein B vs low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib322","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1373\/clinchem.2012.196733","article-title":"Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices","volume":"59","author":"Cole","year":"2013","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib323","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4158\/EP15693.CS","article-title":"AACE\/ACE comprehensive diabetes management algorithm 2015","volume":"21","author":"Garber","year":"2015","journal-title":"Endocr Pract"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib324","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2022.08.002_bib325","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC Committee for Practice Guidelines (CPG),\u00a0ESC National Cardiac Societies 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib326","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib327","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib328","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/000331970305400607","article-title":"Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus","volume":"54","author":"Athyros","year":"2003","journal-title":"Angiology"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib329","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Braunwald E Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE-IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib330","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1479164116637311","article-title":"Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: report from the Swedish National Diabetes Register","volume":"13","author":"Eeg-Olofsson","year":"2016","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib331","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Pocock SJ Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib332","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/01.CIR.0000116389.61864.DE","article-title":"Atherosclerosis Risk in Communities (ARIC) Study Investigators Cardiovascular events in diabetic and\u00a0nondiabetic adults with or without history of myocardial infarction","volume":"109","author":"Lee","year":"2004","journal-title":"Circulation"},{"issue":"9607","key":"10.1016\/j.eprac.2022.08.002_bib333","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.eprac.2022.08.002_bib334","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.08.002_bib335","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2016.07.140","article-title":"Efficacy of high intensity atorvastatin vs moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus","volume":"222","author":"Liu","year":"2016","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib336","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00125-006-0195-6","article-title":"Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study","volume":"49","author":"Bruno","year":"2006","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib337","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1194\/jlr.M700213-JLR200","article-title":"Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese","volume":"48","author":"Chien","year":"2007","journal-title":"J\u00a0Lipid Res"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib338","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib339","article-title":"Effect of switching from statin monotherapy to ezetimibe\/simvastatin combination therapy compared with other intensified lipid-lowering strategies on lipoprotein subclasses in diabetic patients with symptomatic cardiovascular disease","volume":"4","author":"Le","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib340","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.jacc.2018.11.004","article-title":"Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Wilson","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib341","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib342","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2018.07.017","article-title":"Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: analysis of the ODYSSEY long term trial","volume":"276","author":"Taskinen","year":"2018","journal-title":"Atherosclerosis"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib343","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9435","key":"10.1016\/j.eprac.2022.08.002_bib344","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"9374","key":"10.1016\/j.eprac.2022.08.002_bib345","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib346","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCOUTCOMES.115.001980","volume":"9","author":"Kaasenbrood","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib347","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib348","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib349","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A\u00a0comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib350","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of outcomes: Vytorin Efficacy International Trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2022.08.002_bib351","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2016.09.082","article-title":"Clinical outcome of statin plus ezetimibe vs high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis","volume":"225","author":"Ji","year":"2016","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib352","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.eprac.2022.08.002_bib353","first-page":"445","article-title":"Ezetimibe-statin combination therapy","volume":"113","author":"Nu\u00dfbaumer","year":"2016","journal-title":"Dtsch arztebl int"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib354","article-title":"Pcsk9 monoclonal antibodies for the\u00a0primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib355","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2009.10.029","article-title":"Safety and efficacy of ezetimibe added to atorvastatin vs up titration of atorvastatin to 40 mg in patients > or\u00a0= 65 years of age (from the ZETia in the ELDerly [ZETELD] study)","volume":"105","author":"Zieve","year":"2010","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib356","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"issue":"9784","key":"10.1016\/j.eprac.2022.08.002_bib357","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.08.002_bib358","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ (Clin Res Ed)"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib359","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/jc.2019-00195","article-title":"Lipid-lowering agents in older individuals: A systematic review and meta-analysis of randomized clinical trials","volume":"104","author":"Ponce","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib360","article-title":"Impact of aging on the strength of cardiovascular risk factors: A longitudinal study over 40 years","volume":"7","author":"Lind","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib361","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: A meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib362","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.amjcard.2006.06.032","article-title":"Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease","volume":"98","author":"Liu","year":"2006","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib363","first-page":"16","article-title":"Non-hdl cholesterol as a predictor of\u00a0cardiovascular disease in type 2 diabetes: the strong heart study","volume":"26","author":"Lu","year":"2003","journal-title":"Diabetes\u00a0Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib364","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/diacare.24.8.1335","volume":"24","year":"2001","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib365","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: A systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib366","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib367","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib368","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib369","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib370","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib371","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1089\/jwh.2017.6757","article-title":"Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis","volume":"27","author":"Brinton","year":"2018","journal-title":"J\u00a0Womens Health (Larchmt)"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib372","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib373","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib374","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMcp070061","article-title":"Clinical practice. Hypertriglyceridemia","volume":"357","author":"Brunzell","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib375","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib376","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"Christian","year":"2014","journal-title":"Am J Med"},{"issue":"9500","key":"10.1016\/j.eprac.2022.08.002_bib377","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib378","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11886-011-0237-7","article-title":"Rosenblit PD. Do persons with diabetes benefit from combination statin and fibrate therapy?","volume":"14","year":"2012","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib379","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib380","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib381","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib382","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib383","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS-2 THRIVE Collaboration Group. HPS-2 THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib384","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9716","key":"10.1016\/j.eprac.2022.08.002_bib385","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"3 suppl","key":"10.1016\/j.eprac.2022.08.002_bib386","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the Statin Diabetes Safety Task Force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib387","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib388","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pcd.2014.06.001","article-title":"High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care","volume":"9","author":"Mets\u00e4rinne","year":"2015","journal-title":"Prim Care Diabetes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib389","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jdiacomp.2015.04.007","article-title":"Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM project, 2005-2011","volume":"29","author":"Schroeder","year":"2015","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib390","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Mauer M Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib391","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib392","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.eprac.2022.08.002_bib393","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib394","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib395","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A\u00a0unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib396","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib397","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMe2114918","article-title":"Time to eliminate health care disparities in the estimation of kidney function","volume":"385","author":"Williams","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.eprac.2022.08.002_bib398","article-title":"Systematic review on urine albumin testing for early detection of diabetic complications","volume":"9","author":"Newman","year":"2005","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib399","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: A KDIGO controversies conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib400","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/dc14-1203","article-title":"Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS study (Vascular Diabetic Complications in Southeast Sweden)","volume":"38","author":"Nordwall","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib401","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12933-018-0677-0","article-title":"Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study","volume":"17","author":"Cardoso","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib402","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc16-0857","article-title":"Association between blood pressure and adverse renal events in type 1 diabetes","volume":"39","author":"Ku","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib403","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jdiacomp.2016.09.003","article-title":"Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes","volume":"31","author":"Sohn","year":"2017","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib404","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the STENO-2 randomised trial","volume":"59","author":"G\u00e6de","year":"2016","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib405","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-8587(19)30349-3","article-title":"Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial","volume":"7","author":"Griffin","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9131","key":"10.1016\/j.eprac.2022.08.002_bib406","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"10.1016\/j.eprac.2022.08.002_bib407","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib408","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib409","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.eprac.2022.08.002_bib410","doi-asserted-by":"crossref","DOI":"10.1038\/srep20028","article-title":"Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease","volume":"6","author":"Kuo","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib411","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib412","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib413","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2012.07.017","article-title":"Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic review for a KDOQI clinical practice guideline","volume":"60","author":"Slinin","year":"2012","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib414","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00125-019-4812-6","article-title":"Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study","volume":"62","author":"Bjerg","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12933-019-0837-x","article-title":"Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases","volume":"18","author":"Bramlage","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib416","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10157-016-1290-8","article-title":"Prognostic value of proteinuria and glomerular filtration rate on Taiwanese patients with diabetes mellitus and advanced chronic kidney disease: A single center experience","volume":"21","author":"Chen","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib417","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib418","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-019-0961-7","article-title":"Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: A 10-year follow-up study","volume":"18","author":"Garofolo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib419","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jfma.2017.09.015","article-title":"Factors associated with diabetic nephropathy in children, adolescents, and adults with type 1 diabetes","volume":"116","author":"Huang","year":"2017","journal-title":"J\u00a0Formos Med Assoc\u00a0Taiwan Yi Zhi"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib420","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.ajkd.2018.02.364","article-title":"Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) study","volume":"72","author":"Koye","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib421","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/nep.12446","article-title":"Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients","volume":"20","author":"Tanaka","year":"2015","journal-title":"Nephrology (Carlton)"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib422","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2337\/dc15-0641","article-title":"The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes","volume":"38","author":"Thorn","year":"2015","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib423","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib424","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib425","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib426","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib427","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib428","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Pioneer. Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib429","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide vs insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4S","key":"10.1016\/j.eprac.2022.08.002_bib430","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib431","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib432","first-page":"S151","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib433","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertens (Dallas. TX"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib434","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib435","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib436","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib437","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib438","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib439","first-page":"i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib440","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib441","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib442","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.diabet.2009.05.003","article-title":"Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials","volume":"35","author":"Halimi","year":"2009","journal-title":"Diabetes Metab"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib443","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib444","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-REDUCED trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib445","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib446","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib447","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib448","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib449","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/dom.13579","article-title":"Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers","volume":"21","author":"Heerspink","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib450","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib451","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib452","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib453","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib454","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib455","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib456","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME(\u00ae) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib457","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib458","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib459","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib460","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib461","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib462","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2337\/dc21-0300","article-title":"Efficacy and safety of dapagliflozin by baseline glycemic status: A prespecified analysis from the DAPA-CKD trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib463","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib464","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib465","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib466","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib467","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib468","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-REDUCED","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2022.08.002_bib469","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: A systematic review and network meta-analysis","volume":"183","author":"Kawai","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib470","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib471","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib472","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib473","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib474","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide vs placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib475","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib476","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: A post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib477","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib478","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/dom.14126","article-title":"Cardiovascular and renal outcomes by baseline albuminuria status and renal function: results from the LEADER randomized trial","volume":"22","author":"Mosenzon","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib479","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: A post hoc analysis of the LEADER trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib480","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib481","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib482","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib483","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.clinthera.2009.10.020","article-title":"Bowlin SJ Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Koro","year":"2009","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib484","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib485","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib486","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-137-6-200209170-00016","article-title":"Levinsky NG Specialist evaluation in chronic kidney disease: too little, too late","volume":"137","year":"2002","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib487","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1046\/j.1523-1755.2000.00064.x","article-title":"Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease","volume":"57","author":"Becker","year":"2000","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib488","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib489","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib490","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/dc20-2304","article-title":"Thirty-year trends in complications in U.S. Adults with newly diagnosed type 2 diabetes","volume":"44","author":"Fang","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib491","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dme.12119","article-title":"Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries","volume":"30","author":"Ruta","year":"2013","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib492","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib493","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10654-019-00560-z","article-title":"Prevalence, incidence and future projection of diabetic eye disease in Europe: A systematic review and meta-analysis","volume":"35","author":"Li","year":"2020","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib494","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib495","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ophtha.2016.10.031","article-title":"Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States","volume":"124","author":"Wang","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib496","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/dc12-0790","article-title":"Predicting development of proliferative diabetic retinopathy","volume":"36","author":"Harris Nwanyanwu","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib497","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2337\/dc18-2308","article-title":"Risk factors for retinopathy in type 1 diabetes: the DCCT\/EDIC study","volume":"42","author":"Hainsworth","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib498","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/bjophthalmol-2020-316202","article-title":"Bacterial infections as novel risk factors of severe diabetic retinopathy in individuals with type 1 diabetes","volume":"105","author":"Simonsen","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib499","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib500","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.eye.6701476","article-title":"Epidemiology of diabetic retinopathy and macular oedema: A systematic review","volume":"18","author":"Williams","year":"2004","journal-title":"Eye (Lond Engl)"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib501","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/bjophthalmol-2015-307341","article-title":"Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: A scientific approach to reducing healthcare costs","volume":"100","author":"Lund","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib502","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1612836","article-title":"Frequency of evidence-based screening for retinopathy in type 1 diabetes","volume":"376","author":"Nathan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib503","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1600-0420.2004.00350.x","article-title":"Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis","volume":"82","author":"Hansen","year":"2004","journal-title":"Acta ophthalmol Scand"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib504","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00592-017-0974-1","article-title":"Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003-2016","volume":"54","year":"2017","journal-title":"Acta diabetol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198551","article-title":"Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan natives","volume":"13","author":"Bursell","year":"2018","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib506","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaophthalmol.2015.1","article-title":"Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: A randomized clinical trial","volume":"133","author":"Mansberger","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib507","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/dc06-0295","article-title":"The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy","volume":"29","author":"Ahmed","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib508","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2337\/dc20-1671","article-title":"The SEE Study: safety, efficacy, and equity of implementing autonomous artificial intelligence for diagnosing diabetic retinopathy in youth","volume":"44","author":"Wolf","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib509","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1932296820909900","article-title":"Autonomous artificial intelligence in diabetic retinopathy: From algorithm to clinical application","volume":"15","author":"Channa","year":"2021","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib510","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.2017.18152","article-title":"Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes","volume":"318","author":"Ting","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib511","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11892-019-1189-3","article-title":"Artificial intelligence screening for diabetic retinopathy: the real-world emerging application","volume":"19","author":"Bellemo","year":"2019","journal-title":"Curr Diabetes Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib512","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ophtha.2019.07.026","article-title":"Diagnostic accuracy of technology-based eye care services: the Technology-based Eye Care Services Compare Trial Part I","volume":"127","author":"Maa","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib513","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/bjophthalmol-2014-306536","article-title":"Accuracy of a technology-assisted eye exam in evaluation of referable diabetic retinopathy and concomitant ocular diseases","volume":"99","author":"Conlin","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib514","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc11-2282","article-title":"Can the retinal screening interval be safely increased to 2 years for type 2 diabetic patients without retinopathy?","volume":"35","author":"Chalk","year":"2012","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib515","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s00125-013-2928-7","article-title":"Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening Programme","volume":"56","author":"Looker","year":"2013","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib516","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2337\/dc14-1778","article-title":"Progression of diabetes retinal status within community screening programs and potential implications for screening intervals","volume":"38","author":"Leese","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib517","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc10-2308","article-title":"Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy","volume":"34","author":"Agardh","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib518","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: A position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib519","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/diacare.23.8.1084","article-title":"Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group","volume":"23","author":"Diabetes Control and Complications Trial Research Group","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib520","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc20-0904","article-title":"Progression of diabetic retinopathy and predictors of its development and progression during pregnancy in patients with type 1 diabetes: A report of 499 pregnancies","volume":"44","author":"Bourry","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib521","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jdiacomp.2016.02.007","article-title":"Teenage girls with type 1 diabetes have poorer metabolic control than boys and face more complications in early adulthood","volume":"30","author":"Samuelsson","year":"2016","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib522","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0039-6257(01)00187-4","volume":"45","author":"Barr","year":"2000","journal-title":"Surv Ophthalmol. 2001"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib523","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc16-0024","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib524","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3390\/nu11071691","article-title":"Life style intervention improves retinopathy status-the Finnish Diabetes Prevention Study","volume":"11","author":"Aro","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib525","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3904\/kjim.2020.121","article-title":"Weight change and microvascular outcomes in patients with new-onset diabetes: A nationwide cohort study","volume":"36","author":"Koh","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib526","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/M17-2383","article-title":"Microvascular outcomes in patients with diabetes after bariatric surgery vs usual care: A matched cohort study","volume":"169","author":"O'Brien","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib527","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00592-019-01454-y","article-title":"Frequent physical activity is associated with reduced risk of severe diabetic retinopathy in type 1 diabetes","volume":"57","author":"Tikkanen-Dolenc","year":"2020","journal-title":"Acta diabetol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib528","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamaophthalmol.2016.2906","article-title":"Dietary marine \u03c9-3 fatty acids and incident sight-threatening retinopathy in middle-aged and older individuals with type 2 diabetes: prospective investigation from the predimed trial","volume":"134","author":"Sala-Vila","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib529","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9647","key":"10.1016\/j.eprac.2022.08.002_bib530","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-PROTECT 2): A randomised placebo-controlled trial","volume":"372","author":"Sj\u00f8lie","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib531","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9600","key":"10.1016\/j.eprac.2022.08.002_bib532","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib533","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004025","article-title":"Primary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study","volume":"3","author":"Morgan","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib534","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaophthalmol.2014.93","article-title":"Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: A randomized clinical trial","volume":"132","author":"Scott","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib535","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib536","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaophthalmol.2019.5939","article-title":"Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy","volume":"138","author":"Maguire","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib537","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation vs intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib538","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","article-title":"Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vasular endothelial growth factor therapy in daily practice","volume":"38","author":"Weiss","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib539","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/IAE.0000000000003226","article-title":"Lessons learned from pacores in proliferative diabetic retinopathy management, data from Latin America and Spain: the Asbury Lecture 2020","volume":"42","author":"Arevalo","year":"2022","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib540","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0039-6257(99)00036-3","article-title":"Vitrectomy in the management of diabetic retinopathy","volume":"43","author":"Smiddy","year":"1999","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.eprac.2022.08.002_bib541","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2015.12.025","article-title":"Five-year outcomes of ranibizumab with prompt or deferred laser vs laser or triamcinolone plus deferred ranibizumab for diabetic macular edema","volume":"164","author":"Bressler","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib542","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2337\/db19-1046","article-title":"Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) study","volume":"69","author":"Braffett","year":"2020","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib543","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2337\/dc19-1583","article-title":"The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D Exchange","volume":"43","author":"Mizokami-Stout","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib544","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc19-1582","article-title":"Diabetic neuropathy is a substantial burden in people with type 1 diabetes and is strongly associated with socioeconomic disadvantage: A population-representative study from Scotland","volume":"43","author":"Jeyam","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib545","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.2337\/dc18-1411","article-title":"Risk factors for the presence and progression of cardiovascular autonomic neuropathy in type 2 diabetes: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib546","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108235","article-title":"Prevalence of microvascular and macrovascular disease in the glycemia reduction approaches in diabetes - a comparative effectiveness (GRADE) study cohort","volume":"165","author":"Mather","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib547","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: A position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib548","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jdiacomp.2015.09.008","article-title":"High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study)","volume":"29","author":"Ziegler","year":"2015","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib549","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s001250050586","article-title":"Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications study","volume":"39","author":"Tesfaye","year":"1996","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib550","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdiacomp.2014.09.014","article-title":"A\u00a0clinical screening score for diabetic polyneuropathy: KORA F4 and AUDDIAB studies","volume":"29","author":"Bongaerts","year":"2015","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib551","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/dc17-2062","article-title":"Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib552","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/1479164116653240","article-title":"Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities","volume":"13","author":"D'Amato","year":"2016","journal-title":"Diabetes Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib553","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/acn3.531","article-title":"Diabetes and obesity are the main metabolic drivers of peripheral neuropathy","volume":"5","author":"Callaghan","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib554","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaneurol.2016.0057","article-title":"Longitudinal assessment of small fiber neuropathy: evidence of a non-length-dependent distal axonopathy","volume":"73","author":"Khoshnoodi","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.eprac.2022.08.002_bib555","series-title":"Diabetes in America","article-title":"Peripheral and autonomic neuropathy in diabetes","author":"Pop-Busui","year":"2018"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib556","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1097\/j.pain.0000000000001378","article-title":"A\u00a0cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy","volume":"159","author":"Truini","year":"2018","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib557","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2337\/ds18-0036","article-title":"Pop-Busui R Update on the management of diabetic neuropathy","volume":"31","author":"Ang","year":"2018","journal-title":"Diabetes Spectr"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib558","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-020-01259-2","article-title":"Treating pain in diabetic neuropathy: current and developmental drugs","volume":"80","author":"Alam","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib559","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/j.pain.0000000000001744","article-title":"Diabetic polyneuropathy and pain, prevalence, and patient characteristics: A cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes","volume":"161","author":"Gylfadottir","year":"2020","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib560","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1526-4637.2008.00555.x","article-title":"Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA\/KORA Augsburg surveys S2 and S3","volume":"10","author":"Ziegler","year":"2009","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib561","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","article-title":"Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms","volume":"13","author":"Jensen","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib562","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","article-title":"Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy","volume":"27","author":"O'Connor","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib563","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40271-013-0038-8","article-title":"Painful diabetic peripheral neuropathy: results of a survey characterizing the perspectives and misperceptions of patients and healthcare practitioners","volume":"7","author":"Sadosky","year":"2014","journal-title":"Patient"},{"key":"10.1016\/j.eprac.2022.08.002_bib564","article-title":"Diagnostic accuracy of monofilament tests for detecting diabetic peripheral neuropathy: A systematic review and meta-analysis","volume":"2017","author":"Wang","year":"2017","journal-title":"J\u00a0Diabetes Res"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib565","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaneurol.2014.1279","article-title":"Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy","volume":"71","author":"Callaghan","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib566","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/brain\/awab079","article-title":"Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management","volume":"144","author":"Jensen","year":"2021","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib567","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10286-018-0540-0","article-title":"Sudomotor function testing by electrochemical skin conductance: does it really measure sudomotor function?","volume":"29","author":"Rajan","year":"2019","journal-title":"Clin Auton Res"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib568","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib569","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc13-2114","article-title":"Neuropathy and related findings in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"37","author":"Martin","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib570","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib571","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jdiacomp.2015.01.011","article-title":"Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance","volume":"29","author":"Zilliox","year":"2015","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib572","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.2337\/diacare.25.11.2048","article-title":"Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy","volume":"25","author":"Bril","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib573","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1529-8027.2008.00180.x","article-title":"The Utah Early Neuropathy Scale: A sensitive clinical scale for early sensory predominant neuropathy","volume":"13","author":"Singleton","year":"2008","journal-title":"J\u00a0Peripher Nerv Syst JPNS"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib574","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00400697","article-title":"A\u00a0multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population","volume":"36","author":"Young","year":"1993","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib575","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: A report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton","year":"2008","journal-title":"Diabetes Care"},{"issue":"9498","key":"10.1016\/j.eprac.2022.08.002_bib576","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0140-6736(05)67698-2","article-title":"The global burden of diabetic foot disease","volume":"366","author":"Boulton","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eprac.2022.08.002_bib577","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"57","key":"10.1016\/j.eprac.2022.08.002_bib578","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19570","article-title":"A\u00a0systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS)","volume":"19","author":"Crawford","year":"2015","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib579","first-page":"452","volume":"64","author":"Miller","year":"2015","journal-title":"Erratum. J Fam Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib580","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/1573399814666181017104818","article-title":"A\u00a0tale of two eras: mining big data from electronic health records to determine limb salvage rates with podiatry","volume":"15","author":"Schmidt","year":"2019","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib581","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdiacomp.2005.07.005","article-title":"Exercise training can modify the natural history of diabetic peripheral neuropathy","volume":"20","author":"Balducci","year":"2006","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib582","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jdiacomp.2012.05.007","article-title":"The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy","volume":"26","author":"Kluding","year":"2012","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib583","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40279-014-0207-5","article-title":"Exercise intervention studies in patients with peripheral neuropathy: A systematic review","volume":"44","author":"Streckmann","year":"2014","journal-title":"Sports Med (Auckland NZ)"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib584","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/acn3.125","article-title":"Exercise increases cutaneous nerve density in diabetic patients without neuropathy","volume":"1","author":"Singleton","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib585","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"29","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib586","first-page":"475","article-title":"A\u00a0randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy","volume":"14","author":"Otis","year":"2013","journal-title":"J\u00a0Pain"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib587","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s11695-019-04004-1","article-title":"The effect of bariatric surgery on peripheral polyneuropathy: A systematic review and meta-analysis","volume":"29","author":"Aghili","year":"2019","journal-title":"Obes Surg"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib588","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib589","first-page":"CD007076","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib590","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/AJP.0000000000000198","article-title":"Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking","volume":"31","author":"Huffman","year":"2015","journal-title":"Clin J Pain"},{"key":"10.1016\/j.eprac.2022.08.002_bib591","article-title":"Clinical trial assessing the efficacy of gabapentin plus B complex (b1\/b12) vs pregabalin for treating painful diabetic neuropathy","volume":"2016","author":"Mimenza Alvarado","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib592","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/03007995.2016.1151776","article-title":"The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy","volume":"32","author":"Parsons","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib593","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/AJP.0000000000000254","article-title":"Pregabalin in patients with painful diabetic peripheral neuropathy using an NSAID for other pain conditions: A double-blind crossover study","volume":"32","author":"Raskin","year":"2016","journal-title":"Clin J Pain"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib594","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.dsx.2016.07.003","article-title":"A study on comparative efficacy and cost effectiveness of pregabalin and duloxetine used in diabetic neuropathic pain","volume":"11","author":"Roy","year":"2017","journal-title":"Diabetes Metab Syndr"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib595","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2013a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib596","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/00325481.2017.1384691","article-title":"Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia","volume":"129","author":"Arnold","year":"2017","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib597","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MJT.0000000000000100","article-title":"Examining the time to improvement of sleep interference with pregabalin in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia","volume":"22","author":"Parsons","year":"2015","journal-title":"Am J Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib598","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/papr.12469","article-title":"Does duration of neuropathic pain impact the effectiveness of pregabalin?","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"Pain Pract Off J World Inst Pain"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib599","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jdi.12361","article-title":"Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study","volume":"7","author":"Yasuda","year":"2016","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.eprac.2022.08.002_bib600","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2147\/DDDT.S185995","article-title":"A\u00a0comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy","volume":"13","author":"Majdinasab","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib601","first-page":"42","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy: A randomized, double-blind, placebo-controlled study","volume":"18","author":"Simpson","year":"2017","journal-title":"J\u00a0Pain"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib602","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12883-016-0752-7","article-title":"Capsaicin 8% patch repeat treatment plus standard of care (SOC) vs SOC alone in painful diabetic peripheral neuropathy: A randomised, 52-week, open-label, safety study","volume":"16","author":"Vinik","year":"2016","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib604","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2337\/dc13-2291","article-title":"A\u00a0randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib605","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib606","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jamaneurol.2021.0538","article-title":"Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: A randomized clinical trial","volume":"78","author":"Petersen","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib607","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2337\/dc21-1813","article-title":"Durability of high-frequency 10-kHz spinal cord stimulation for patients with painful diabetic neuropathy refractory to conventional treatments: 12-month results from a randomized controlled trial","volume":"45","author":"Petersen","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib608","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1932296821997921","article-title":"The impact of diabetic neuropathy on activities of\u00a0daily\u00a0living, postural balance and risk of falls - a systematic review","volume":"1932296821997921","author":"Khan","year":"2022","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib609","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/jdi.13542","article-title":"Falls and fractures associated with type 2 diabetic polyneuropathy: A cross-sectional nationwide questionnaire study","volume":"12","author":"Khan","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib610","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00125-019-04979-7","article-title":"Short-term strength and balance training does not improve quality of life but improves functional status in individuals with diabetic peripheral neuropathy: A randomised controlled trial","volume":"62","author":"Venkataraman","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib611","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc20-1842","article-title":"Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD trial","volume":"44","author":"Tang","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib612","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc15-0081","article-title":"Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed type 2 Diabetes Study (VNDS)","volume":"38","author":"Zoppini","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib613","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/ATVBAHA.120.314102","article-title":"Type 2 diabetes mellitus is independently associated with decreased neural baroreflex sensitivity: the Paris Prospective Study III","volume":"40","author":"Cseh","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.eprac.2022.08.002_bib614","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2020.102646","article-title":"Cardiovascular autonomic neuropathy: A silent killer with long reach","volume":"225","author":"Ang","year":"2020","journal-title":"Auton Neurosci Basic Clin"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib615","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/pedi.12633","article-title":"Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth cohort study","volume":"19","author":"Jaiswal","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib616","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00125-015-3534-7","article-title":"Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey","volume":"58","author":"Ziegler","year":"2015","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib617","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib618","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2012.10.028","article-title":"Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT\/EDIC study (diabetes control and complications trial\/epidemiology of diabetes interventions and complications)","volume":"61","author":"Pop-Busui","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib619","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.jacc.2004.09.033","article-title":"Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction","volume":"44","author":"Pop-Busui","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib620","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2337\/dc16-1397","article-title":"Cardiovascular autonomic neuropathy and cardiovascular outcomes in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) study","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib621","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jcmg.2010.09.014","article-title":"Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes","volume":"3","author":"Sacre","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib622","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jdiacomp.2016.03.008","article-title":"Cardiovascular autonomic neuropathy associates with nephropathy lesions in American Indians with type 2 diabetes","volume":"30","author":"Wheelock","year":"2016","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib623","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1210\/jc.2018-02729","article-title":"Association of cardiovascular autonomic dysfunction with peripheral arterial stiffness in patients with type 1 diabetes","volume":"104","author":"Nattero-Ch\u00e1vez","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib624","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-018-0683-2","article-title":"Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: A preliminary report","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib625","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2215\/CJN.11441114","article-title":"Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes","volume":"10","author":"Orlov","year":"2015","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib626","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","article-title":"Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management","volume":"27","author":"Spallone","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib627","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdi.13635","article-title":"Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients","volume":"13","author":"Pop-Busui","year":"2022","journal-title":"J\u00a0Diabetes Investig"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib628","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the\u00a0Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib629","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/dc16-2426","article-title":"Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial","volume":"40","author":"Lachin","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib630","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib631","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/diacare.29.04.06.dc05-1729","article-title":"The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program","volume":"29","author":"Carnethon","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib632","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"Diabetic neuropathies: A statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib633","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1212\/01.WNL.0000149522.32823.EA","article-title":"Distal symmetric polyneuropathy: A definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation","volume":"64","author":"England","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib634","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.2337\/dc06-0525","article-title":"Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes","volume":"29","author":"Dyck","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib635","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib636","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ana.21952","article-title":"Treatment-induced diabetic neuropathy: A reversible painful autonomic neuropathy","volume":"67","author":"Gibbons","year":"2010","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib637","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/dmrr.1225","article-title":"Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management","volume":"27","author":"Tesfaye","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib638","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/met.2005.3.113","article-title":"Small fiber neuropathy is associated with the metabolic syndrome","volume":"3","author":"Pittenger","year":"2005","journal-title":"Metab Syndr Relat Disord"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib639","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/diacare.24.8.1448","article-title":"Bromberg MB Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy","volume":"24","author":"Singleton","year":"2001","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib640","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mus.1136","article-title":"Painful sensory polyneuropathy associated with impaired glucose tolerance","volume":"24","author":"Singleton","year":"2001","journal-title":"Muscle Nerve"},{"issue":"10157","key":"10.1016\/j.eprac.2022.08.002_bib641","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.eprac.2022.08.002_bib642","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib643","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib644","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib645","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib646","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib647","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","article-title":"Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America","volume":"25","author":"Dunlay","year":"2019","journal-title":"J\u00a0Card Fail"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib648","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib649","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib650","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"10254","key":"10.1016\/j.eprac.2022.08.002_bib651","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib652","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib653","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib654","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.2147\/IJGM.S327075","article-title":"Stroke risk factors in United States: an analysis of the 2013-2018 National Health and Nutrition Examination Survey","volume":"14","author":"Ren","year":"2021","journal-title":"Int J Gen Med"},{"issue":"10138","key":"10.1016\/j.eprac.2022.08.002_bib655","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(18)30314-3","article-title":"Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data","volume":"391","author":"Gregg","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib656","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4239\/wjd.v7.i18.449","article-title":"Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: evidence on health outcomes and antidiabetic treatment in United States adults","volume":"7","author":"Liu","year":"2016","journal-title":"World J Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib657","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/dc17-1091","article-title":"Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial","volume":"40","author":"Sharma","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib658","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.685821","article-title":"Admission and readmission\/death patterns in hospitalized and non-hospitalized first-ever-in-a-lifetime stroke patients during the first year: A population-based incidence study","volume":"12","author":"Abreu","year":"2021","journal-title":"Front Neurol"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib659","article-title":"Diabetes mellitus is associated with poor in-hospital and long-term outcomes in young and midlife stroke survivors","volume":"10","author":"MacIntosh","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.eprac.2022.08.002_bib660","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjcard.2021.05.043","article-title":"Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus","volume":"154","author":"Grewal","year":"2021","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib661","first-page":"2117","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: A systematic review and meta-analysis","volume":"267","author":"Malhotra","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib662","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9493","key":"10.1016\/j.eprac.2022.08.002_bib663","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib664","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib665","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaneurol.2019.0079","article-title":"Pioglitazone therapy in patients with stroke and prediabetes: A post hoc analysis of the IRIS randomized clinical trial","volume":"76","author":"Spence","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib666","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib667","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib668","first-page":"1346","volume":"25","author":"Mechanick","year":"2019","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib669","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20120223","article-title":"Proietto J The defence of body weight: A physiological basis for weight regain after weight loss","volume":"124","author":"Sumithran","year":"2013","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib670","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Garvey WT Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib671","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/ATVBAHA.111.241885","article-title":"Insulin resistance and coronary heart disease in nondiabetic individuals","volume":"32","author":"Reaven","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib672","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4158\/EP161688.PS","article-title":"Garvey WT Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib673","first-page":"131","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes\u00a0Facts"},{"issue":"suppl 3","key":"10.1016\/j.eprac.2022.08.002_bib674","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib675","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4158\/EP14280.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease","volume":"20","author":"Garvey","year":"2014","journal-title":"Endocr Pract"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib676","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib677","first-page":"83","article-title":"Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults\u2013study on optimal cut-off points of body mass index and waist circumference in Chinese adults","volume":"15","author":"Zhou","year":"2002","journal-title":"Biomed Environ Sci"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib678","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib679","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition therapy for adults with diabetes or prediabetes: A consensus report","volume":"42","author":"Evert","year":"2019","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib680","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","article-title":"A\u00a0randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study","volume":"169","author":"Foster","year":"2009","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib681","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5665\/sleep.2618","article-title":"Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes","volume":"36","author":"Kuna","year":"2013","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib682","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults","volume":"35","author":"Winslow","year":"2012","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib683","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib684","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11695-007-9086-2","article-title":"Resolution of nonalcoholic steatohepatits after gastric bypass surgery","volume":"17","author":"Liu","year":"2007","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib685","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1572-0241.2006.00419.x","article-title":"Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery","volume":"101","author":"Barker","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib686","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib687","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/dom.12430","article-title":"Effectiveness of lifestyle-based weight loss interventions for adults with type 2 diabetes: A systematic review and meta-analysis","volume":"17","author":"Terranova","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib688","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib689","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/oby.2008.637","article-title":"One-year weight losses in the Look AHEAD study: factors associated with success","volume":"17","author":"Wadden","year":"2009","journal-title":"Obesity (Silver Spring)"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib690","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look ahead trial","volume":"170","author":"Wing","year":"2010","journal-title":"Arch Intern Med"},{"issue":"10120","key":"10.1016\/j.eprac.2022.08.002_bib691","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib692","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DIRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib693","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.diabres.2010.04.019","article-title":"Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review","volume":"89","author":"Esposito","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib694","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa0708681","article-title":"Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet","volume":"359","author":"Shai","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib695","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/0003-4819-151-5-200909010-00004","article-title":"Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: A randomized trial","volume":"151","author":"Esposito","year":"2009","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib696","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1464-5491.2009.02798.x","article-title":"Adherence to a Mediterranean diet and glycaemic control in type 2 diabetes mellitus","volume":"26","author":"Esposito","year":"2009","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib697","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1463-1326.2009.01151.x","article-title":"A\u00a0low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: A 1-year prospective randomized intervention study","volume":"12","author":"Elhayany","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib698","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10654-018-0427-3","article-title":"Evaluating Mediterranean diet and risk of chronic disease in cohort studies: an umbrella review of meta-analyses","volume":"33","author":"Galbete","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib699","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ejcn.2014.243","article-title":"Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: A meta-analysis","volume":"69","author":"Huo","year":"2015","journal-title":"Eur J Clin Nutr"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib700","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.numecd.2010.03.005","article-title":"Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study","volume":"21","author":"Itsiopoulos","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib701","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/nu10101361","article-title":"Relevance of the glycemic index and glycemic load for body weight, diabetes, and cardiovascular disease","volume":"10","author":"Vega-L\u00f3pez","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib702","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/dc08-0687","article-title":"One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes","volume":"32","author":"Brehm","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib703","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc08-2108","article-title":"Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet vs a low-fat diet on weight and glycemic control in type 2 diabetes","volume":"32","author":"Davis","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib704","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jama.2018.0245","article-title":"Effect of low-fat vs low-carbohydrate diet on 12-month rweight loss in overweight adults and the association with genotype pattern or insulin secretion: the dietfits randomized clinical trial","volume":"319","author":"Gardner","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib705","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41387-017-0006-9","article-title":"Twelve-month outcomes of a randomized trial of a moderate-carbohydrate vs very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes","volume":"7","author":"Saslow","year":"2017","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.eprac.2022.08.002_bib706","first-page":"m4743","article-title":"Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data","volume":"372","author":"Goldenberg","year":"2021","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.eprac.2022.08.002_bib707","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.diabres.2018.02.026","article-title":"Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis","volume":"139","author":"Sainsbury","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib708","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/nqy096","article-title":"Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: A systematic review including grade assessments","volume":"108","author":"van Zuuren","year":"2018","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib709","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000354","article-title":"Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes","volume":"5","author":"Snorgaard","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib710","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-012-2567-4","article-title":"In type 2 diabetes, randomisation to advice to follow a low-carbohydrate diet transiently improves glycaemic control compared with advice to follow a low-fat diet producing a similar weight loss","volume":"55","author":"Guldbrand","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib711","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/dom.13164","article-title":"Effects of an energy-restricted low-carbohydrate, high unsaturated fat\/low saturated fat diet vs a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial","volume":"20","author":"Tay","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib712","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/dom.12191","article-title":"Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes","volume":"16","author":"Mayer","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2022.08.002_bib713","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.687658","article-title":"Low carbohydrate dietary approaches for people with type 2 diabetes-a narrative review","volume":"8","author":"Wheatley","year":"2021","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib714","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nut.2014.06.011","article-title":"Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base","volume":"31","author":"Feinman","year":"2015","journal-title":"Nutrition"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib715","first-page":"60","article-title":"Long-term low-carbohydrate diets and type 2 diabetes risk: A systematic review and meta-analysis of observational studies","volume":"17","author":"Noto","year":"2016","journal-title":"J\u00a0Gen Fam Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib716","doi-asserted-by":"crossref","first-page":"1588s","DOI":"10.3945\/ajcn.2009.26736H","article-title":"A\u00a0low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: A randomized, controlled, 74-wk clinical trial","volume":"89","author":"Barnard","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib717","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1753-4887.2009.00198.x","article-title":"Vegetarian and vegan diets in type 2 diabetes management","volume":"67","author":"Barnard","year":"2009","journal-title":"Nutr Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib718","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/pmed.1999.0529","article-title":"Toward improved management of\u00a0NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet","volume":"29","author":"Nicholson","year":"1999","journal-title":"Prev Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib719","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcjd.2016.02.011","article-title":"A comprehensive review of the literature supporting recommendations from the Canadian Diabetes Association for the use of a plant-based diet for management of type 2 diabetes","volume":"40","author":"Rinaldi","year":"2016","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib720","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/ds16-0057","article-title":"Vegetarian diets in the prevention and management of diabetes and its complications","volume":"30","author":"Pawlak","year":"2017","journal-title":"Diabetes Spectr"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib721","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/dc10-0676","article-title":"Effects of the dietary approaches to stop hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: A randomized crossover clinical trial","volume":"34","author":"Azadbakht","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib722","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jch.12597","article-title":"Effects of the DASH diet and walking on blood pressure in patients with type 2 diabetes and uncontrolled hypertension: A randomized controlled trial","volume":"17","author":"Paula","year":"2015","journal-title":"J\u00a0Clin Hypertens (Greenwich Conn)"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib723","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jand.2017.08.024","article-title":"Diet quality as assessed by the healthy eating index, alternate healthy eating index, Dietary Approaches to Stop Hypertension score, and health outcomes: an updated systematic review and meta-analysis of cohort studies","volume":"118","author":"Schwingshackl","year":"2018","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib724","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil\u00a0or\u00a0nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib725","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/dc18-0836","article-title":"Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the predimed-plus trial","volume":"42","author":"Salas-Salvad\u00f3","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib726","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib727","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.2337\/dc10-9990","article-title":"Exercise and type 2 diabetes","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib728","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib729","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib730","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1001\/jama.2012.67929","article-title":"Association of an intensive lifestyle intervention with remission of type 2 diabetes","volume":"308","author":"Gregg","year":"2012","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib731","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa1110294","article-title":"Lifestyle change and mobility in obese adults with type 2 diabetes","volume":"366","author":"Rejeski","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib732","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/dc13-1928","article-title":"Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD trial","volume":"37","author":"Rubin","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib733","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","article-title":"Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib734","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib735","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib736","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","article-title":"The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: A randomized, placebo-controlled trial","volume":"4","author":"Hanefeld","year":"2002","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib737","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib738","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib739","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.ijo.0802925","article-title":"Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland","volume":"29","author":"Ruof","year":"2005","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib740","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib741","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10278","key":"10.1016\/j.eprac.2022.08.002_bib742","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib743","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate vs phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib744","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib745","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1467-789X.2004.00125.x","article-title":"A\u00a0systematic review of the clinical effectiveness of orlistat used for the management of obesity","volume":"5","author":"O'Meara","year":"2004","journal-title":"Obes Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib746","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib747","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"10.1016\/j.eprac.2022.08.002_bib748","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib749","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jdiacomp.2013.04.011","article-title":"New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)","volume":"27","author":"Henry","year":"2013","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib750","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone sr\/bupropion sr on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib751","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone sr\/bupropion sr combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"9741","key":"10.1016\/j.eprac.2022.08.002_bib752","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib753","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: A randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib754","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9701","key":"10.1016\/j.eprac.2022.08.002_bib755","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib756","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance Randomized Study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib757","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib758","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib759","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib760","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib761","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib762","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2337\/diacare.10.5.563","article-title":"Type ii diabetic subjects lose less weight than their overweight nondiabetic spouses","volume":"10","author":"Wing","year":"1987","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib763","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib764","first-page":"395","article-title":"Weight gain as an adverse effect of some commonly prescribed drugs: A systematic review","volume":"100","author":"Leslie","year":"2007","journal-title":"QJM Mon J Assoc Phys"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib765","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy vs metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib766","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib767","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3810\/pgm.2013.05.2660","article-title":"Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the duration trials","volume":"125","author":"Grimm","year":"2013","journal-title":"Postgrad Med"},{"issue":"9662","key":"10.1016\/j.eprac.2022.08.002_bib768","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide vs glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib769","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GETGOAL-MONO)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib770","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide vs exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib771","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib772","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10192","key":"10.1016\/j.eprac.2022.08.002_bib773","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide vs subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): A randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib774","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib775","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib776","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib777","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery vs intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.eprac.2022.08.002_bib778","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sj\u00f6str\u00f6m","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib779","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sj\u00f6str\u00f6m","year":"2012","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib780","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib781","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.soard.2016.01.016","article-title":"Three-year follow-up comparing metabolic surgery vs medical weight management in patients with type 2 diabetes and bmi 30-35. The role of sRAGE biomarker as predictor of satisfactory outcomes","volume":"12","author":"Horwitz","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib782","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jama.2017.21055","article-title":"Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities","volume":"319","author":"Jakobsen","year":"2018","journal-title":"JAMA"},{"issue":"10271","key":"10.1016\/j.eprac.2022.08.002_bib783","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery vs conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib784","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/clinem\/dgaa006","article-title":"Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial","volume":"105","author":"Courcoulas","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib785","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa2002449","article-title":"Life expectancy after bariatric surgery in the Swedish obese subjects study","volume":"383","author":"Carlsson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib786","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib787","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1381\/0960892055002202","article-title":"Bioenterics intragastric balloon: the Italian experience with 2,515 patients","volume":"15","author":"Genco","year":"2005","journal-title":"Obes Surg"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib788","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.soard.2014.12.006","article-title":"The REDUCE pivotal trial: A prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity","volume":"11","author":"Ponce","year":"2015","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib789","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.soard.2014.03.005","article-title":"Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study","volume":"10","author":"Marinos","year":"2014","journal-title":"Surg Obes Relat Dis"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib790","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s11695-017-3096-5","article-title":"Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European Registry Study","volume":"28","author":"Nystr\u00f6m","year":"2018","journal-title":"Obes Surg"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib792","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/dc16-0383","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study","volume":"39","author":"Rajagopalan","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib793","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gutjnl-2019-318349","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study","volume":"69","author":"van Baar","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib794","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000487078","article-title":"Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes","volume":"36","author":"Hadefi","year":"2018","journal-title":"Dig Dis (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib795","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/obr.12815","article-title":"Treatment of obesity in older persons-a systematic review","volume":"20","author":"Haywood","year":"2019","journal-title":"Obes Rev Off J Int Assoc Study Obes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib796","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4158\/EP-2017-0072","article-title":"Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery vs medical therapy at 5 years","volume":"24","author":"Crawford","year":"2018","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib797","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract."},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib798","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1210\/jc.2008-0481","article-title":"The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss","volume":"93","author":"Fleischer","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib799","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00198-013-2463-x","article-title":"Fracture risk following bariatric surgery: A population-based study","volume":"25","author":"Nakamura","year":"2014","journal-title":"Osteoporos Int J Established Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"10.1016\/j.eprac.2022.08.002_bib800","first-page":"e5085","article-title":"Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study","volume":"345","author":"Lalmohamed","year":"2012","journal-title":"BMJ (Clin Res Ed)"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib801","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jdiacomp.2017.02.012","article-title":"Updated risk factors should be used to predict development of diabetes","volume":"31","author":"Bethel","year":"2017","journal-title":"J\u00a0Diabetes Its Complications"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib802","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.285.16.2109","article-title":"Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study","volume":"285","author":"de Vegt","year":"2001","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib803","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib804","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwf145","article-title":"Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study","volume":"156","author":"Laaksonen","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib805","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP.14.7.933","article-title":"Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists","volume":"14","author":"Garber","year":"2008","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib806","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/oby.20585","article-title":"The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity","volume":"22","author":"Guo","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eprac.2022.08.002_bib807","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib808","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052036","article-title":"Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis","volume":"7","author":"Gast","year":"2012","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib809","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jacc.2019.11.046","article-title":"Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib810","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","article-title":"Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?","volume":"263","author":"Haffner","year":"1990","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib811","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib812","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1741826711421687","article-title":"Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials","volume":"18","author":"Hopper","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib813","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3390\/nu11061373","article-title":"Comparison of the effectiveness of lifestyle modification with other treatments on the incidence of type 2 diabetes in people at high risk: A network meta-analysis","volume":"11","author":"Yamaoka","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib814","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dc10-1288","article-title":"Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the predimed-reus nutrition intervention randomized trial","volume":"34","author":"Salas-Salvad\u00f3","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-1725","article-title":"Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial","volume":"160","author":"Salas-Salvad\u00f3","year":"2014","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib816","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.clnu.2014.09.005","article-title":"Diabetes mellitus and abnormal glucose tolerance development after gestational diabetes: A three-year, prospective, randomized, clinical-based, Mediterranean lifestyle interventional study with parallel groups","volume":"34","author":"P\u00e9rez-Ferre","year":"2015","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib817","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.159.3.285","article-title":"Effects of dietary patterns on blood pressure: subgroup analysis of the dietary approaches to stop hypertension (DASH) randomized clinical trial","volume":"159","author":"Svetkey","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib818","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. Dash-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib819","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/dc09-0228","article-title":"Adherence to the DASH diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study","volume":"32","author":"Liese","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib820","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/aje\/kwv268","article-title":"Dietary protein intake and risk of type 2 diabetes in US men and women","volume":"183","author":"Malik","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib821","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0264-4","article-title":"Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies","volume":"47","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib822","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","article-title":"Effect of weight loss with lifestyle intervention on risk of diabetes","volume":"29","author":"Hamman","year":"2006","journal-title":"Diabetes Care"},{"issue":"9702","key":"10.1016\/j.eprac.2022.08.002_bib823","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study Diabetes prevention program research","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib824","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib825","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/diabetes.54.1.158","article-title":"Physical activity in the prevention\u00a0of type 2 diabetes: the Finnish diabetes prevention study","volume":"54","author":"Laaksonen","year":"2005","journal-title":"Diabetes"},{"issue":"9548","key":"10.1016\/j.eprac.2022.08.002_bib826","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study","volume":"368","author":"Lindstr\u00f6m","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib827","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib828","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention study: A 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib829","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41387-018-0022-4","article-title":"Vegetarian diet, change in dietary patterns, and diabetes risk: A prospective study","volume":"8","author":"Chiu","year":"2018","journal-title":"Nutr Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib830","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.clnu.2017.03.015","article-title":"Legume consumption is inversely associated with type 2 diabetes incidence in adults: A prospective assessment from the PREDIMED study","volume":"37","author":"Becerra-Tom\u00e1s","year":"2018","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib831","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/nu9060603","article-title":"Adherence to a vegetarian diet and diabetes risk: A systematic review and meta-analysis of observational studies","volume":"9","author":"Lee","year":"2017","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib832","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamainternmed.2019.2195","article-title":"Association between plant-based dietary patterns and risk of type 2 diabetes: A systematic review and meta-analysis","volume":"179","author":"Qian","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib833","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/nu13062123","article-title":"The impact of vegan diet in the prevention and treatment of type 2 diabetes: A systematic review","volume":"13","author":"Pollakova","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib834","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3945\/ajcn.110.004333","article-title":"Low-carbohydrate diet scores and risk of type 2 diabetes in men","volume":"93","author":"de Koning","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib835","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ejcn.2011.34","article-title":"Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: A systematic review and meta-analysis of cohort studies","volume":"65","author":"Bendsen","year":"2011","journal-title":"Eur J Clin Nutr"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib836","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1210\/jc.2004-0683","article-title":"insulin resistance, and obesity: zoning in\u00a0on\u00a0data for Atkins dieters living in South Beach","volume":"89","author":"Lara-Castro","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib837","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pcd.2015.12.004","article-title":"Consumption of citrus and cruciferous vegetables with incident type 2 diabetes mellitus based on a meta-analysis of prospective study","volume":"10","author":"Jia","year":"2016","journal-title":"Prim Care Diabetes"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib838","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00125-018-4582-6","article-title":"Fibre supplementation for the prevention of type 2 diabetes and improvement of glucose metabolism: the randomised controlled Optimal Fibre Trial (OPTIFIT)","volume":"61","author":"Honsek","year":"2018","journal-title":"Diabetologia"},{"issue":"9933","key":"10.1016\/j.eprac.2022.08.002_bib839","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0140-6736(14)60613-9","article-title":"Prevention and management of type 2 diabetes: dietary components and nutritional strategies","volume":"383","author":"Ley","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib840","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00125-014-3404-8","article-title":"A\u00a0priori-defined diet quality indexes and risk of type 2 diabetes: the multiethnic cohort","volume":"58","author":"Jacobs","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib841","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/sms.13567","article-title":"The ability of exercise to meaningfully improve glucose tolerance in people living with prediabetes: A meta-analysis","volume":"30","author":"Hrubeniuk","year":"2020","journal-title":"Scand J Med Sci Sports"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib842","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1123\/jpah.2016-0632","article-title":"Effect of physical activity intervention in prediabetes: A systematic review with meta-analysis","volume":"14","author":"Jadhav","year":"2017","journal-title":"J\u00a0Phys Act Health"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib843","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00125-016-4051-z","article-title":"Effects of exercise training alone vs a combined exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: A randomised controlled trial","volume":"59","author":"Slentz","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2022.08.002_bib844","article-title":"The effectiveness of lifestyle adaptation for the prevention of prediabetes in adults: A systematic review","volume":"2017","author":"Kerrison","year":"2017","journal-title":"J\u00a0Diabetes Res"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib845","article-title":"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","volume":"12","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib846","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2337\/dc06-1842","article-title":"Physical activity of moderate intensity and risk of type 2 diabetes: A systematic review","volume":"30","author":"Jeon","year":"2007","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib847","doi-asserted-by":"crossref","first-page":"e3143","DOI":"10.1002\/dmrr.3143","article-title":"Two-year-supervised resistance training prevented diabetes incidence in people with prediabetes: A randomised control trial","volume":"35","author":"Dai","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib848","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172610","article-title":"Resist diabetes: A randomized clinical trial for resistance training maintenance in adults with prediabetes","volume":"12","author":"Davy","year":"2017","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib849","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11531380-000000000-00000","article-title":"Resistance training in the treatment of the metabolic syndrome: A systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism","volume":"40","author":"Strasser","year":"2010","journal-title":"Sports Med (Auckland NZ)"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib850","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-147-6-200709180-00005","article-title":"Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: A randomized trial","volume":"147","author":"Sigal","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib851","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5868-11-2","article-title":"Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: A systematic review with meta-analysis","volume":"11","author":"Aguiar","year":"2014","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"25B","key":"10.1016\/j.eprac.2022.08.002_bib852","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib853","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2337\/dc10-1548","article-title":"Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib854","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.diabres.2017.12.017","article-title":"High-intensity interval training vs continuous training on physiological and metabolic variables in prediabetes and type 2 diabetes: A meta-analysis","volume":"137","author":"De Nardi","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib855","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.282.15.1433","article-title":"Walking compared with vigorous physical activity and risk of type 2 diabetes in women: A prospective study","volume":"282","author":"Hu","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib856","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1249\/MSS.0000000000001248","article-title":"Replacement effects of sedentary time on metabolic outcomes: The Maastricht study","volume":"49","author":"Van Der Berg","year":"2017","journal-title":"Med\u00a0Sci Sports Exerc"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib857","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40279-019-01183-w","article-title":"Effects of interrupting prolonged sitting with physical activity breaks on blood glucose, insulin and triacylglycerol measures: A systematic review and meta-analysis","volume":"50","author":"Loh","year":"2020","journal-title":"Sports Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib858","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014267","article-title":"Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: A cross-sectional analysis of adults at risk of type 2 diabetes","volume":"7","author":"Edwardson","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib859","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1249\/MSS.0000000000001218","article-title":"Change in sedentary time, physical activity, bodyweight, and HbA1c in high-risk adults","volume":"49","author":"McCarthy","year":"2017","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib860","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2337\/dc18-2270","article-title":"The effect of liquid meal replacements on cardiometabolic risk factors in overweight\/obese individuals with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Noronha","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib861","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12875-015-0394-7","article-title":"Effects of a lifestyle program in subjects with impaired fasting glucose, a pragmatic cluster-randomized controlled trial","volume":"16","author":"Hesselink","year":"2015","journal-title":"BMC Fam Pract"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib862","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.2196\/jmir.4709","article-title":"The effect of technology-mediated diabetes prevention interventions on weight: A meta-analysis","volume":"19","author":"Bian","year":"2017","journal-title":"J\u00a0Med Internet Res"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib863","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.4897","article-title":"Diabetes prevention and weight loss with a fully automated behavioral intervention by email, web, and mobile Phone: A randomized controlled trial among persons with prediabetes","volume":"17","author":"Block","year":"2015","journal-title":"J\u00a0Med Internet Res"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib864","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2337\/dc19-0295","article-title":"Long-term weight loss maintenance in the continuation of a randomized diabetes prevention translational study: the healthy living partnerships to prevent diabetes (HELP PD) continuation trial","volume":"42","author":"Vitolins","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002095","article-title":"Cardiometabolic risk factor changes observed in diabetes prevention programs in US settings: A systematic review and meta-analysis","volume":"13","author":"Mudaliar","year":"2016","journal-title":"PLOS Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib866","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2337\/dc17-2222","article-title":"Global diabetes prevention interventions: A systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose","volume":"41","author":"Galaviz","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib867","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1139\/apnm-2016-0456","article-title":"Efficacy of a randomized trial examining commercial weight loss programs and exercise on metabolic syndrome in overweight and obese women","volume":"42","author":"Baetge","year":"2017","journal-title":"Appl Physiol Nutr Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib868","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00592-018-1249-1","article-title":"Dietary changes in a diabetes prevention intervention among people with prediabetes: the Diabetes Community Lifestyle Improvement Program trial","volume":"56","author":"Ford","year":"2019","journal-title":"Acta diabetol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib869","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0145721718759982","article-title":"Evaluation of a diabetes prevention program lifestyle intervention in older adults: A randomized controlled study in three senior\/community centers of varying socioeconomic status","volume":"44","author":"Kramer","year":"2018","journal-title":"Diabetes Educ"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib870","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib871","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1112082","article-title":"Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects","volume":"367","author":"Carlsson","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib872","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-8587(14)70214-1","article-title":"Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study","volume":"2","author":"Booth","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10077","key":"10.1016\/j.eprac.2022.08.002_bib873","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide vs placebo for\u00a0type\u00a02 diabetes risk reduction and weight management in individuals with\u00a0prediabetes: A randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib874","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Sj\u00f6str\u00f6m L Xenical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib875","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7570\/jomes.2019.28.3.158","article-title":"The role of anti-obesity medication in prevention of diabetes and its complications","volume":"28","author":"Oh","year":"2019","journal-title":"J\u00a0Obes Metab Syndr"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib876","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/dom.12632","article-title":"Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the scale and phase II randomized trials","volume":"18","author":"Ard","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib877","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.orcp.2014.09.003","article-title":"Effects of weight regain following intentional weight loss on glucoregulatory function in overweight and obese adults with pre-diabetes","volume":"9","author":"Beavers","year":"2015","journal-title":"Obes Res Clin Pract"},{"issue":"360","key":"10.1016\/j.eprac.2022.08.002_bib878","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib879","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.4260","article-title":"Prevalence of the metabolic syndrome in the United States, 2003-2012","volume":"313","author":"Aguilar","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib880","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/archinte.167.10.1068","article-title":"Prediction of incident diabetes mellitus in middle-aged adults: the Framingham offspring study","volume":"167","author":"Wilson","year":"2007","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib881","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-151-11-200912010-00005","article-title":"Development and validation of a patient self-assessment score for diabetes risk","volume":"151","author":"Bang","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib882","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003232","article-title":"Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study","volume":"17","author":"Wilkinson","year":"2020","journal-title":"PLOS Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib883","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/jc.2015-2691","article-title":"Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes","volume":"100","author":"Guo","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib884","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2337\/dc18-1079","article-title":"Use of a metabolic syndrome severity Z score to track risk during treatment of prediabetes: an analysis of the diabetes prevention program","volume":"41","author":"DeBoer","year":"2018","journal-title":"Diabetes Care"},{"issue":"44","key":"10.1016\/j.eprac.2022.08.002_bib885","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001935","article-title":"Cardiometabolic risk profiles in patients with impaired fasting glucose and\/or hemoglobin A1c 5.7%\u00a0to 6.4%: evidence for a gradient according to diagnostic criteria: the predaps study","volume":"94","author":"Gir\u00e1ldez-Garc\u00eda","year":"2015","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib886","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9149(76)90061-8","article-title":"A\u00a0general cardiovascular risk profile: the Framingham study","volume":"38","author":"Kannel","year":"1976","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib887","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2337\/dc17-0088","article-title":"Cardiometabolic disease staging predicts effectiveness of\u00a0weight-loss therapy to prevent type 2 diabetes: pooled results from phase\u00a0III clinical trials assessing phentermine\/topiramate extended release","volume":"40","author":"Guo","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib888","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.diabres.2015.01.027","article-title":"Preventing the progression to type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions","volume":"107","author":"Stevens","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib889","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2337\/dc18-1970","article-title":"Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib890","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154054","article-title":"The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial","volume":"104","author":"Guardado-Mendoza","year":"2020","journal-title":"Metabolism"},{"issue":"9323","key":"10.1016\/j.eprac.2022.08.002_bib891","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib892","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the stop-niddm trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib893","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2015.05.504","article-title":"Acarbose monotherapy and type 2 diabetes prevention in eastern and western prediabetes: an ethnicity-specific meta-analysis","volume":"37","author":"Hu","year":"2015","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib894","article-title":"Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","volume":"12","author":"Moelands","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib895","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib896","article-title":"Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus","volume":"11","author":"Ipsen","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib897","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2337\/dc18-1970","article-title":"Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"9735","key":"10.1016\/j.eprac.2022.08.002_bib898","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(10)60746-5","article-title":"Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study","volume":"376","author":"Zinman","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib899","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2337\/dc15-0730","article-title":"Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics","volume":"38","author":"Powers","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib900","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jand.2018.03.007","article-title":"Academy of Nutrition and Dietetics: Revised 2017 standards of practice and standards of professional performance for registered dietitian nutritionists (competent, proficient, and expert) in diabetes care","volume":"118","author":"Davidson","year":"2018","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib901","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jand.2017.03.022","article-title":"Academy of Nutrition and Dietetics nutrition practice guideline for type 1 and type 2 diabetes in adults: systematic review of evidence for medical nutrition therapy effectiveness and recommendations for integration into the nutrition care process","volume":"117","author":"Franz","year":"2017","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib902","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3945\/ajcn.116.139626","article-title":"A systematic review and meta-analysis of nutrition therapy compared with dietary advice in patients with type 2 diabetes","volume":"106","author":"M\u00f8ller","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib903","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.jand.2014.07.020","article-title":"The effect of medical nutrition therapy by a registered dietitian nutritionist in patients with prediabetes participating in a randomized controlled clinical research trial","volume":"114","author":"Parker","year":"2014","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib904","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1139\/h2012-025","article-title":"Dietitian-coached management in combination with annual endocrinologist follow up improves global metabolic and cardiovascular health in diabetic participants after 24 months","volume":"37","author":"Battista","year":"2012","journal-title":"Appl Physiol Nutr Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib905","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jand.2017.11.021","article-title":"Position of the academy of nutrition and dietetics: the role of medical nutrition therapy and registered dietitian nutritionists in the prevention and treatment of prediabetes and type 2 diabetes","volume":"118","author":"Briggs Early","year":"2018","journal-title":"J\u00a0Acad Nutr Diet"},{"key":"10.1016\/j.eprac.2022.08.002_bib906","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.5888\/pcd11.130349","article-title":"A\u00a0self-management intervention for African Americans with comorbid diabetes and hypertension: A pilot randomized controlled trial","volume":"11","author":"Lynch","year":"2014","journal-title":"Prev Chronic Dis"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib907","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2337\/dci17-0025","article-title":"2017 national standards for diabetes self-management education and support","volume":"40","author":"Beck","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib908","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005317","article-title":"Effects of the first line diabetes care (FiLDCare) self-management education and support project on knowledge, attitudes, perceptions, self-management practices and glycaemic control: A quasi-experimental study conducted in the Northern Philippines","volume":"4","author":"Ku","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib909","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.pec.2015.11.003","article-title":"Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control","volume":"99","author":"Chrvala","year":"2016","journal-title":"Patient Educ Couns. patient ed"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib910","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pcd.2019.05.001","article-title":"The health effects of medical nutrition therapy by dietitians in patients with diabetes: A systematic review and meta-analysis: nutrition therapy and diabetes","volume":"13","author":"Razaz","year":"2019","journal-title":"Prim Care Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib911","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ejcn.2015.205","article-title":"The effect of dietary counselling on food intakes in pregnant women at risk for gestational diabetes: A secondary analysis of a randomised controlled trial RADIEL","volume":"70","author":"Valkama","year":"2016","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib912","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0145721715584404","article-title":"Does diabetes self-management education\u00a0in conjunction with primary care improve glycemic control in Hispanic patients? A systematic review and meta-analysis","volume":"41","author":"Ferguson","year":"2015","journal-title":"Diabetes Educ"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib913","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0002-8223(95)00277-4","article-title":"Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus","volume":"95","author":"Franz","year":"1995","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib914","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jada.2007.05.015","article-title":"Effects of lifestyle intervention on health care costs: improving control with activity and nutrition (ICAN)","volume":"107","author":"Wolf","year":"2007","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib915","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jech.53.5.311","article-title":"Nutritional counselling in general practice: A cost effective analysis","volume":"53","author":"Pritchard","year":"1999","journal-title":"J\u00a0Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib916","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3945\/ajcn.2009.27684","article-title":"Food label use and awareness of nutritional information and recommendations among persons with chronic disease","volume":"90","author":"Lewis","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"4 suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib917","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jada.2008.01.024","article-title":"Carbohydrate issues: type and amount","volume":"108","author":"Wheeler","year":"2008","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1467-789X.2008.00560.x","article-title":"On the role and fate of sugars in human nutrition and health. Introduction","volume":"10","author":"Palou","year":"2009","journal-title":"Obes Rev Off J Int Assoc Study Obes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib919","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc11-2216","article-title":"Macronutrients, food groups, and eating patterns in the management of diabetes: A systematic review of the literature, 2010","volume":"35","author":"Wheeler","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib920","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10654-017-0352-x","article-title":"A\u00a0network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus","volume":"33","author":"Schwingshackl","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib921","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3945\/ajcn.117.153148","article-title":"Food groups and risk of all-cause mortality: A systematic review and meta-analysis of prospective studies","volume":"105","author":"Schwingshackl","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib922","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/ds19-0073","article-title":"An update on the Mediterranean, vegetarian, and DASH eating patterns in people with type 2 diabetes","volume":"33","author":"Benson","year":"2020","journal-title":"Diabetes Spectr"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib923","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1080\/10408398.2019.1624498","article-title":"Effect of different dietary patterns on glycemic control in individuals with type 2 diabetes mellitus: A systematic review","volume":"60","author":"de Carvalho","year":"2020","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib924","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.numecd.2019.02.004","article-title":"Dietary patterns and management of type 2 diabetes: A systematic review of randomised clinical trials","volume":"29","author":"Papamichou","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib925","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2337\/diacare.26.8.2288","article-title":"Biologic and quality-of-life outcomes from the Mediterranean lifestyle program: A randomized clinical trial","volume":"26","author":"Toobert","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib926","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1464-5491.2003.01086.x","article-title":"Comparison of a high-carbohydrate and a high-monounsaturated fat, olive oil-rich diet on the susceptibility of LDL to oxidative modification in subjects with type 2 diabetes mellitus","volume":"21","author":"Rodr\u00edguez-Villar","year":"2004","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib927","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial","volume":"30","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib928","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2337\/diacare.6.3.268","article-title":"Pritikin N Long-term use of a high-complex-carbohydrate, high-fiber, low-fat diet and exercise in the treatment of niddm patients","volume":"6","author":"Barnard","year":"1983","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib929","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.924977","article-title":"Mozaffarian D Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: A systematic review and meta-analysis","volume":"121","author":"Micha","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib930","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2337\/dc15-0572","article-title":"Randomized controlled trial investigating the effects of a low-glycemic index diet on pregnancy outcomes in women at high risk of gestational diabetes mellitus: the GI Baby 3 study","volume":"39","author":"Markovic","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib931","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2337\/dc08-1886","article-title":"Type of vegetarian diet, body weight, and prevalence of type 2 diabetes","volume":"32","author":"Tonstad","year":"2009","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib932","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc06-0606","article-title":"A\u00a0low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes","volume":"29","author":"Barnard","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib933","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib934","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003053","article-title":"Mann J Dietary fibre and whole grains in diabetes management: systematic review and meta-analyses","volume":"17","author":"Reynolds","year":"2020","journal-title":"PLOS Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib935","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4158\/EP.9.5.417","article-title":"Chausmer AB American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals","volume":"9","author":"Mechanick","year":"2003","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib936","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study","volume":"101","author":"Aroda","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib937","first-page":"729","article-title":"Associations between metformin use and vitamin B(12) levels, anemia, and neuropathy in patients with diabetes: A meta-analysis","volume":"11","author":"Yang","year":"2019","journal-title":"J\u00a0Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib938","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/fampra\/cml008","article-title":"Oral vitamin B12 vs intramuscular vitamin B12 for vitamin B12 deficiency: A systematic review of randomized controlled trials","volume":"23","author":"Butler","year":"2006","journal-title":"Fam Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib939","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1249\/MSS.0b013e3181b3b16d","article-title":"Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes","volume":"42","author":"Manders","year":"2010","journal-title":"Med Sci Sports Exerc"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib940","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00125-009-1354-3","article-title":"Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patients","volume":"52","author":"Hansen","year":"2009","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib941","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1249\/01.mss.0000235352.09061.1d","article-title":"Influence of acute exercise on hyperglycemia in insulin-treated type 2 diabetes","volume":"38","author":"Praet","year":"2006","journal-title":"Med Sci Sports Exerc"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib942","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2337\/dc07-0183","article-title":"Exercise training improves glycemic control in long-standing insulin-treated type 2 diabetic patients","volume":"30","author":"De Feyter","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib943","unstructured":"2018 Physical Activity Guidelines Advisory Committee. 2018 physical activity guidelines advisory committee scientific report. In: Serv US, (Doha)H, ed. Washington, DC [EL 4; NE]."},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib944","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.286.10.1218","article-title":"Sigal RJ Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials","volume":"286","author":"Boul\u00e9","year":"2001","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib945","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2010.1710","article-title":"Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial","volume":"304","author":"Church","year":"2010","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib946","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/archinternmed.2010.380","article-title":"Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: A randomized controlled trial: the Italian Diabetes and Exercise study (IDES)","volume":"170","author":"Balducci","year":"2010","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib947","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: A position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib948","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2012.3130","article-title":"Physical activity and mortality in individuals with diabetes mellitus: A prospective study and meta-analysis","volume":"172","author":"Sluik","year":"2012","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib949","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2337\/dc17-0615","article-title":"Physical activity reduces risk of premature mortality in patients with type 1 diabetes with and without kidney disease","volume":"40","author":"Tikkanen-Dolenc","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib950","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00125-003-1160-2","article-title":"Sigal RJ Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus","volume":"46","author":"Boul\u00e9","year":"2003","journal-title":"Diabetologia"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib951","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.119.044865","article-title":"Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD trial","volume":"141","author":"Pandey","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib952","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2337\/dc12-2194","article-title":"Categorical analysis of the impact of aerobic and resistance exercise training, alone and in combination, on cardiorespiratory fitness levels in patients with type 2 diabetes: results from the HART-D study","volume":"36","author":"Johannsen","year":"2013","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib953","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.2337\/dc06-1317","article-title":"Hopkins WG Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis","volume":"29","author":"Snowling","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib954","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2337\/diacare.26.5.1580","article-title":"Singh MA Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights","volume":"26","author":"Willey","year":"2003","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib956","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/obr.12317","article-title":"The effects of high-intensity interval training on glucose regulation and insulin resistance: A meta-analysis","volume":"16","author":"Jelleyman","year":"2015","journal-title":"Obes Rev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib957","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1249\/MSS.0b013e3181930355","article-title":"Sitting time and mortality from all causes, cardiovascular disease, and cancer","volume":"41","author":"Katzmarzyk","year":"2009","journal-title":"Med Sci Sports Exerc"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib958","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2337\/dc15-2336","article-title":"Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities","volume":"39","author":"Dempsey","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib959","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7326\/0003-4819-159-8-201310150-00007","article-title":"Korownyk C Lifestyle interventions for patients with and at risk for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Schellenberg","year":"2013","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib960","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.amjmed.2019.04.035","article-title":"Leisure-time running reduces the risk of incident type 2 diabetes","volume":"132","author":"Wang","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib961","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diabres.2016.01.011","article-title":"The effectiveness of regular leisure-time physical activities on long-term glycemic control in people with type 2 diabetes: A systematic review and meta-analysis","volume":"113","author":"Pai","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib962","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/jdi.12548","article-title":"Effects of yoga in adults with type 2 diabetes mellitus: A meta-analysis","volume":"8","author":"Cui","year":"2017","journal-title":"J\u00a0Diabetes Investig"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib963","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.maturitas.2014.09.008","article-title":"A\u00a0systematic review and meta-analysis of tai chi for treating type 2 diabetes","volume":"80","author":"Lee","year":"2015","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib964","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00592-017-1023-9","article-title":"Boul\u00e9 NG Aquatic exercise for adults with type 2 diabetes: A meta-analysis","volume":"54","author":"Rees","year":"2017","journal-title":"Acta diabetol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib965","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2337\/dc07-9927","article-title":"Screening for coronary artery disease in patients with diabetes","volume":"30","author":"Bax","year":"2007","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib966","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S2213-8587(15)00468-4","article-title":"Shared decision making in endocrinology: Present and future directions","volume":"4","author":"Rodriguez-Gutierrez","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib967","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib968","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/dom.14455","article-title":"Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis","volume":"23","author":"Powell","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib969","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pcd.2016.08.001","article-title":"Vos RC Personalised treatment targets in type 2 diabetes patients: the Dutch approach","volume":"11","author":"Boels","year":"2017","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib970","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.13051","article-title":"Glycaemic outcomes of an individualized treatment approach for older vulnerable patients: A randomized, controlled study in type 2 diabetes mellitus (IMPERIUM)","volume":"20","author":"Heller","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib971","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jcjd.2018.05.008","article-title":"Semaglutide: review and place in therapy for adults with type 2 diabetes","volume":"43","author":"Goldenberg","year":"2019","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib972","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib973","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib974","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLOS Med"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib976","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib977","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib978","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib979","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib980","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial","volume":"340","author":"de Jager","year":"2010","journal-title":"BMJ (Clin Res Ed)"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib981","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dme.12688","article-title":"Predictors of response in initial users of metformin and sulphonylurea derivatives: A systematic review","volume":"32","author":"Martono","year":"2015","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib982","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib983","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib984","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11892-014-0473-5","article-title":"A\u00a0new look at old therapy","volume":"14","author":"Thul\u00e9","year":"2014","journal-title":"Curr Diabetes Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib985","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/jdi.12889","article-title":"Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea","volume":"10","author":"Omori","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib986","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.109.881003","volume":"121","author":"Gerstein","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib987","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc06-1854","article-title":"Henyan NN Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis","volume":"30","author":"Riche","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib988","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010333","article-title":"Adiposity predicts cognitive decline in older persons with diabetes: A 2-year follow-up","volume":"5","author":"Abbatecola","year":"2010","journal-title":"PLOS ONE"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib989","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Nissen SE Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib990","doi-asserted-by":"crossref","first-page":"dgz252","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high\u00a0risk of type 2 diabetes mellitus: A meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib991","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s12325-009-0072-z","article-title":"Loomba R Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status","volume":"26","author":"Stein","year":"2009","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib992","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib993","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern\u00a0Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib994","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib995","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (adopt)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib996","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib997","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","article-title":"Hamburg M Regulatory action on rosiglitazone by the U.S. Food and Drug Administration","volume":"363","author":"Woodcock","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9681","key":"10.1016\/j.eprac.2022.08.002_bib998","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. record","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib999","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMp1309610","article-title":"The cardiovascular safety of diabetes drugs\u2013insights from the rosiglitazone experience","volume":"369","author":"Hiatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1000","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/1753-0407.12057","article-title":"Diabetes and cancer relationships","volume":"5","author":"Wang","year":"2013","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1002","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","article-title":"Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis","volume":"58","author":"Levin","year":"2015","journal-title":"Diabetologia"},{"issue":"30","key":"10.1016\/j.eprac.2022.08.002_bib1003","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026431","article-title":"Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials","volume":"100","author":"Duan","year":"2021","journal-title":"Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib1004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.13137","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"20","author":"Tran","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc09-2191","article-title":"Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study","volume":"33","author":"Arnolds","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1006","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/dmrr.646","article-title":"Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin","volume":"22","author":"Riddle","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1007","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1008","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1009","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3810\/pgm.2009.05.1997","article-title":"Adding liraglutide to oral antidiabetic drug monotherapy: Efficacy and weight benefits","volume":"121","author":"Nauck","year":"2009","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human glp-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabetic Med"},{"issue":"39","key":"10.1016\/j.eprac.2022.08.002_bib1013","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008161","article-title":"Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1014","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1016","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/dom.12602","article-title":"Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study","volume":"18","author":"Odawara","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1017","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/dom.12661","article-title":"Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: A double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 study)","volume":"18","author":"Aroda","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1019","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12325-017-0476-0","article-title":"Effectiveness and persistence of liraglutide treatment among patients with type 2 diabetes treated in primary care and specialist settings: A subgroup analysis from the evidence study, a prospective, 2-year follow-up, observational, post-marketing study","volume":"34","author":"Martinez","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/dme.13185","article-title":"Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with type 2 diabetes: A meta-analysis of sub-population data from seven phase III trials","volume":"34","author":"Shomali","year":"2017","journal-title":"Diabetic Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1021","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007990802597951","article-title":"Efficacy and safety of biphasic insulin aspart 70\/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea","volume":"25","author":"Bergenstal","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1023","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3810\/pgm.2010.05.2149","article-title":"Exenatide is non-inferior to insulin in reducing HbA1c: An integrated analysis of 1423 patients with type 2 diabetes","volume":"122","author":"Blevins","year":"2010","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1024","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/dc17-1114","article-title":"Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial","volume":"41","author":"Billings","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/1753-0407.12952","article-title":"Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GETGOAL-O study","volume":"11","author":"Dailey","year":"2019","journal-title":"J Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1026","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jdi.12793","article-title":"Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial","volume":"9","author":"Kaneko","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.eprac.2022.08.002_bib1027","doi-asserted-by":"crossref","first-page":"h5364","DOI":"10.1136\/bmj.h5364","article-title":"Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: Randomised clinical trial (MDI Liraglutide trial)","volume":"351","author":"Lind","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1028","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/dom.13252","article-title":"Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration","volume":"20","author":"Pantalone","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dom.12574","article-title":"Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1030","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jdiacomp.2017.05.010","article-title":"Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks","volume":"31","author":"Leiter","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1031","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1032","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1033","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide\u2013the FDA's review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1034","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc15-2780","article-title":"Pancreatic safety of sitagliptin in the TECOS study","volume":"40","author":"Buse","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dci16-0035","article-title":"DPP-4 inhibitor-related pancreatitis: Rare but real","volume":"40","author":"DeVries","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1036","first-page":"1","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1037","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1038","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1210\/jc.2015-4097","article-title":"Combination of saxagliptin and metformin is effective as initial therapy in new-onset type 2 diabetes mellitus with severe hyperglycemia","volume":"101","author":"Amblee","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1039","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/dom.13040","article-title":"Glycemic improvement with a fixed-dose combination of DPP-4 inhibitor\u00a0+ metformin in patients with type 2 diabetes (GIFT study)","volume":"20","author":"Bajaj","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10208","key":"10.1016\/j.eprac.2022.08.002_bib1040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1041","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/00325481.2016.1238280","article-title":"Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia","volume":"128","author":"Ross","year":"2016","journal-title":"Postgrad Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1042","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1753-0407.12284","article-title":"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial","volume":"8","author":"Wang","year":"2016","journal-title":"J\u00a0of diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1043","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3949\/ccjm.75.4.305","article-title":"What role will 'gliptins' play in glycemic control?","volume":"75","author":"Bloomgarden","year":"2008","journal-title":"Cleveland Clinic J of medicine"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib1044","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2022.08.002_bib1045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1046","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s12325-017-0595-7","article-title":"Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: A pooled analysis of randomized clinical trials","volume":"34","author":"Ning","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2022.08.002_bib1047","unstructured":"Nesina (alogliptin [as alogliptin benzoate]) product monograph, page 4. In: Inc. TC, ed.2021."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1048","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/1753-0407.12065","article-title":"Sodium glucose transporter 2 inhibition: A new approach to diabetes treatment","volume":"5","author":"Bloomgarden","year":"2013","journal-title":"J Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1049","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1050","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT-2 inhibitor-associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1051","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1052","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou","year":"2019","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1053","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: A pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J Am Geriatric Soc"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1054","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2022.08.002_bib1054a","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206286","article-title":"DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1056","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4093\/dmj.2018.0054","article-title":"Acarbose add-on therapy in patients with type 2 diabetes mellitus with metformin and sitagliptin failure: A multicenter, randomized, double-blind, placebo-controlled study","volume":"43","author":"Yang","year":"2019","journal-title":"Diabetes Metab J"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1057","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jdiacomp.2016.01.023","article-title":"Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: Results of a worldwide, non-interventional, observational study data pool","volume":"30","author":"Schnell","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1058","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1059","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-2009","article-title":"Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes","volume":"33","author":"Gaziano","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1060","article-title":"Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus","volume":"9","author":"Weiss","year":"2021","journal-title":"Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1061","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/dc20-0978","article-title":"Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT","volume":"44","author":"Abdul-Ghani","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1062","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78 945 patients","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1063","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/dom.13332","article-title":"HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups","volume":"20","author":"Sidorenkov","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1064","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib1065","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1066","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A\u00a026-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1067","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1463-1326.2010.01232.x","article-title":"Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine","volume":"12","author":"Home","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1068","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1069","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1070","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/dom.12920","article-title":"Comparative effectiveness and safety of different basal insulins in a real-world setting","volume":"19","author":"Ji","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1071","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jama.2018.7993","article-title":"Association of initiation of basal insulin analogs vs Neutral Protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes","volume":"320","author":"Lipska","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1072","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/dom.13708","article-title":"Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine u100: Results from switch 2","volume":"21","author":"Heller","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1073","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/dom.13071","article-title":"Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 u\/ml or insulin glargine 100 u\/ml (EDITION 1 and EDITION 2 subgroup analysis)","volume":"20","author":"Roussel","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/j.eprac.2022.08.002_bib1074","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2021.6530","article-title":"Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes","volume":"325","author":"Karter","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1075","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1076","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11535380-000000000-00000","article-title":"Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada","volume":"8","author":"Tunis","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib1077","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJM199211123272005","article-title":"Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus","volume":"327","author":"Yki-J\u00e4rvinen","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1078","first-page":"405","article-title":"Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal\u00a0insulin optimization: A 24-week randomized non-inferiority trial","volume":"8","author":"Jin","year":"2016","journal-title":"J\u00a0Diabetes"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1079","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/dom.12528","article-title":"Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: A 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)","volume":"17","author":"Vora","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/dme.12982","article-title":"Twice-daily insulin degludec\/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-na\u00efve adults with type 2 diabetes","volume":"33","author":"Franek","year":"2016","journal-title":"Diabetic Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163350","article-title":"Efficacy and safety of once-daily insulin degludec\/insulin aspart versus insulin glargine (u100) for 52 weeks in insulin-na\u00efve patients with type 2 diabetes: A randomized controlled trial","volume":"11","author":"Kumar","year":"2016","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1082","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jdi.13038","article-title":"Comparison of the efficacy and safety of insulin degludec\/aspart (twice-daily injections), insulin glargine 300 u\/ml, and insulin glulisine (basal-bolus therapy)","volume":"10","author":"Kawaguchi","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1083","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1507\/endocrj.EJ17-0020","article-title":"Insulin lispro 25\/75 and insulin lispro 50\/50 as starter insulin in japanese patients with type 2 diabetes: Subanalysis of the classify randomized trial","volume":"64","author":"Watada","year":"2017","journal-title":"Endocrine J"},{"key":"10.1016\/j.eprac.2022.08.002_bib1084","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diabres.2019.02.023","article-title":"Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs","volume":"150","author":"Yang","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1085","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc19-2550","article-title":"Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D","volume":"43","author":"Blevins","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1086","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/dme.13866","article-title":"Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant type 2 diabetes","volume":"36","author":"Bowering","year":"2019","journal-title":"Diabetic Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1087","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/dme.14202","article-title":"Hypoglycaemia is reduced with use of inhaled Technosphere(\u00ae) Insulin relative to insulin aspart in type 1 diabetes mellitus","volume":"37","author":"Seaquist","year":"2020","journal-title":"Diabetic Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1088","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.2337\/dc15-0629","article-title":"Inhaled Technosphere Insulin versus inhaled technosphere placebo in insulin-na\u00efve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1089","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S2213-8587(15)00280-6","article-title":"Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: A systematic review and meta-analysis","volume":"3","author":"Pittas","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9950","key":"10.1016\/j.eprac.2022.08.002_bib1090","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0140-6736(14)61037-0","article-title":"Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): A randomised open-label controlled trial","volume":"384","author":"Reznik","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1091","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40801-019-00173-8","article-title":"Effectiveness of V-Go(\u00ae) for patients with type 2 diabetes in a real-world setting: A prospective observational study","volume":"7","author":"Grunberger","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1092","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1185\/03007991003634759","article-title":"Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs","volume":"26","author":"Peyrot","year":"2010","journal-title":"Curr Med Res Opin."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1093","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc09-0395","article-title":"Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes","volume":"32","author":"Riddle","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1094","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1463-1326.2011.01408.x","article-title":"Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study III)","volume":"13","author":"Bell","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib1095","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1096","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1097","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1098","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial","volume":"44","author":"Giugliano","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1099","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2337\/dc21-0393","article-title":"Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial","volume":"44","author":"Rosenstock","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsb\u00f8ll","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1101","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1102","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eprac.2021.05.006","article-title":"Treatment patterns and outcomes, before and after humulin R U-500 initiation, among high-dose type 2 diabetes mellitus patients in the united states","volume":"27","author":"Hood","year":"2021","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1103","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/193229681200600229","article-title":"Clinical use of U-500 regular insulin: Review and meta-analysis","volume":"6","author":"Reutrakul","year":"2012","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2022.08.002_bib1104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP-2019-0607","article-title":"Concentrated insulins: Clinical update of therapeutic options","volume":"26","author":"Umpierrez","year":"2020","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1105","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4158\/EP15612.OR","article-title":"Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: A randomized, titration-to-target clinical trial","volume":"21","author":"Hood","year":"2015","journal-title":"Endocrine Pract"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib1106","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","article-title":"Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review","volume":"289","author":"DeWitt","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1107","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc13-3010","article-title":"Factors associated with weight gain in people with type 2 diabetes starting on insulin","volume":"37","author":"Balkau","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1108","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4158\/EP13005.RA","article-title":"Hypoglycemia: Minimizing its impact in type 2 diabetes","volume":"19","author":"Moghissi","year":"2013","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1109","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","article-title":"Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration","volume":"50","year":"2007","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib1110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1111","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 units\/ml versus glargine 100 units\/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1112","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108972","article-title":"Reprint of: Classification of diabetes mellitus","author":"Adler","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1113","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7326\/0003-4819-157-5-201209040-00508","article-title":"Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis","volume":"157","author":"Yeh","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1114","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrendo.2016.15","article-title":"Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia","volume":"12","author":"Umpierrez","year":"2016","journal-title":"Nature Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM198307213090307","article-title":"The metabolic derangements and treatment of diabetic ketoacidosis","volume":"309","author":"Foster","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1116","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/diab.29.11.926","article-title":"Effects of acute insulin deficiency on glucose and ketone body turnover in man: Evidence for the primacy of overproduction of glucose and ketone bodies in the genesis of diabetic ketoacidosis","volume":"29","author":"Miles","year":"1980","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1117","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00125-018-4785-x","article-title":"Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis","volume":"62","author":"Voss","year":"2019","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1118","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1119","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2337\/diabetes.53.8.2079","article-title":"Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises","volume":"53","author":"Stentz","year":"2004","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1120","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/diacare.27.8.1873","article-title":"Treatment of diabetic ketoacidosis with subcutaneous insulin aspart","volume":"27","author":"Umpierrez","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.amjmed.2004.05.010","article-title":"Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis","volume":"117","author":"Umpierrez","year":"2004","journal-title":"Am J Med"},{"issue":"25","key":"10.1016\/j.eprac.2022.08.002_bib1122","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1123","article-title":"Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus","volume":"2014","author":"Fullerton","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1124","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","article-title":"Insulin analogues in type 1 diabetes mellitus: Getting better all the time","volume":"13","author":"Mathieu","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2022.08.002_bib1125","article-title":"Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus","volume":"1","author":"Misso","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1126","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-0028-1119405","article-title":"Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: A meta-analysis","volume":"117","author":"Monami","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12020-016-1039-x","article-title":"Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: A systematic review and meta-analysis","volume":"55","author":"Benkhadra","year":"2017","journal-title":"Endocrine"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib1128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21200","article-title":"A\u00a0cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: The repose trial","volume":"21","author":"Heller","year":"2017","journal-title":"Health Technol Assess"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1129","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1932296817704445","article-title":"Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: Results from the diamond trial","volume":"11","author":"Ruedy","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc20-1674","article-title":"Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data from the international pediatric registry SWEET","volume":"44","author":"Cardona-Hernandez","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1131","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S2213-8587(17)30217-6","article-title":"Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): A multicentre, randomised controlled trial","volume":"5","author":"Beck","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2022.08.002_bib1132","doi-asserted-by":"crossref","first-page":"g5459","DOI":"10.1136\/bmj.g5459","article-title":"Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: Systematic review and network meta-analysis","volume":"349","author":"Tricco","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1133","article-title":"(ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus","volume":"3","author":"Hemmingsen","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194801","article-title":"Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials","volume":"13","author":"Laranjeira","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial","volume":"318","author":"Lane","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1136","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/endrev\/bnaa015","article-title":"The evolution of insulin and how it informs therapy and treatment choices","volume":"41","author":"Hirsch","year":"2020","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1137","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/pedi.12263","article-title":"Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes","volume":"16","author":"Thalange","year":"2015","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1138","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","article-title":"Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study group of insulin glargine in type 1 diabetes","volume":"23","author":"Ratner","year":"2000","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1139","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","article-title":"A\u00a016-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with Insulin Glargine in Type 1 Diabetes","volume":"23","author":"Raskin","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000664","article-title":"Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the uk","volume":"7","author":"Thalange","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1141","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1210\/jc.2019-01021","article-title":"Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: A prospective study","volume":"104","author":"Fadini","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1142","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/dom.14109","article-title":"Lower risk of severe hypoglycaemia with insulin glargine 300 u\/ml versus glargine 100 u\/ml in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials","volume":"22","author":"Danne","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1143","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s13300-020-00982-z","article-title":"Comparative effectiveness of switching from first-generation basal insulin to glargine 300 u\/ml or degludec 100 u\/ml in type 1 diabetes: The RESTORE-1 study","volume":"12","author":"Laviola","year":"2021","journal-title":"Diabetes Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1144","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 units\/ml versus glargine 100 units\/ml in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (edition 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1145","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.numecd.2015.06.005","article-title":"Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. Insulin glargine: A meta-analysis of seven clinical trials","volume":"25","author":"Russell-Jones","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1146","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bcp.14188","article-title":"Cost-effectiveness of long-acting insulin analogues vs intermediate\/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years","volume":"86","author":"Lee","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1147","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/dia.2020.0180","article-title":"Comparison of second-generation basal insulin analogs: A review of the evidence from continuous glucose monitoring","volume":"23","author":"Battelino","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1148","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/dom.14161","article-title":"Effects of insulin degludec and insulin glargine u300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study","volume":"22","author":"Miura","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1149","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13300-020-00781-6","article-title":"InRange: Comparison of the second-generation basal insulin analogues glargine 300 u\/ml and degludec 100 u\/ml in persons with type 1 diabetes using continuous glucose monitoring-study design","volume":"11","author":"Battelino","year":"2020","journal-title":"Diabetes Ther"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1151","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.2337\/diacare.21.10.1726","article-title":"Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes","volume":"21","author":"Brunelle","year":"1998","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1152","first-page":"Cd012161","article-title":"Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus","volume":"2016","author":"Fullerton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1153","article-title":"Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: A systematic review and meta-analysis","volume":"11","author":"Melo","year":"2019","journal-title":"Diabetol Metab\u00a0Syndr"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1154","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/dc16-1771","article-title":"Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (ONSET 1)","volume":"40","author":"Russell-Jones","year":"2017","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1155","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/dom.14100","article-title":"Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study","volume":"22","author":"Klaff","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1156","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.13610","article-title":"A\u00a0randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5)","volume":"21","author":"Klonoff","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1157","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/dom.13205","article-title":"Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial","volume":"20","author":"Mathieu","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1158","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/dia.2018.0200","article-title":"Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: The STAT study","volume":"20","author":"Akturk","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1159","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2337\/dc15-0075","article-title":"Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial","volume":"38","author":"Bode","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1160","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.2337\/dc09-2268","article-title":"Interventions with adherence-promoting components in pediatric type 1 diabetes: Meta-analysis of their impact on glycemic control","volume":"33","author":"Hood","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1161","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001971","article-title":"Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial","volume":"9","author":"Sterner Isaksson","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2213-8587(13)70144-X","article-title":"Efficacy of carbohydrate counting in type 1 diabetes: A systematic review and meta-analysis","volume":"2","author":"Bell","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1163","first-page":"337","article-title":"Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: A systematic review and meta-analysis","volume":"62","author":"Vaz","year":"2018","journal-title":"Arch Endocrinol Metab"},{"issue":"7367","key":"10.1016\/j.eprac.2022.08.002_bib1164","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bmj.325.7367.746","article-title":"Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose adjustment for normal eating (DAFNE) randomised controlled trial","volume":"325","author":"DAFNE Study Group","year":"2002","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1165","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/dc16-1770","article-title":"Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial","volume":"40","author":"Bowering","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1166","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcjd.2018.03.010","article-title":"Improving glycemic control in adults and children with type 1 diabetes with the use of smartphone-based mobile applications: A systematic review","volume":"43","author":"Sun","year":"2019","journal-title":"Can J Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1167","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/dia.2019.0427","article-title":"Efficacy of Insulclock in patients with poorly controlled type 1 diabetes mellitus: A pilot, randomized clinical trial","volume":"22","author":"Gomez-Peralta","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1168","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/dia.2019.0411","article-title":"Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen","volume":"22","author":"Adolfsson","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1169","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2337\/dc18-1631","article-title":"Nonadherence to insulin therapy detected by bluetooth-enabled pen cap is associated with poor glycemic control","volume":"42","author":"Munshi","year":"2019","journal-title":"Diabetes Care"},{"issue":"42","key":"10.1016\/j.eprac.2022.08.002_bib1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22420","article-title":"Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: The scipi rct","volume":"22","author":"Blair","year":"2018","journal-title":"Health Technol Assess"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1171","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A\u00a0double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1172","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabetic Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1173","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A\u00a0randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1174","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1370\/afm.1174","article-title":"Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus","volume":"8","author":"Lee","year":"2010","journal-title":"Ann Fam Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1175","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2983","article-title":"Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials","volume":"34","author":"Meng","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1176","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1177","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1178","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2022.08.002_bib1179","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis: A diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1181","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1182","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes","volume":"44","author":"Brown","year":"2021","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib1183","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1184","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/dia.2016.0421","article-title":"Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1185","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/dme.12950","article-title":"Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: A longitudinal follow-up study","volume":"32","author":"Rosenlund","year":"2015","journal-title":"Diabetic Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1186","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1210\/jc.2015-2839","article-title":"Effect of sensor-augmented pump treatment versus multiple daily injections on albuminuria: A 1-year randomized study","volume":"100","author":"Rosenlund","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1187","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/dia.2011.0294","article-title":"Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study","volume":"14","author":"Buse","year":"2012","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1188","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1089\/dia.2018.0199","article-title":"Impact of sensor-augmented pump therapy with predictive low-glucose suspend function on glycemic control and patient satisfaction in adults and children with type 1 diabetes","volume":"20","author":"Beato-V\u00edbora","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1189","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0043-110479","article-title":"Experiences in sensor-augmented pump therapy in families with two children with type 1 diabetes: A qualitative study","volume":"126","author":"Bomba","year":"2018","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1190","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1089\/dia.2016.0171","article-title":"Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: A comisair study","volume":"18","author":"\u0160oupal","year":"2016","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1191","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00592-019-01326-5","article-title":"Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: An updated meta-analysis of randomized clinical trials","volume":"56","author":"Pala","year":"2019","journal-title":"Acta Diabetologica"},{"key":"10.1016\/j.eprac.2022.08.002_bib1192","article-title":"Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: A systematic review and meta-analysis of randomized-controlled trials","author":"Fang","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"10155","key":"10.1016\/j.eprac.2022.08.002_bib1193","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(18)31947-0","article-title":"Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial","volume":"392","author":"Tauschmann","year":"2018","journal-title":"Lancet"},{"issue":"k1310","key":"10.1016\/j.eprac.2022.08.002_bib1194","article-title":"Artificial pancreas treatment for outpatients with type 1 diabetes: Systematic review and meta-analysis","volume":"361","author":"Bekiari","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2020.0535","article-title":"A\u00a0real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system","volume":"23","author":"Lum","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.eprac.2022.08.002_bib1196","first-page":"237","article-title":"The surgical therapy of hyperinsulinism","volume":"3","author":"Whipple","year":"1938","journal-title":"J\u00a0Int Chir"},{"key":"10.1016\/j.eprac.2022.08.002_bib1197","doi-asserted-by":"crossref","unstructured":"Cryer PE. In: Jefferson L, Cherrington A, eds. Handbook of physiology: A critical, comprehensive presentation of physiological knowledge and concepts. New York: Oxford University Press, 2001: 1057-1092. [EL 4; NE]","DOI":"10.1002\/cphy.cp070235"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1198","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1199","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc17-1624","volume":"40","author":"Agiostratidou","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMra1215228","article-title":"Mechanisms of hypoglycemia-associated autonomic failure in diabetes","volume":"369","author":"Cryer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1201","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2965","article-title":"Effects of alcohol on plasma glucose and prevention of alcohol-induced hypoglycemia in type 1 diabetes-a systematic review with GRADE","volume":"34","author":"Tetzschner","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1202","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2337\/dc16-2723","article-title":"Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT\/EDIC study","volume":"40","author":"Gubitosi-Klug","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/diab.46.2.271","article-title":"Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group","volume":"46","year":"1997","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1204","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pcd.2013.10.001","article-title":"Predictors of hypoglycaemia in insulin-treated type 2 diabetes patients in primary care: A retrospective database analysis","volume":"8","author":"Kostev","year":"2014","journal-title":"Prim Care Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/dom.12282","article-title":"Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK\u2013a nested case-control analysis","volume":"16","author":"Bruderer","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1206","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/dc13-1384","article-title":"Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: The Edinburgh type 2 diabetes study","volume":"37","author":"Feinkohl","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1207","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1208","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2337\/dc11-2054","article-title":"Increased mortality of patients with diabetes reporting severe hypoglycemia","volume":"35","author":"McCoy","year":"2012","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1209","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.amjmed.2011.08.008","article-title":"Death during intensive glycemic therapy of diabetes: Mechanisms and implications","volume":"124","author":"Cryer","year":"2011","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1210","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","article-title":"Hypoglycemia in diabetes","volume":"26","author":"Cryer","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/erp.11.87","article-title":"Economic burden of hypoglycemia in patients with type 2 diabetes","volume":"12","author":"Liu","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1212","first-page":"385","article-title":"Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the united states","volume":"27","author":"Bajpai","year":"2021","journal-title":"Manag Care Spec Pharm"},{"key":"10.1016\/j.eprac.2022.08.002_bib1213","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vhri.2019.01.002","article-title":"The cost of hypoglycemia associated with type 2 diabetes mellitus in taiwan","volume":"18","author":"Strizek","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1214","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/dom.13657","article-title":"Direct medical costs in the preceding, event and subsequent years of a first severe hypoglycaemia episode requiring hospitalization: A population-based cohort study","volume":"21","author":"Wong","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/emermed-2015-205637","article-title":"Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: A systematic review and meta-analysis","volume":"34","author":"Carlson","year":"2017","journal-title":"Emerg Med J"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1216","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/dom.13231","article-title":"Optimizing the management of hypoglycaemia in individuals with type 2 diabetes: A randomized crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens","volume":"20","author":"Krebs","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1217","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/dme.13576","article-title":"Weight-based carbohydrate treatment of hypoglycaemia in people with type 1 diabetes using insulin pump therapy: A randomized crossover clinical trial","volume":"35","author":"McTavish","year":"2018","journal-title":"Diabetic Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1218","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/jdi.12759","article-title":"Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial","volume":"9","author":"Kiyosue","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1219","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.dsx.2015.09.021","article-title":"Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight\/obese type 2 diabetes","volume":"10","author":"Talaviya","year":"2016","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1479164115610470","article-title":"Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus","volume":"13","author":"Tsch\u00f6pe","year":"2016","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.eprac.2022.08.002_bib1221","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.diabres.2015.12.010","article-title":"Glycemic excursions are positively associated with changes in duration of asymptomatic hypoglycemia after treatment intensification in patients with type 2 diabetes","volume":"113","author":"Wang","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1222","first-page":"365","article-title":"Effects of acarbose and siglitine on blood glucose fluctuation and islet \u03b2-cell function in patients with type 2 diabetes mellitus","volume":"33","author":"Wang","year":"2019","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1223","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/03007995.2016.1277200","article-title":"A\u00a0randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone","volume":"33","author":"Wang","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"35","key":"10.1016\/j.eprac.2022.08.002_bib1224","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007533","article-title":"Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus","volume":"96","author":"Wu","year":"2017","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1225","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-8587(18)30105-0","article-title":"Dorzagliatin monotherapy in chinese patients with type 2 diabetes: A dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study","volume":"6","author":"Zhu","year":"2018","journal-title":"The Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1226","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/dom.13134","article-title":"Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial","volume":"20","author":"Guzman","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1227","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1210\/jc.2017-00591","article-title":"Efficacy and safety of mini-dose glucagon for treatment of nonsevere hypoglycemia in adults with type 1 diabetes","volume":"102","author":"Haymond","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1228","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc16-1472","article-title":"Low-carbohydrate diet impairs the effect of glucagon in the treatment of insulin-induced mild hypoglycemia: A randomized crossover study","volume":"40","author":"Ranjan","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1229","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/dom.12627","article-title":"Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes","volume":"18","author":"Ranjan","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11892-019-1216-4","article-title":"Novel preparations of glucagon for the prevention and treatment of hypoglycemia","volume":"19","author":"Hawkes","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1231","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002137","article-title":"Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: Two randomized crossover non-inferiority studies","volume":"9","author":"Christiansen","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1232","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1932296814557518","article-title":"Intranasal glucagon: A promising approach for treatment of severe hypoglycemia","volume":"9","author":"Pontiroli","year":"2015","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1233","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"Glucagon nasal powder: A promising alternative to intramuscular glucagon in youth with type 1 diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1234","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1236","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1932296814565131","article-title":"Development of a highly stable,\u00a0nonaqueous glucagon formulation for delivery via infusion pump systems","volume":"9","author":"Newswanger","year":"2015","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1237","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1238","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/dom.13562","article-title":"Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus","volume":"21","author":"H\u00f6velmann","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1239","article-title":"First aid glucose administration routes for symptomatic hypoglycaemia","volume":"4","author":"De Buck","year":"2019","journal-title":"Cochrane\u00a0Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10545-015-9864-2","article-title":"Alternative nighttime nutrition regimens in glycogen storage disease type i: A controlled crossover study","volume":"38","author":"Hochuli","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1241","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/dc18-0051","article-title":"Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes","volume":"41","author":"Rickels","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1242","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","article-title":"A\u00a0systematic\u00a0review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin","volume":"30","author":"Gangji","year":"2007","journal-title":"Diabetes Care"},{"issue":"9 Pt 1","key":"10.1016\/j.eprac.2022.08.002_bib1243","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00009","article-title":"Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes","volume":"134","author":"Fritsche","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1244","first-page":"523","article-title":"Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia","volume":"85","author":"Fritsche","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1245","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bcpt.12957","article-title":"A\u00a0systematic review on insulin overdose cases: Clinical course, complications and treatment options","volume":"122","author":"Johansen","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1246","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2337\/dc15-0858","article-title":"Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011","volume":"39","author":"Pathak","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1247","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcjd.2018.08.061","article-title":"Derivation and validation of a risk-prediction tool for hypoglycemia in hospitalized adults with diabetes: The hypoglycemia during hospitalization (HyDHo) score","volume":"43","author":"Shah","year":"2019","journal-title":"Can J Diabetes"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1248","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4158\/EP-2019-0554","article-title":"Real-world improvements in hypoglycemia in an insulin-dependent cohort with diabetes mellitus pre\/post tandem basal-iq technology remote software update","volume":"26","author":"Pinsker","year":"2020","journal-title":"Endocr Pract"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib1249","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib1250","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1251","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1097\/CCM.0b013e3181b083f7","article-title":"Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis","volume":"37","author":"Falciglia","year":"2009","journal-title":"Critical Care Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1252","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc10-0304","article-title":"Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery","volume":"33","author":"Frisch","year":"2010","journal-title":"Diabetes Care"},{"issue":"9206","key":"10.1016\/j.eprac.2022.08.002_bib1253","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1254","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jdiacomp.2017.11.010","article-title":"Stress hyperglycemia in general surgery: Why should we care?","volume":"32","author":"Davis","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e31827b6bbc","article-title":"Importance of perioperative glycemic control in general surgery: A report from the surgical care and outcomes assessment program","volume":"257","author":"Kwon","year":"2013","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1256","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/dme.13325","article-title":"The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: The multinational, prospective, observational triage study","volume":"34","author":"Kutz","year":"2017","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1257","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1210\/jc.2011-2100","article-title":"Glycemic control in non-critically ill hospitalized patients: A systematic review and meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1258","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1590\/1806-9282.65.1.24","article-title":"Intensive treatment of hyperglycemia in the acute phase of myocardial infarction: The tenuous balance between effectiveness and safety - a systematic review and meta-analysis of randomized clinical trials","volume":"65","author":"Negreiros","year":"2019","journal-title":"Rev Assoc Med Bras"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1259","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1503\/cmaj.090206","article-title":"Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE-SUGAR study data","volume":"180","author":"Griesdale","year":"2009","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1260","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jama.300.8.933","article-title":"Benefits and risks of tight glucose control in critically ill adults: A meta-analysis","volume":"300","author":"Wiener","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1261","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCOUTCOMES.111.963298","article-title":"Glucose variability and mortality in patients hospitalized with acute myocardial infarction","volume":"5","author":"Lipska","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1262","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4158\/EP13131.OR","article-title":"Glucose variability is an independent predictor of mortality in hospitalized patients treated with total parenteral nutrition","volume":"20","author":"Farrokhi","year":"2014","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1263","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1097\/CCM.0b013e31818b38d2","article-title":"Glycemic variability: A strong independent predictor of mortality in critically ill patients","volume":"36","author":"Krinsley","year":"2008","journal-title":"Critical Care Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1264","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.2337\/dc12-2430","article-title":"Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients","volume":"36","author":"Mendez","year":"2013","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1265","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/diacare.23.12.1774","article-title":"Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: A retrospective cohort study of resource use","volume":"23","author":"Donnan","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1266","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(20)30381-8","article-title":"Management of diabetes\u00a0and hyperglycaemia in the hospital","volume":"9","author":"Pasquel","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.eprac.2022.08.002_bib1267","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.104.517839","article-title":"Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes","volume":"111","author":"Kosiborod","year":"2005","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2022.08.002_bib1268","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc22-S016","article-title":"16. Diabetes care in the hospital: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1269","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jdiacomp.2017.01.003","article-title":"Hospitalization costs and clinical outcomes in cabg patients treated with intensive insulin therapy","volume":"31","author":"Cardona","year":"2017","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.eprac.2022.08.002_bib1270","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/698265","article-title":"Intensive insulin therapy for septic patients: A meta-analysis of randomized controlled trials","volume":"2014","author":"Song","year":"2014","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1271","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/0003-4819-154-4-201102150-00008","article-title":"Intensive insulin therapy in hospitalized patients: A systematic review","volume":"154","author":"Kansagara","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1272","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0148607106030002164","article-title":"Insulin therapy and in-hospital mortality in critically ill patients: Systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Pittas","year":"2006","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib1273","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/archinte.164.18.2005","article-title":"Insulin therapy for critically ill hospitalized patients: A meta-analysis of randomized controlled trials","volume":"164","author":"Pittas","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1274","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00134-016-4523-0","article-title":"Glycemic control, mortality, and hypoglycemia in critically ill patients: A systematic review and network meta-analysis of randomized controlled trials","volume":"43","author":"Yamada","year":"2017","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1275","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.2337\/dc14-0479","article-title":"Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1276","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000113","article-title":"Inpatient HbA1c testing: A prospective observational study","volume":"3","author":"Nanayakkara","year":"2015","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1277","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168471","article-title":"Using automated HbA1c testing to detect diabetes mellitus in orthopedic inpatients and its effect on outcomes","volume":"12","author":"Ekinci","year":"2017","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1278","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12245-016-0107-6","article-title":"Point-of-care capillary hba1c measurement in the emergency department: A useful tool to detect unrecognized and uncontrolled diabetes","volume":"9","author":"Gomez-Peralta","year":"2016","journal-title":"Int J Emerg Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1279","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.mayocp.2016.12.020","article-title":"New-onset diabetes after acute and critical illness: A systematic review","volume":"92","author":"Jivanji","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1280","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000460","article-title":"Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: Impact on 30-day readmission rate and hospital cost","volume":"6","author":"Bansal","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1281","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1464-5491.2001.00470.x","article-title":"Evaluation of a hospital\u00a0diabetes specialist nursing service: A randomized controlled trial","volume":"18","author":"Davies","year":"2001","journal-title":"Diabetic Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1282","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11892-020-01374-0","article-title":"The financial impact of an inpatient diabetes management service","volume":"21","author":"Haque","year":"2021","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1283","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/20009666.2019.1593782","article-title":"Retrospective study of inpatient diabetes management service, length of stay and 30-day readmission rate of patients with diabetes at a community hospital","volume":"9","author":"Mandel","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1284","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/M16-1413","article-title":"Association between a virtual glucose management service and glycemic control in hospitalized adult patients: An observational study","volume":"166","author":"Rushakoff","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2017.08.014","article-title":"Effect of follow-up by a hospital diabetes care team on diabetes control at one year after discharge from the hospital","volume":"133","author":"Garg","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1286","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4158\/EP15655.OR","article-title":"The synergy to enable glycemic control following emergency department discharge program for adults with type 2 diabetes: Step-diabetes","volume":"21","author":"Magee","year":"2015","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1287","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1932296820949282","article-title":"Utility of computer-guided decision support system in discharge insulin dosing and diabetes-related readmissions","volume":"15","author":"Ullal","year":"2021","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1288","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2337\/diacare.27.2.461","article-title":"Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit","volume":"27","author":"Goldberg","year":"2004","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1289","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/00003246-200109000-00010","article-title":"Intravenous insulin nomogram improves blood glucose control in the critically ill","volume":"29","author":"Brown","year":"2001","journal-title":"Critical Care Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.11124\/01938924-201513050-00013","article-title":"The effect of insulin therapy algorithms on blood glucose levels in patients following cardiac surgery: A systematic review","volume":"13","author":"Higgs","year":"2015","journal-title":"JBI Database System Rev Implement Rep"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1291","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00134-009-1542-0","article-title":"Tight glycemic control and computerized decision-support systems: A systematic review","volume":"35","author":"Eslami","year":"2009","journal-title":"Intensive Care\u00a0Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1292","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ecl.2019.11.002","article-title":"Diabetes technology in the inpatient setting for management of hyperglycemia","volume":"49","author":"Davis","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1293","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ecl.2017.10.005","article-title":"Perioperative management of hyperglycemia and diabetes in cardiac surgery patients","volume":"47","author":"Galindo","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1294","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/dia.2006.0015","article-title":"Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit","volume":"9","author":"Juneja","year":"2007","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1295","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/diacare.28.10.2418","article-title":"Glucommander: A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation","volume":"28","author":"Davidson","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1296","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1197\/jamia.M2292","article-title":"Computer-based insulin infusion protocol improves glycemia control over manual protocol","volume":"14","author":"Boord","year":"2007","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1297","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/014860710803200118","article-title":"A\u00a0computerized insulin infusion titration protocol improves glucose control with less hypoglycemia compared to a manual titration protocol in a trauma intensive care unit","volume":"32","author":"Dortch","year":"2008","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1298","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00134-008-1033-8","article-title":"Tight glycaemic control by an automated algorithm with time-variant sampling in medical icu patients","volume":"34","author":"Pachler","year":"2008","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1299","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1932296817750899","article-title":"Comparison of computer-guided versus standard insulin infusion regimens in patients with diabetic ketoacidosis","volume":"12","author":"Ullal","year":"2018","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/ds16-0061","article-title":"Evaluating the implementation of the EndoTool glycemic control software system","volume":"31","author":"John","year":"2018","journal-title":"Diabetes Spectr"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1301","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4158\/EP161402.OR","article-title":"Use of a computer-guided glucose management system to improve glycemic control and address national quality measures: A 7-year, retrospective observation study at a tertiary care teaching hospital","volume":"23","author":"Tanenberg","year":"2017","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1302","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/jhm.816","article-title":"A\u00a0comparison study of continuous insulin infusion protocols in the medical intensive care unit: Computer-guided vs. Standard column-based algorithms","volume":"5","author":"Newton","year":"2010","journal-title":"Journal Hosp Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1303","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1186\/cc8129","article-title":"Computerized intensive insulin dosing can mitigate hypoglycemia and achieve tight glycemic control when glucose measurement is performed frequently and on time","volume":"13","author":"Juneja","year":"2009","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1304","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7812\/TPP\/12.959","article-title":"Development of a computerized intravenous insulin application (AutoCal) at Kaiser Permanente Northwest, integrated into Kaiser Permanente HealthConnect: Impact on safety and nursing workload","volume":"16","author":"Olinghouse","year":"2012","journal-title":"Perm J"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1305","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.mayocp.2013.07.003","article-title":"Software-guided insulin dosing: Tight glycemic control and decreased glycemic derangements in critically ill patients","volume":"88","author":"Saur","year":"2013","journal-title":"Mayo Clinic Proc"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1306","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/dia.2007.0225","article-title":"Outcomes of a cardiothoracic intensive care web-based online intravenous insulin infusion calculator study at a medical university hospital","volume":"9","author":"Hermayer","year":"2007","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1307","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1932296816664746","article-title":"Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting","volume":"11","author":"Aloi","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1308","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/dc09-0169","article-title":"Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: A randomized controlled trial","volume":"32","author":"Umpierrez","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1309","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fendo.2017.00106","article-title":"Review of evidence for adult diabetic ketoacidosis management protocols","volume":"8","author":"Tran","year":"2017","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1310","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/dme.12757","article-title":"Management of hyperosmolar hyperglycaemic state in adults with diabetes","volume":"32","author":"Scott","year":"2015","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1312","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1313","doi-asserted-by":"crossref","first-page":"e2673","DOI":"10.1210\/clinem\/dgab126","article-title":"Biochemical parameters of diabetes ketoacidosis in patients with end-stage kidney disease and preserved renal function","volume":"106","author":"Galindo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1314","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000763","article-title":"Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis","volume":"8","author":"Galindo","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1315","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2337\/dc19-1168","article-title":"Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: A retrospective, hospital-based cohort study","volume":"43","author":"Pasquel","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1316","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jdiacomp.2018.08.014","article-title":"Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: A pilot randomized study","volume":"32","author":"Fayfman","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1317","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000703","article-title":"Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery","volume":"7","author":"Cardona","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1318","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/dom.14241","article-title":"Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial","volume":"23","author":"Cardona","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1319","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4158\/EP12196.OR","article-title":"Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit","volume":"19","author":"Abuannadi","year":"2013","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1320","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.jvca.2013.06.021","article-title":"Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: A randomized, double-blind, placebo-controlled study","volume":"28","author":"Kohl","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1321","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/ALN.0000000000001838","article-title":"Clinical effectiveness of intravenous exenatide infusion in perioperative glycemic control after coronary artery bypass graft surgery: A phase II\/III randomized trial","volume":"127","author":"Besch","year":"2017","journal-title":"Anesthesiology"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1322","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/dom.13029","article-title":"Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial","volume":"19","author":"Lip\u0161","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5-6","key":"10.1016\/j.eprac.2022.08.002_bib1323","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000494768","article-title":"GLP1 receptor agonist liraglutide is an effective therapeutic option for perioperative glycemic control in type 2 diabetes within enhanced recovery after surgery (eras) protocols","volume":"59","author":"Kaneko","year":"2018","journal-title":"Eur Surg Res"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1324","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/dom.13927","article-title":"Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: A multicentre randomized superiority trial","volume":"22","author":"Hulst","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1325","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1932296816629985","article-title":"Transition from intravenous to subcutaneous insulin in critically ill adults","volume":"10","author":"Doolin","year":"2016","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1326","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dia.2010.0124","article-title":"Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: Transition to target study","volume":"13","author":"Shomali","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1327","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eprac.2021.01.016","article-title":"Inpatient hyperglycemia and transitions of care: A systematic review","volume":"27","author":"Lansang","year":"2021","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1328","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11892-015-0595-4","article-title":"Transitioning safely from intravenous to subcutaneous insulin","volume":"15","author":"Kreider","year":"2015","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1329","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001557","article-title":"Clinical decision support\u00a0to improve management of diabetes and dysglycemia in the hospital: A path to optimizing practice and outcomes","volume":"9","author":"Pichardo-Lowden","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"26","key":"10.1016\/j.eprac.2022.08.002_bib1330","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMcp1001115","article-title":"Clinical practice. Glycemic control in the ICU","volume":"363","author":"Kavanagh","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1331","doi-asserted-by":"crossref","first-page":"462","DOI":"10.12788\/jhm.3654","article-title":"Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: Who can slide?","volume":"16","author":"Migdal","year":"2021","journal-title":"J Hosp Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1332","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/1932296820964264","article-title":"Continuous glucose monitoring in critically ill patients with COVID-19: Results of an emergent pilot study","volume":"14","author":"Sadhu","year":"2020","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1333","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2885","article-title":"Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis","volume":"33","author":"Christensen","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1334","first-page":"Cd011296","article-title":"Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus","volume":"11","author":"Colunga-Lozano","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1335","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2015.05.011","article-title":"Sliding-scale insulin used for blood glucose control: A meta-analysis of randomized controlled trials","volume":"64","author":"Lee","year":"2015","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1336","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc18-2342","article-title":"Early intervention for diabetes in medical and surgical inpatients decreases hyperglycemia and hospital-acquired infections: A cluster randomized trial","volume":"42","author":"Kyi","year":"2019","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.eprac.2022.08.002_bib1337","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMcp060094","article-title":"Clinical practice. Management of hyperglycemia in the hospital setting","volume":"355","author":"Inzucchi","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1338","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc12-0578","article-title":"A\u00a0randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency","volume":"35","author":"Baldwin","year":"2012","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1339","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/dc10-2434","article-title":"Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes","volume":"34","author":"Rubin","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1340","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/193229681200600505","article-title":"Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes","volume":"6","author":"Farrokhi","year":"2012","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1341","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2337\/dc14-1796","article-title":"Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes","volume":"38","author":"Vellanki","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1342","doi-asserted-by":"crossref","unstructured":"Vellanki P, Cardona S, Galindo RJ, et al. Efficacy and Safety of Intensive Versus Nonintensive supplemental insulin with a basal-Bolus insulin regimen in hospitalized patients with type 2 diabetes: A Randomized Clinical Study. Diabetes Care. 2022:dc211606. https:\/\/doi.org\/10.2337\/dc21-1606. Epub ahead of print","DOI":"10.2337\/dc21-1606"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1343","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2337\/dc19-1940","article-title":"A\u00a0randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: Glargine U300 hospital trial","volume":"43","author":"Pasquel","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1344","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.4158\/EP171804.OR","article-title":"Comparison of efficacy and safety of glargine and detemir insulin in the management of inpatient hyperglycemia and diabetes","volume":"23","author":"Galindo","year":"2017","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1345","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001518","article-title":"Efficacy and safety of insulin\u00a0glargine 300 U\/ml (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: Results of the phase iv COBALTA trial","volume":"8","author":"Perez","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1346","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.14544","article-title":"Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes","volume":"24","author":"Galindo","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1347","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/jc.2008-1441","article-title":"Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes","volume":"94","author":"Umpierrez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1348","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/dmrr.1217","article-title":"Benefits of a simple glycaemic protocol in an orthopaedic surgery ward: A randomized prospective study","volume":"28","author":"Schroeder","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1349","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc15-0160","article-title":"Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes","volume":"38","author":"Bellido","year":"2015","journal-title":"Diabetes Care"},{"issue":"3-4","key":"10.1016\/j.eprac.2022.08.002_bib1350","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/07853890.2019.1613672","article-title":"Glycaemic\u00a0efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-surg study","volume":"51","author":"P\u00e9rez-Belmonte","year":"2019","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1351","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/dc18-1760","article-title":"A\u00a0randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes","volume":"42","author":"Fayfman","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1352","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdi.13093","article-title":"Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients","volume":"11","author":"Fushimi","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1353","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4158\/EP-2018-0524","article-title":"Clinical characteristics of patients with type 2 diabetes mellitus continued on oral antidiabetes medications in the hospital","volume":"26","author":"Amir","year":"2020","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1354","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.2337\/dc13-0277","article-title":"Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: A pilot, randomized, controlled study","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1355","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/dom.13587","article-title":"Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial","volume":"21","author":"Vellanki","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1356","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000394","article-title":"Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients","volume":"5","author":"Garg","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1357","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","article-title":"Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): A multicentre, prospective, open-label, non-inferiority randomised trial","volume":"5","author":"Pasquel","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1358","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1007\/s12325-020-01434-7","article-title":"Dpp4 inhibitors in the management of hospitalized patients with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials","volume":"37","author":"Rabizadeh","year":"2020","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1359","doi-asserted-by":"crossref","first-page":"Ho2","DOI":"10.7326\/M21-2789","article-title":"Annals for hospitalists inpatient notes - how we treat hyperglycemia in the hospital","volume":"174","author":"Pasquel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1361","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1378\/chest.09-1737","article-title":"Toward understanding tight glycemic control in the icu: A systematic review and metaanalysis","volume":"137","author":"Marik","year":"2010","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1362","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1161\/CIRCULATIONAHA.107.740498","article-title":"Glucometrics in patients hospitalized with acute myocardial infarction: Defining the optimal outcomes-based measure of risk","volume":"117","author":"Kosiborod","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1363","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4065\/mcp.2009.0394","article-title":"Hypoglycemia and outcome in critically ill patients","volume":"85","author":"Egi","year":"2010","journal-title":"Mayo Clinic proceedings"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1364","first-page":"422","article-title":"Mortality in hospitalized patients with hypoglycemia and severe hyperglycemia","volume":"62","author":"Stagnaro-Green","year":"1995","journal-title":"Mt Sinai J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1365","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2337\/diacare.26.5.1485","article-title":"Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring","volume":"26","author":"Desouza","year":"2003","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1366","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjmed.2011.07.011","article-title":"Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities","volume":"124","author":"Boucai","year":"2011","journal-title":"Am J Med"},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib1367","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.2009.496","article-title":"Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction","volume":"301","author":"Kosiborod","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1368","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.11.021","article-title":"Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia","volume":"123","author":"Gamble","year":"2010","journal-title":"The Am J Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1369","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/dme.14115","article-title":"The effect of hypoglycaemia during hospital admission on health-related outcomes for people with diabetes: A systematic review and meta-analysis","volume":"36","author":"Lake","year":"2019","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1370","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.30913","article-title":"Development and validation of a machine learning model to predict near-term risk of iatrogenic hypoglycemia in hospitalized patients","volume":"4","author":"Mathioudakis","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1371","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4158\/EP14367.OR","article-title":"Impact of a hypoglycemia reduction bundle and a systems approach to inpatient glycemic management","volume":"21","author":"Maynard","year":"2015","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1372","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/19322968211008513","article-title":"Retrospective quality improvement study of insulin-induced hypoglycemia and implementation of hospital-wide initiatives","volume":"15","author":"Shelton","year":"2021","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1373","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jhm.977","article-title":"Incidence of hypoglycemia following insulin-based acute stabilization of hyperkalemia treatment","volume":"7","author":"Schafers","year":"2012","journal-title":"J Hosp Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1374","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/ckj\/sfu026","article-title":"Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease","volume":"7","author":"Apel","year":"2014","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1375","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2337\/dc21-1579","article-title":"Hypoglycemic and hyperglycemic crises among u.S. Adults with diabetes and end-stage kidney disease: Population-based study, 2013-2017","volume":"45","author":"Galindo","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1376","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1177\/1060028015607559","article-title":"Incidence of hypoglycemia in patients with low egfr treated with insulin and dextrose for hyperkalemia","volume":"49","author":"Pierce","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1377","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/2042098618768725","article-title":"Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia","volume":"9","author":"Farina","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1378","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2337\/diacare.26.4.1064","article-title":"Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia","volume":"26","author":"Greci","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1379","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13054-016-1471-6","article-title":"Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: A systematic review and meta-analysis","volume":"20","author":"Ali Abdelhamid","year":"2016","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1380","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ajem.2018.09.053","article-title":"Comparison of two glycemic discharge goals in ED patients with hyperglycemia, a randomized trial","volume":"37","author":"Driver","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1381","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/dom.14347","article-title":"Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge","volume":"23","author":"Pasquel","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1384","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1385","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/1932296818801607","article-title":"A\u00a0milestone in point of care capillary blood glucose monitoring of critically ill hospitalized patients","volume":"12","author":"Klonoff","year":"2018","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1386","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.2010-2729","article-title":"Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD","volume":"96","author":"Burt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1387","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000607","article-title":"Clinical characteristics and outcomes of symptomatic and asymptomatic hypoglycemia in hospitalized patients with diabetes","volume":"6","author":"Cardona","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1388","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107976","article-title":"Hypoglycemia symptoms are reduced in hospitalized patients with diabetes","volume":"35","author":"Criner","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1389","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.2337\/dc19-2073","article-title":"Comparison of the FreeStyle Libre Pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen","volume":"43","author":"Galindo","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1390","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/1932296820954163","article-title":"Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline","volume":"14","author":"Galindo","year":"2020","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1391","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1932296820932903","article-title":"Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic","volume":"14","author":"Galindo","year":"2020","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1392","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.2337\/dc20-0840","article-title":"Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: The glucose telemetry system, a randomized clinical trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1393","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1932296817748964","article-title":"The effect of continuous glucose monitoring in preventing inpatient hypoglycemia in general wards: The glucose telemetry system","volume":"12","author":"Spanakis","year":"2018","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1394","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000990","article-title":"Association of glucose variability at the last day of hospitalization with 30-day readmission in adults with diabetes","volume":"8","author":"Spanakis","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1396","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2337\/dc20-2856","article-title":"Accuracy of Dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes","volume":"44","author":"Davis","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1397","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2337\/dc20-2219","article-title":"Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic","volume":"44","author":"Agarwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1398","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2337\/dc20-2085","article-title":"Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: Proof of concept","volume":"44","author":"Davis","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1399","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.2337\/dc20-2386","article-title":"Continuous glucose monitoring in the operating room and cardiac intensive care unit","volume":"44","author":"Perez-Guzman","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1400","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.2337\/dc06-9914","article-title":"Nutrition recommendations and interventions for diabetes\u20132006: A position statement of the American Diabetes Association","volume":"29","author":"Bantle","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1401","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0148607109335234","article-title":"Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)","volume":"33","author":"McClave","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1402","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-017-0882-3","article-title":"Nutrition and hyperglycemia management in the inpatient setting (meals on demand, parenteral, or enteral nutrition)","volume":"17","author":"Drincic","year":"2017","journal-title":"Curr Diab Rep."},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1403","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4158\/EP-2018-0150","article-title":"The management of hyperglycemia in noncritically ill hospitalized patients treated with continuous enteral or parenteral nutrition","volume":"24","author":"Vennard","year":"2018","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1404","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/jcm8070935","article-title":"Management of glucose control in noncritically ill, hospitalized patients receiving parenteral and\/or enteral nutrition: A systematic review","volume":"8","author":"Laesser","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1405","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2337\/dc08-1436","article-title":"Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: A randomized controlled clinical trial","volume":"32","author":"Korytkowski","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1406","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0884533611400231","article-title":"Postoperative diet advancement: Surgical dogma vs evidence-based medicine","volume":"26","author":"Warren","year":"2011","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.eprac.2022.08.002_bib1407","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13054-015-1108-1","article-title":"Diabetes-specific enteral nutrition formula in hyperglycemic, mechanically ventilated, critically ill patients: A prospective, open-label, blind-randomized, multicenter study","volume":"19","author":"Mesejo","year":"2015","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1408","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jama.2021.7217","article-title":"Trends in gestational diabetes at first live birth by race and ethnicity in the us, 2011-2019","volume":"326","author":"Shah","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1409","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM198302033080502","article-title":"Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy","volume":"308","author":"Pettitt","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1410","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.2337\/diabetes.49.12.2208","article-title":"Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: A study of discordant sibships","volume":"49","author":"Dabelea","year":"2000","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1411","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dmr.5610060101","article-title":"Diabetes mellitus in the Pima Indians: Incidence, risk factors and pathogenesis","volume":"6","author":"Knowler","year":"1990","journal-title":"Diabetes Metab Rev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1412","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2337\/diab.37.5.622","article-title":"Congenital susceptibility to NIDDM. Role of intrauterine environment","volume":"37","author":"Pettitt","year":"1988","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1413","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2337\/dc10-1455","article-title":"Frequent monitoring of A1c during pregnancy as a treatment tool to guide therapy","volume":"34","author":"Jovanovic","year":"2011","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.eprac.2022.08.002_bib1414","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1001\/jama.294.21.2751","article-title":"Manifestations of chronic disease during pregnancy","volume":"294","author":"Kaaja","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1415","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI200524531","article-title":"Gestational diabetes mellitus","volume":"115","author":"Buchanan","year":"2005","journal-title":"The Journal of clinical investigation"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1416","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1464-5491.2010.02995.x","article-title":"The risk of overt diabetes mellitus among women with gestational diabetes: A population-based study","volume":"27","author":"Chodick","year":"2010","journal-title":"Diabetic Med"},{"issue":"9677","key":"10.1016\/j.eprac.2022.08.002_bib1417","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(09)60731-5","article-title":"Type 2 diabetes mellitus after\u00a0gestational diabetes: A systematic review and meta-analysis","volume":"373","author":"Bellamy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.08.002_bib1418","series-title":"Classification of diabetes mellitus","year":"2019"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2022.08.002_bib1419","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.2337\/dc07-s207","article-title":"Low birth weight as a risk factor for gestational diabetes, diabetes, and impaired glucose tolerance during pregnancy","volume":"30","author":"Pettitt","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1420","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2337\/dc08-2077","article-title":"Fetuses of obese mothers develop insulin resistance in utero","volume":"32","author":"Catalano","year":"2009","journal-title":"Diabetes Care"},{"issue":"6809","key":"10.1016\/j.eprac.2022.08.002_bib1421","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/bmj.303.6809.1019","article-title":"Fetal and infant growth and impaired glucose tolerance at age 64","volume":"303","author":"Hales","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2022.08.002_bib1422","unstructured":"American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1423","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/01.AOG.0000245446.85868.73","article-title":"Rates of\u00a0postpartum glucose testing after gestational diabetes mellitus","volume":"108","author":"Russell","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1424","first-page":"1","article-title":"Nih consensus development conference: Diagnosing gestational diabetes mellitus","volume":"29","author":"Vandorsten","year":"2013","journal-title":"NIH consensus and state-of-the-science statements"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1425","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/AOG.0b013e31820fc6cf","article-title":"Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes","volume":"117","author":"Durnwald","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1426","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211243","article-title":"One hour versus two hours postprandial glucose measurement in gestational diabetes: A prospective study","volume":"25","author":"Weisz","year":"2005","journal-title":"J\u00a0Perinatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1427","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.06.010","article-title":"Randomized controlled trial of insulin detemir versus nph for the treatment of pregnant women with diabetes","volume":"213","author":"Herrera","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1428","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14740338.2015.1013533","article-title":"The use of insulin detemir during pregnancy: A safety evaluation","volume":"14","author":"Koren","year":"2015","journal-title":"Expert Opin Drug Safety"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1429","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00404-015-3692-3","article-title":"Safety of insulin analogs during pregnancy: A meta-analysis","volume":"292","author":"Lv","year":"2015","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1430","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/AOG.0000000000000285","article-title":"Trends in glyburide compared with insulin use for gestational diabetes treatment in the united states, 2000-2011","volume":"123","author":"Camelo Castillo","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1431","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/dmd.109.031245","article-title":"Pharmacokinetics of metformin during pregnancy","volume":"38","author":"Eyal","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1432","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015557","article-title":"Treatments for gestational diabetes: A systematic review and meta-analysis","volume":"7","author":"Farrar","year":"2017","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1433","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109985","article-title":"Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: A meta-analysis","volume":"9","author":"Poolsup","year":"2014","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib1434","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1435","doi-asserted-by":"crossref","first-page":"34.e31","DOI":"10.1016\/j.ajog.2013.03.022","article-title":"Randomized trial of metformin vs insulin in the management of gestational diabetes","volume":"209","author":"Spaulonci","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1436","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/diab.46.2.265","article-title":"Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group","volume":"46","author":"Anderson","year":"1997","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1437","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-0039-1694733","article-title":"Basal insulin analogs versus Neutral Protamine Hagedorn for type 2 diabetics","volume":"37","author":"Fishel Bartal","year":"2020","journal-title":"Am J Perinatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1438","article-title":"Different insulin types and regimens for pregnant women with pre-existing diabetes","volume":"2","author":"O'Neill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1439","first-page":"Pi29","article-title":"Pregnancy complications and perinatal outcome in diabetic women treated with humalog (insulin lispro) or regular human insulin during pregnancy","volume":"10","author":"Cypryk","year":"2004","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00592-008-0024-0","article-title":"Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: An italian experience","volume":"45","author":"Lapolla","year":"2008","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1441","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1464-5491.2003.00840.x","article-title":"Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (humalog)","volume":"20","author":"Masson","year":"2003","journal-title":"Diabetic Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1442","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc06-1887","article-title":"Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women","volume":"30","author":"Mathiesen","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1443","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.numecd.2009.12.010","article-title":"Use of insulin detemir during pregnancy","volume":"20","author":"Sciacca","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1444","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1464-5491.2009.02852.x","article-title":"Use of insulin detemir in pregnancy: A report on 10 type 1 diabetic women","volume":"26","author":"Lapolla","year":"2009","journal-title":"Diabetic Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1445","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dmrr.1213","article-title":"Basal insulin analogues in diabetic pregnancy: A literature review and baseline results of a randomised, controlled trial in type 1 diabetes","volume":"27","author":"Mathiesen","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1446","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2337\/dc11-2264","article-title":"Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes","volume":"35","author":"Mathiesen","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1447","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12958-022-00905-6","article-title":"Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: A nationwide population-based study","volume":"20","author":"Fornes","year":"2022","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1448","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14700","article-title":"Metformin for pregnancy and beyond: The pros and cons","volume":"39","author":"Newman","year":"2022","journal-title":"Diabetic Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1449","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2337\/diacare.25.7.1159","article-title":"Self-management education for adults with type 2 diabetes: A meta-analysis of the effect on glycemic control","volume":"25","author":"Norris","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1450","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jand.2018.06.303","volume":"119","author":"Marincic","year":"2019","journal-title":"J\u00a0Acad Nutr Dietetics"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1451","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/dc12-0080","article-title":"Structured type 1 diabetes education delivered within routine care: Impact on glycemic control and diabetes-specific quality of life","volume":"36","author":"Cooke","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1452","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0145721708323640","article-title":"Meta-analysis of quality of life outcomes following diabetes self-management training","volume":"34","author":"Cochran","year":"2008","journal-title":"Diabetes Educ"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1453","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12020-016-1168-2","article-title":"Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: A systematic review and meta-analysis","volume":"55","author":"He","year":"2017","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1454","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2337\/dc07-1871","article-title":"Nutritionist visits, diabetes classes, and hospitalization rates and charges: The urban diabetes study","volume":"31","author":"Robbins","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1455","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MLR.0000000000000653","article-title":"One-year outcomes of diabetes self-management training among medicare beneficiaries newly diagnosed with diabetes","volume":"55","author":"Strawbridge","year":"2017","journal-title":"Medical care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1456","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jdiacomp.2015.11.017","article-title":"Costs and effects of a telephonic diabetes self-management support intervention using health educators","volume":"30","author":"Schechter","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1457","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dme.13281","article-title":"Economic evaluation of chronic disease self-management for people with diabetes: A systematic review","volume":"34","author":"Teljeur","year":"2017","journal-title":"Diabetic Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1458","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jvs.2019.08.244","article-title":"A\u00a0systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers","volume":"71","author":"Musuuza","year":"2020","journal-title":"J Vasc Surg"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1459","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13288","article-title":"Multidisciplinary collaborative care in the management of patients with uncontrolled diabetes: A systematic review and meta-analysis","volume":"73","author":"Siaw","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1460","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/1060028017711454","article-title":"Impact of diabetes care by pharmacists as part of health care team in ambulatory settings: A systematic review and meta-analysis","volume":"51","author":"Fazel","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eprac.2022.08.002_bib1461","first-page":"21","article-title":"The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios","volume":"7","author":"McGill","year":"2017","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1462","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3122\/jabfm.2021.01.200187","article-title":"Interdisciplinary primary care team expertise and diabetes care management","volume":"34","author":"Miller-Rosales","year":"2021","journal-title":"J Am Board Fam Med"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.08.002_bib1463","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jcjd.2017.10.005","article-title":"Organization of diabetes care","volume":"42","author":"Clement","year":"2018","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1465","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12913-018-3186-7","article-title":"The effect of diabetes self-management education on hba1c and quality of life in african-americans: A systematic review and meta-analysis","volume":"18","author":"Cunningham","year":"2018","journal-title":"BMC Health Services Res"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1466","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/dme.12780","article-title":"Diabetes self-management programmes in older adults: A systematic review and meta-analysis","volume":"32","author":"Sherifali","year":"2015","journal-title":"Diabetic Med"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1467","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11892-015-0608-3","article-title":"Diabetes self-management interventions for adults with type 2 diabetes living in rural areas: A systematic literature review","volume":"15","author":"Lepard","year":"2015","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1468","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1017\/S1463423616000335","article-title":"Effectiveness of a community-based diabetes self-management education (dsme) program in a rural agricultural setting","volume":"18","author":"Paz-Pacheco","year":"2017","journal-title":"Prim Health Care Res Dev"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1469","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/jamia\/ocx025","article-title":"Do health information technology self-management interventions improve glycemic control in medically underserved adults with diabetes? A systematic review and meta-analysis","volume":"24","author":"Heitkemper","year":"2017","journal-title":"J Am Med Inform Assoc"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1470","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dme.13340","article-title":"Effectiveness of group-based self-management education for individuals with type 2 diabetes: A systematic review with meta-analyses and meta-regression","volume":"34","author":"Odgers-Jewell","year":"2017","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1471","first-page":"50","article-title":"Patient-centered community diabetes education program improves glycemic control in African-American patients with poorly controlled type 2 diabetes: Importance of point of care metabolic measurements","volume":"26","author":"Gaillard","year":"2015","journal-title":"J Natl Black Nurses Assoc"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1472","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jcjd.2019.04.010","article-title":"Culturally tailored self-management interventions for South Asians with type 2 diabetes: A systematic review","volume":"43","author":"Navodia","year":"2019","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1473","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/dme.12865","article-title":"Culturally appropriate health education for type 2 diabetes in ethnic minority groups: An updated cochrane review of randomized controlled trials","volume":"33","author":"Creamer","year":"2016","journal-title":"Diabetic Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1474","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/dc05-1942","article-title":"A\u00a0systematic review of interventions to improve diabetes care in socially disadvantaged populations","volume":"29","author":"Glazier","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1475","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archinternmed.2011.70","article-title":"Comparative effectiveness of goal setting in diabetes mellitus group clinics: Randomized clinical trial","volume":"171","author":"Naik","year":"2011","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1476","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12902-017-0222-2","article-title":"Impact of a structured multicomponent educational intervention program on metabolic control of patients with type 2 diabetes","volume":"17","author":"do Ros\u00e1rio Pinto","year":"2017","journal-title":"BMC Endocrine Disord"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1477","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11606-017-4023-0","article-title":"Telephone-delivered behavioral skills intervention for African American adults with type 2 diabetes: A randomized controlled trial","volume":"32","author":"Egede","year":"2017","journal-title":"J\u00a0General Intern Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1478","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.pec.2018.02.006","article-title":"The efficacy of telehealth delivered educational approaches for patients with chronic diseases: A systematic review","volume":"101","author":"Rush","year":"2018","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.eprac.2022.08.002_bib1479","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12913-016-1262-4","article-title":"Effect of a patient decision aid (pda) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict","volume":"16","author":"Bailey","year":"2016","journal-title":"BMC Health Services Res"},{"key":"10.1016\/j.eprac.2022.08.002_bib1480","article-title":"Development and evaluation of a computer-based, self-management tool for people recently diagnosed with type 2 diabetes","volume":"2016","author":"Booth","year":"2016","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.eprac.2022.08.002_bib1481","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fendo.2019.00348","article-title":"Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: A 2-year non-randomized clinical trial","volume":"10","author":"Athinarayanan","year":"2019","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1482","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.2196\/jmir.4052","article-title":"Long-term outcomes of a web-based diabetes prevention program: 2-year results of a single-arm longitudinal study","volume":"17","author":"Sepah","year":"2015","journal-title":"J\u00a0Med Internet Res"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1483","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/1932296817713506","article-title":"A\u00a0systematic review of reviews evaluating technology-enabled diabetes self-management education and support","volume":"11","author":"Greenwood","year":"2017","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1484","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jand.2018.11.013","article-title":"Impact of ENHANCED (diEtitiaNs Helping pAtieNts CarE for Diabetes) Telemedicine Randomized Controlled Trial on Diabetes Optimal Care Outcomes in Patients with Type 2 Diabetes","volume":"119","author":"Benson","year":"2019","journal-title":"J\u00a0Acad Nutr Dietetics"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1485","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.2196\/jmir.6944","article-title":"Insuonline, an electronic game for medical education on insulin therapy: A randomized controlled trial with primary care physicians","volume":"19","author":"Diehl","year":"2017","journal-title":"J\u00a0Med Internet Res"},{"issue":"50","key":"10.1016\/j.eprac.2022.08.002_bib1486","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013632","article-title":"Increased self-care activities and glycemic control rate in relation to health education via wechat among diabetes patients: A randomized clinical trial","volume":"97","author":"Dong","year":"2018","journal-title":"Medicine"},{"issue":"40","key":"10.1016\/j.eprac.2022.08.002_bib1487","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004664","article-title":"Impact of the conversation map tools in patients with type 2 diabetes mellitus: A PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Yang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.eprac.2022.08.002_bib1488","article-title":"Effect of a nurse-led diabetes self-management education program on glycosylated hemoglobin among adults with type 2 diabetes","volume":"2018","author":"Azami","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1489","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/dme.13092","article-title":"Optimizing diabetes control in people with type 2 diabetes through nurse-led telecoaching","volume":"33","author":"Odnoletkova","year":"2016","journal-title":"Diabetic Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1490","doi-asserted-by":"crossref","first-page":"102","DOI":"10.6061\/clinics\/2015(02)06","article-title":"Improvement in medication\u00a0adherence and self-management of diabetes with a clinical pharmacy program: A randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital","volume":"70","author":"Cani","year":"2015","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1491","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jep.12606","article-title":"Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: Results from a randomized controlled trial","volume":"24","author":"Aguiar","year":"2018","journal-title":"J\u00a0Eval Clin Pract"},{"issue":"23-24","key":"10.1016\/j.eprac.2022.08.002_bib1492","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1111\/jocn.13991","article-title":"Systematic review of peer education intervention programmes among individuals with type 2 diabetes","volume":"26","author":"Gatlin","year":"2017","journal-title":"J\u00a0Clin Nursing"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1493","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/1479164117696229","article-title":"Health effectiveness of community health workers as a diabetes self-management intervention","volume":"14","author":"Aponte","year":"2017","journal-title":"Diabetes Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1494","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0145721718777855","article-title":"Integration and utilization of peer leaders for diabetes self-management support: Results from project SEED (Support, Education, and Evaluation in Diabetes)","volume":"44","author":"Piatt","year":"2018","journal-title":"Diabetes Educ"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1495","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12913-018-3710-9","article-title":"The impact of integrating medical assistants and community health workers on diabetes care management in community health centers","volume":"18","author":"Rodriguez","year":"2018","journal-title":"BMC Health Services Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1497","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1186\/s12913-018-3655-z","volume":"18","author":"Campbell","year":"2018","journal-title":"BMC Health Services Res"},{"issue":"2-3","key":"10.1016\/j.eprac.2022.08.002_bib1498","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10880-015-9422-y","article-title":"Multisystemic therapy improves the patient-provider relationship in families of adolescents with poorly controlled insulin dependent diabetes","volume":"22","author":"Carcone","year":"2015","journal-title":"J\u00a0Clin Psychol Med Settings"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1499","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1037\/hea0000406","article-title":"A\u00a0model of parental distress and factors that mediate its link with parental monitoring of youth diabetes care, adherence, and glycemic control","volume":"35","author":"Robinson","year":"2016","journal-title":"Health Psychol"},{"key":"10.1016\/j.eprac.2022.08.002_bib1500","article-title":"Family support and its association with glycemic control in adolescents with type 1 diabetes mellitus in Riyadh, Saudi Arabia","volume":"2020","author":"AlHaidar","year":"2020","journal-title":"J\u00a0Diabetes Res"},{"issue":"Suppl 27","key":"10.1016\/j.eprac.2022.08.002_bib1501","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/pedi.12702","article-title":"ISPAD clinical practice\u00a0consensus guidelines 2018: Diabetes in adolescence","volume":"19","author":"Cameron","year":"2018","journal-title":"Pediatr diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2022.08.002_bib1502","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.2337\/dc22-S014","article-title":"14. Children and adolescents: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1503","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/pedi.12526","article-title":"Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes","volume":"19","author":"Kriska","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2022.08.002_bib1504","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ypmed.2016.10.020","article-title":"Effects of aerobic, resistance, and combined exercise training on insulin resistance markers in overweight or obese children and adolescents: A systematic review and meta-analysis","volume":"93","author":"Marson","year":"2016","journal-title":"Prev Med"},{"issue":"Suppl 27","key":"10.1016\/j.eprac.2022.08.002_bib1505","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/pedi.12736","article-title":"ISPAD clinical practice consensus guidelines 2018: Psychological care of children and adolescents with type 1 diabetes","volume":"19","author":"Delamater","year":"2018","journal-title":"Pediatr diabetes"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1506","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1037\/ccp0000608","article-title":"Supporting teen problem-solving (STEPS) 3 year outcomes: Preventing diabetes-specific emotional distress and depressive symptoms in adolescents with type 1 diabetes","volume":"88","author":"Weissberg-Benchell","year":"2020","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.eprac.2022.08.002_bib1507","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.psyneuen.2016.04.019","article-title":"Symptoms of depression and anxiety in youth with type 1 diabetes: A systematic review and meta-analysis","volume":"70","author":"Buchberger","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"13","key":"10.1016\/j.eprac.2022.08.002_bib1508","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1177\/1359105316669580","article-title":"Psychological factors associated with diabetes self-management among adolescents with type 1 diabetes: A systematic review","volume":"23","author":"Martinez","year":"2018","journal-title":"J Health Psychol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1509","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ijpo.12263","article-title":"Intervention for childhood obesity based on parents only or parents and child compared with follow-up alone","volume":"13","author":"Yackobovitch-Gavan","year":"2018","journal-title":"Pediatr Obes"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1510","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1037\/fam0000330","article-title":"Family dinner frequency interacts with dinnertime context in associations with child and parent BMI outcomes","volume":"31","author":"Horning","year":"2017","journal-title":"J Fam Psychol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1511","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ijpo.12218","article-title":"Parental beliefs about portion size, not children's own beliefs, predict child BMI","volume":"13","author":"Potter","year":"2018","journal-title":"Pediatr Obes"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1512","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2105\/AJPH.2018.304696","article-title":"Multicomponent obesity prevention intervention in low-income preschoolers: Primary and subgroup analyses of the net-works randomized clinical trial, 2012-2017","volume":"108","author":"French","year":"2018","journal-title":"Am J Public Health"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1513","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/oby.22300","article-title":"Effects of a community-based diabetes prevention program for latino youth with obesity: A randomized controlled trial","volume":"26","author":"Soltero","year":"2018","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1514","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/obr.12245","article-title":"Longitudinal impact of sleep on overweight and obesity in children and adolescents: A systematic review and bias-adjusted meta-analysis","volume":"16","author":"Fatima","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.eprac.2022.08.002_bib1515","article-title":"Exercise and bmi in overweight and obese children and adolescents: A systematic review and trial sequential meta-analysis","volume":"2015","author":"Kelley","year":"2015","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1516","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JSM.0000000000000419","article-title":"Associations\u00a0between pedometer-determined physical activity and adiposity\u00a0in children and adolescents: Systematic review","volume":"28","author":"Miguel-Berges","year":"2018","journal-title":"Clin J Sport Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1517","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00431-018-3091-4","article-title":"Healthy lifestyle promotion in primary schools through the board game kaledo: A pilot cluster randomized trial","volume":"177","author":"Viggiano","year":"2018","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1518","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ijpo.12438","article-title":"Home-based exergaming among children with overweight and obesity: A randomized clinical trial","volume":"13","author":"Staiano","year":"2018","journal-title":"Pediatr Obes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1519","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamapediatrics.2013.3436","article-title":"Effects of a pediatric weight management program with and without active video games a randomized trial","volume":"168","author":"Trost","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1520","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ijpo.12117","article-title":"A\u00a0randomized controlled trial of dance exergaming for exercise training in overweight and obese adolescent girls","volume":"12","author":"Staiano","year":"2017","journal-title":"Pediatr Obes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1521","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/her\/cyw011","article-title":"A\u00a0youth mentor-led nutritional intervention in urban recreation centers: A promising strategy for childhood obesity prevention in low-income neighborhoods","volume":"31","author":"Sato","year":"2016","journal-title":"Health Educ Res."},{"key":"10.1016\/j.eprac.2022.08.002_bib1522","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.5888\/pcd14.170130","article-title":"Compa\u00f1eros: High school students mentor middle school students to address obesity among Hispanic adolescents","volume":"14","author":"Arlinghaus","year":"2017","journal-title":"Prev Chronic Dis."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1523","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12889-017-5006-0","article-title":"Follow-up of a healthy lifestyle education program (the edal study): Four years after cessation of randomized controlled trial intervention","volume":"18","author":"Llaurad\u00f3","year":"2018","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1524","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.amepre.2018.01.017","article-title":"Effects of before-school physical activity on obesity prevention and wellness","volume":"54","author":"Whooten","year":"2018","journal-title":"Am J Prevent Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1525","doi-asserted-by":"crossref","first-page":"k211","DOI":"10.1136\/bmj.k211","article-title":"Effectiveness of a childhood obesity prevention programme delivered through schools, targeting 6 and 7 year olds: Cluster randomised controlled trial (WAVES study)","volume":"360","author":"Adab","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12887-017-0975-9","article-title":"Effective nationwide school-based participatory extramural program on adolescent body mass index, health knowledge and behaviors","volume":"18","author":"Heo","year":"2018","journal-title":"BMC Pediatr"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1527","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nutres.2015.01.002","article-title":"A\u00a0meta-analysis of school-based obesity prevention programs demonstrates limited efficacy of decreasing childhood obesity","volume":"35","author":"Hung","year":"2015","journal-title":"Nutr Res."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1528","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/obr.12446","article-title":"The effects of school-based lifestyle interventions on body mass index and blood pressure: A multivariate multilevel meta-analysis of randomized controlled trials","volume":"17","author":"Oosterhoff","year":"2016","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1529","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1139\/apnm-2017-0348","article-title":"Effectiveness of a school-based program focusing on diet and health habits taught through physical exercise","volume":"43","author":"Pablos","year":"2018","journal-title":"Appl Physiol Nutr Metab."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1530","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/josh.12544","article-title":"Nutrition education and body mass index in grades k-12: A systematic review","volume":"87","author":"Price","year":"2017","journal-title":"J Sch Health."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1531","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jneb.2016.12.007","article-title":"A\u00a0multicomponent, school-based intervention, the shaping healthy choices program, improves nutrition-related outcomes","volume":"49","author":"Scherr","year":"2017","journal-title":"J Nutr Educ Behav"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1532","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204560","article-title":"Effectiveness of school-based physical activity and nutrition interventions with direct parental involvement on children's BMI and energy balance-related behaviors - a systematic review","volume":"13","author":"Verjans-Janssen","year":"2018","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1533","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000486512","article-title":"Current guidelines for obesity prevention in childhood and adolescence","volume":"11","author":"Weihrauch-Bl\u00fcher","year":"2018","journal-title":"Obes Facts"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1534","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/dme.13589","article-title":"Transfer from paediatric to adult care for young adults with type 2 diabetes: The search for diabetes in youth study","volume":"35","author":"Agarwal","year":"2018","journal-title":"Diabetic Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1535","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dme.13782","article-title":"Diabetes transition care and adverse events: A population-based cohort study in Ontario, Canada","volume":"35","author":"Shulman","year":"2018","journal-title":"Diabetic Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1536","article-title":"Transition of care for adolescents from\u00a0paediatric services to adult health services","volume":"4","author":"Campbell","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1537","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.pedn.2015.05.022","article-title":"Systematic review of the impact of transition interventions for adolescents with chronic illness on transfer from pediatric to adult healthcare","volume":"30","author":"Chu","year":"2015","journal-title":"J Pediatr Nurs."},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1538","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamapediatrics.2017.3233","article-title":"Effect of financial incentives on glucose monitoring adherence and glycemic control among adolescents and young adults with type 1 diabetes: A randomized clinical trial","volume":"171","author":"Wong","year":"2017","journal-title":"JAMA Pediatr."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1539","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pedi.12373","article-title":"Stabilization of glycemic control and improved quality of life using a shared medical appointment model in adolescents with type 1 diabetes in suboptimal control","volume":"18","author":"Floyd","year":"2017","journal-title":"Pediatr diabetes"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1540","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jadohealth.2016.10.002","article-title":"Components of interventions that improve transitions to adult care for adolescents with type 1 diabetes","volume":"60","author":"Schultz","year":"2017","journal-title":"J Adolesc Health."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1541","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2337\/dc18-2187","article-title":"Closing the gap: Results of the multicenter Canadian randomized controlled trial of structured transition in young adults with type 1 diabetes","volume":"42","author":"Spaic","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1542","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237571","article-title":"Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes","volume":"15","author":"Wahabi","year":"2020","journal-title":"PloS one"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1543","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/01443615.2014.925856","article-title":"Type 2 diabetes in pregnancy:\u00a0Rates of fetal malformations and level of preconception care","volume":"34","author":"Callec","year":"2014","journal-title":"J\u00a0Obstet Gynaecol."},{"key":"10.1016\/j.eprac.2022.08.002_bib1544","author":"Goldwire Tutt"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.48083\/VVMV5977","article-title":"Does type 1 diabetes affect male infertility: Type 1 diabetes exchange registry-based analysis","volume":"2","author":"Raheem","year":"2021","journal-title":"Soc Int Urol J"},{"key":"10.1016\/j.eprac.2022.08.002_bib1546","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fendo.2018.00268","article-title":"Diabetes mellitus and infertility: Different pathophysiological effects in type 1 and type 2 on sperm function","volume":"9","author":"Condorelli","year":"2018","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1547","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/humupd\/dmx033","article-title":"Diabetes-induced hyperglycemia impairs male reproductive function: A systematic review","volume":"24","author":"Maresch","year":"2018","journal-title":"Hum Reprod Update."},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1548","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00125-014-3376-8","article-title":"Fertility is reduced in women and in men with type 1 diabetes: Results from the Type 1 Diabetes Genetics Consortium (T1DGC)","volume":"57","author":"Wiebe","year":"2014","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1549","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bju.14558","article-title":"Undiagnosed prediabetes is highly prevalent in primary infertile men - results from a cross-sectional study","volume":"123","author":"Boeri","year":"2019","journal-title":"BJU international"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1550","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.2047-2927.2012.00031.x","article-title":"Seminal, ultrasound and psychobiological parameters correlate with metabolic syndrome in male members of infertile couples","volume":"1","author":"Lotti","year":"2013","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1551","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jdiacomp.2016.04.002","article-title":"Diabetes mellitus and functional sperm characteristics: A meta-analysis of observational studies","volume":"30","author":"Pergialiotis","year":"2016","journal-title":"Diabetes Complications."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1552","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/andr.12097","article-title":"Reproductive function in male patients with type 1 diabetes mellitus","volume":"3","author":"La Vignera","year":"2015","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1553","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/humupd\/dmx021","article-title":"The diagnosis of male infertility: An analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities","volume":"23","author":"Barratt","year":"2017","journal-title":"Human reproduction update"},{"key":"10.1016\/j.eprac.2022.08.002_bib1554","doi-asserted-by":"crossref","DOI":"10.1038\/s41443-021-00496-7","article-title":"Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome","author":"Louters","year":"2021","journal-title":"Int J Impotence Research."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1555","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/diacare.26.4.1181","article-title":"Thyroid dysfunction in patients with type 1 diabetes: A longitudinal study","volume":"26","author":"Umpierrez","year":"2003","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1556","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1210\/jc.2018-02697","article-title":"Functional hypogonadotropic hypogonadism in men: Underlying neuroendocrine mechanisms and natural history","volume":"104","author":"Dwyer","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1557","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(19)30345-6","article-title":"Diabetes: A metabolic and reproductive disorder in women","volume":"8","author":"Thong","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1558","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.mito.2010.03.002","article-title":"Maternal diabetes and oocyte quality","volume":"10","author":"Wang","year":"2010","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1559","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/mrd.22299","article-title":"The effect of peri-conception hyperglycaemia and the involvement of the hexosamine biosynthesis pathway in mediating oocyte and embryo developmental competence","volume":"81","author":"Frank","year":"2014","journal-title":"Mol Reprod Dev"},{"key":"10.1016\/j.eprac.2022.08.002_bib1560","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.maturitas.2016.11.019","article-title":"Ovarian aging in women with diabetes: An overview","volume":"96","author":"Wellons","year":"2017","journal-title":"Maturitas"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1561","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2337\/diabetes.50.8.1857","article-title":"Menopause in type 1 diabetic women: Is it premature?","volume":"50","author":"Dorman","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1562","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/humupd\/dms024","article-title":"Female reproduction and type 1 diabetes: From mechanisms to clinical findings","volume":"18","author":"Codner","year":"2012","journal-title":"Hum Reprod Update."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1563","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1210\/clinem\/dgaa513","article-title":"Anti-m\u00fcllerian hormone and ovarian reserve: Update on assessing ovarian function","volume":"105","author":"Moolhuijsen","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1564","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2018-00642","article-title":"Midluteal progesterone: A marker of treatment outcomes in couples with unexplained infertility","volume":"103","author":"Hansen","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1565","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","volume":"12","author":"Tso","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1566","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1743-6109.2012.02717.x","article-title":"Hormonal association and sexual dysfunction in patients with impaired fasting glucose: A cross-sectional and longitudinal study","volume":"9","author":"Corona","year":"2012","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1567","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/13685538.2014.936000","article-title":"The prevalence of prediabetes in population of polish men with late-onset hypogonadism","volume":"17","author":"Rabijewski","year":"2014","journal-title":"Aging Male."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1568","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074173","article-title":"Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome","volume":"8","author":"Ho","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.eprac.2022.08.002_bib1569","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000485999","article-title":"Metabolic syndrome in male hypogonadism","volume":"49","author":"Rastrelli","year":"2018","journal-title":"Front Horm Res."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1570","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5653\/cerm.2019.00290","article-title":"Misuse of testosterone replacement therapy in men in infertile couples and its influence on infertility treatment","volume":"46","author":"Song","year":"2019","journal-title":"Clin Exp Reprod Med."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1571","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/dc18-2388","article-title":"Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study","volume":"42","author":"Yassin","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1572","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1074248417691136","article-title":"Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: A real-life observational registry\u00a0study setting comparing treated and untreated (control) groups","volume":"22","author":"Traish","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1573","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2013.05.002","article-title":"Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes","volume":"27","author":"Corona","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1574","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1111\/j.1743-6109.2010.01931.x","article-title":"Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study","volume":"7","author":"Aversa","year":"2010","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1575","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/SLA.0000000000000819","article-title":"New-onset diabetes after distal pancreatectomy: A systematic review","volume":"261","author":"De Bruijn","year":"2015","journal-title":"Ann Surg."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1576","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.transproceed.2018.02.075","article-title":"Association of body mass index and the risk of new-onset diabetes after kidney transplantation: A meta-analysis","volume":"50","author":"Chang","year":"2018","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1577","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ctr.12510","article-title":"Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipients","volume":"29","author":"Gaynor","year":"2015","journal-title":"Clin Transplant."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1578","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/TP.0000000000002811","article-title":"Body weight parameters are related to morbidity and mortality after liver transplantation: A systematic review and meta-analysis","volume":"103","author":"Beckmann","year":"2019","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1579","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CJI.0000000000000218","article-title":"Diabetes and blood glucose disorders under anti-PD1","volume":"41","author":"Magis","year":"2018","journal-title":"J Immunother."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1580","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1432-2277.2008.00804.x","article-title":"New onset diabetes mellitus after liver transplantation and hepatitis c virus infection: Meta-analysis of clinical studies","volume":"22","author":"Chen","year":"2009","journal-title":"Transpl Int."},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1581","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/j.1600-6143.2005.01040.x","article-title":"Post-transplant diabetes mellitus and hcv seropositive status after renal transplantation: Meta-analysis of clinical studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1582","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.transproceed.2006.10.098","article-title":"Short-term results under three different immunosuppressive regimens at one center","volume":"38","author":"Schaefer","year":"2006","journal-title":"Transplantation Proc"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1583","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1584","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ndt\/gfp617","article-title":"Impaired glucose homeostasis in renal transplant recipients receiving basiliximab","volume":"25","author":"Aaseb\u00f8","year":"2010","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1585","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1556\/APhysiol.101.2014.3.13","article-title":"Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation","volume":"101","author":"Borda","year":"2014","journal-title":"Acta Physiol Hung."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1586","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/07435800.2015.1094088","article-title":"Hypomagnesemia linked to new-onset diabetes mellitus after\u00a0kidney transplantation: A systematic review and meta-analysis","volume":"41","author":"Cheungpasitporn","year":"2016","journal-title":"Endocr Res."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1587","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcjd.2016.03.001","article-title":"The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis","volume":"40","author":"Cheungpasitporn","year":"2016","journal-title":"Can J Diabetes."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1588","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: Evidence from the symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1589","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.humimm.2019.08.006","article-title":"Immune phenotype predicts new onset diabetes after kidney transplantation","volume":"80","author":"Ducloux","year":"2019","journal-title":"Hum Immunol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1590","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1591","first-page":"121","article-title":"Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: A prospective, randomized, controlled study","volume":"9","author":"Gheith","year":"2011","journal-title":"Exp Clin Transplant."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1592","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1593","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/TP.0b013e3181c518cc","article-title":"Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis","volume":"89","author":"Knight","year":"2010","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1594","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/01.tp.0000282914.20578.7b","article-title":"Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis c virus: Impact on hepatic fibrosis progression at one year","volume":"84","author":"Kato","year":"2007","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1595","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A\u00a0prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1596","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/tri.12605","article-title":"Does belatacept improve outcomes for kidney transplant recipients? A systematic review","volume":"28","author":"Talawila","year":"2015","journal-title":"Transpl Int."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1597","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.24385","article-title":"Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and meta-analysis of controlled studies","volume":"54","author":"Goralczyk","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1598","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.dsx.2019.04.020","article-title":"Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy","volume":"13","author":"Thiruvengadam","year":"2019","journal-title":"Diabetes Metab Syndr."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1599","first-page":"806","article-title":"New-onset diabetes mellitus after heart transplantation - incidence, risk factors and impact on clinical outcome","volume":"81","author":"Kim","year":"2017","journal-title":"Circ\u00a0J."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1600","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1601","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CMR.0000000000000585","article-title":"Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients","volume":"29","author":"Gauci","year":"2019","journal-title":"Melanoma Res"},{"issue":"108633","key":"10.1016\/j.eprac.2022.08.002_bib1602","article-title":"Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes","volume":"172","author":"Leiter","year":"2021","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.eprac.2022.08.002_bib1603","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108115","article-title":"Immune checkpoints inhibitors and hyperglycemia: A meta-analysis of randomized controlled trials","volume":"162","author":"Monami","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib1604","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025488","article-title":"A\u00a0systematic review and meta-analysis on the regulation of programmed cell death-1 on t-cells in type 2 diabetes","volume":"100","author":"Nyambuya","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1605","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00262-020-02699-1","article-title":"Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review","volume":"70","author":"Zhao","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1606","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1607","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1608","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-011-2174-9","article-title":"Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: A randomised controlled trial","volume":"54","author":"van Raalte","year":"2011","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1609","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00125-013-3016-8","article-title":"Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: A randomised controlled trial","volume":"56","author":"van Raalte","year":"2013","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1610","first-page":"639","article-title":"Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction","volume":"64","author":"den Uyl","year":"2012","journal-title":"American Academy of Sleep Medicine position statement. J Clin Sleep Med."},{"issue":"15","key":"10.1016\/j.eprac.2022.08.002_bib1611","doi-asserted-by":"crossref","first-page":"F167","DOI":"10.1097\/00002030-199815000-00001","article-title":"Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in hiv-1-infected patients","volume":"12","author":"Walli","year":"1998","journal-title":"AIDS."},{"key":"10.1016\/j.eprac.2022.08.002_bib1612","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1613","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ajt.12518","article-title":"Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation\u2013a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Haidinger","year":"2014","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1614","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Str\u00f8m Halden","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1615","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.transproceed.2004.12.085","article-title":"Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus","volume":"37","author":"Oberholzer","year":"2005","journal-title":"Transplantation Proc."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1616","first-page":"1726","article-title":"Prospective randomized study of conversion from tacrolimus to cyclosporine a to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation","volume":"18","author":"Wissing","year":"2018","journal-title":"J Transplant."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1617","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: A randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1618","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1619","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.transproceed.2007.06.035","article-title":"Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation","volume":"39","author":"Ramos-Cebri\u00e1n","year":"2007","journal-title":"Transplantation Proc."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1620","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/TP.0b013e3181605ebf","article-title":"Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia","volume":"85","author":"Sharif","year":"2008","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1621","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: A multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1622","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.sleh.2015.10.004","article-title":"National Sleep Foundation's updated sleep duration recommendations: Final report","volume":"1","author":"Hirshkowitz","year":"2015","journal-title":"Sleep Health"},{"key":"10.1016\/j.eprac.2022.08.002_bib1623","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejim.2016.11.010","article-title":"Continuous positive airway pressure and diabetes risk in sleep apnea patients: A systemic review and meta-analysis","volume":"39","author":"Chen","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1624","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1164\/rccm.200909-1423OC","article-title":"Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes","volume":"181","author":"Aronsohn","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1625","first-page":"2115","article-title":"Sleep is essential to health: An american academy of sleep medicine position statement","volume":"17","author":"Ramar","year":"2021","journal-title":"American Academy of Sleep Medicine position statement. J Clin Sleep Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1626","article-title":"Use and performance of the STOP-bang questionnaire for obstructive sleep apnea screening across geographic regions: A systematic review and meta-analysis","volume":"4","author":"Pivetta","year":"2021","journal-title":"JAMA Netw Open. J Clin Sleep Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1627","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3389\/fendo.2018.00714","article-title":"The clinical impact of systematic screening for obstructive sleep apnea in a type 2 diabetes population-adherence to the screening-diagnostic process and the acceptance\u00a0and adherence to the CPAP therapy compared to regular sleep clinic patients","volume":"9","author":"Westlake","year":"2018","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1628","first-page":"486","article-title":"The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes","volume":"194","author":"Shaw","year":"2016","journal-title":"American Academy of Sleep Medicine position statement. J Clin Sleep Med."},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1629","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1164\/rccm.201510-1942OC","article-title":"Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes. A randomized clinical trial","volume":"194","author":"Mart\u00ednez-Cer\u00f3n","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.eprac.2022.08.002_bib1630","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2015.5","article-title":"Effects of continuous positive airway pressure therapy on glycaemic control, insulin sensitivity and body mass index in patients with obstructive sleep apnoea and type 2 diabetes: A systematic review and meta-analysis","volume":"25","author":"Feng","year":"2015","journal-title":"NPJ Prim Care Respir Med."},{"key":"10.1016\/j.eprac.2022.08.002_bib1631","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.sleep.2018.12.017","article-title":"Efficacy of continuous positive airway pressure (CPAP) preventing type 2 diabetes mellitus in patients with obstructive sleep apnea hypopnea syndrome (OSAHS) and insulin resistance: A systematic review and meta-analysis","volume":"62","author":"Abud","year":"2019","journal-title":"Sleep Med."},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1632","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1633","doi-asserted-by":"crossref","first-page":"317","DOI":"10.5665\/sleep.5436","article-title":"The effect of changes in cardiorespiratory fitness and weight on obstructive sleep apnea severity in overweight adults with type 2 diabetes","volume":"39","author":"Kline","year":"2016","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1634","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jsr.12559","article-title":"Effects of a lifestyle intervention on REM sleep-related OSA severity in obese individuals with type 2 diabetes","volume":"26","author":"Shechter","year":"2017","journal-title":"J Sleep Res."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1635","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1164\/rccm.201912-2511OC","article-title":"Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study","volume":"203","author":"Kuna","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1636","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11325-016-1428-7","article-title":"Cpap therapy for patients with sleep apnea and type 2 diabetes mellitus improves control of blood pressure","volume":"21","author":"Lam","year":"2017","journal-title":"Sleep Breath."},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1637","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc19-2006","article-title":"Continuous positive airway pressure treatment, glycemia, and diabetes risk in obstructive sleep apnea and comorbid cardiovascular disease","volume":"43","author":"Loffler","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1638","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/dom.14247","article-title":"Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis","volume":"23","author":"Shang","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1639","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2337\/diacare.23.7.934","article-title":"Depression and poor glycemic control: A meta-analytic review of the literature","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1640","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archgenpsychiatry.2010.176","article-title":"Increased mortality risk in women with depression and diabetes mellitus","volume":"68","author":"Pan","year":"2011","journal-title":"Arch Gen Psychiatry."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1641","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181218","article-title":"Reduction of diabetes-related distress predicts improved depressive symptoms: A secondary analysis of the DIAMOS study","volume":"12","author":"Reimer","year":"2017","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1642","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020412","volume":"8","author":"Pols","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1643","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11606-018-4705-2","article-title":"The importance of addressing depression and diabetes distress in adults with type 2 diabetes","volume":"34","author":"Owens-Gary","year":"2019","journal-title":"J\u00a0General Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1644","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/dme.13779","article-title":"WHO-5 and BDI-II are acceptable screening instruments for depression in people with diabet","volume":"35","author":"Rauwerda","year":"2018","journal-title":"Diabet. Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1645","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S1352465817000492","article-title":"Is cognitive behavioural therapy focusing on depression and anxiety effective for people with long-term physical health conditions? A controlled trial in the context of type 2 diabetes mellitus","volume":"46","author":"Wroe","year":"2018","journal-title":"Behav Cogn Psychother."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1646","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1359105317713360","article-title":"The effectiveness of cognitive behavioural therapy for depressed patients with diabetes: A systematic review","volume":"24","author":"Kanapathy","year":"2019","journal-title":"J Health Psychol."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1647","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2337\/dc18-2400","article-title":"Program ACTIVE II: Outcomes from a randomized, multistate community-based depression treatment for rural and urban adults with type 2 diabetes","volume":"42","author":"de Groot","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1648","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2017.07.001","article-title":"Promotora assisted depression and self-care management among predominantly Latinos with concurrent chronic illness: Safety net care system clinical trial results","volume":"61","author":"Ell","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1649","doi-asserted-by":"crossref","DOI":"10.2196\/12246","article-title":"A\u00a0web-based cognitive behavior therapy intervention to improve social and occupational functioning in adults with type 2 diabetes (the SpringBoarD trial): Randomized controlled trial","volume":"21","author":"Clarke","year":"2019","journal-title":"J Med Internet Res."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1650","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10865-018-9984-x","article-title":"Internet-delivered cognitive behaviour therapy for chronic health conditions: A systematic review and meta-analysis","volume":"42","author":"Mehta","year":"2019","journal-title":"J Behav Med."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1651","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.comppsych.2013.02.001","article-title":"Depression and\u00a0major weight gain: A 6-year prospective follow-up of outpatients","volume":"54","author":"Heiskanen","year":"2013","journal-title":"Compr Psychiatry."},{"issue":"27","key":"10.1016\/j.eprac.2022.08.002_bib1652","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1056\/NEJMoa1003955","article-title":"Collaborative care for patients with depression and chronic illnesses","volume":"363","author":"Katon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1653","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.12659\/MSM.899571","article-title":"Improvement of glycemic control in insulin-dependent diabetics with depression by concomitant treatment with antidepressants","volume":"22","author":"Radojkovic","year":"2016","journal-title":"Med Sci Monit."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1654","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PSY.0000000000000707","article-title":"The association between selective serotonin reuptake inhibitors and glycemia: A systematic review and meta-analysis of randomized controlled trials","volume":"81","author":"Tharmaraja","year":"2019","journal-title":"Psychosom Med."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1655","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pcd.2018.09.003","article-title":"Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients","volume":"13","author":"Rachdi","year":"2019","journal-title":"Prim Care Diabetes."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1656","first-page":"360","article-title":"Psychosocial and clinical outcomes of a cognitive behavioral therapy for Asians and Pacific Islanders with type 2 diabetes: A randomized clinical trial","volume":"74","author":"Inouye","year":"2015","journal-title":"Hawaii J Med Public Health."},{"key":"10.1016\/j.eprac.2022.08.002_bib1657","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diabres.2016.07.022","article-title":"A\u00a0randomized, controlled trial of a stress management intervention for latinos with type 2 diabetes delivered by community health workers: Outcomes for psychological wellbeing, glycemic control, and cortisol","volume":"120","author":"Wagner","year":"2016","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.eprac.2022.08.002_bib1658","author":"World Health Organization"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1659","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/1403494819885727","article-title":"Social inequality in lifestyle, motivation to change lifestyle and received health advice in individuals with diabetes: A nationwide study","volume":"48","author":"Andersen","year":"2020","journal-title":"Scand J Public Health."},{"issue":"Suppl 4","key":"10.1016\/j.eprac.2022.08.002_bib1660","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.2105\/AJPH.2014.302200","article-title":"Social determinants of health equity","volume":"104","author":"Marmot","year":"2014","journal-title":"Am J Public Health."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1661","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40618-015-0384-6","article-title":"Socioeconomic status and prevalence of self-reported diabetes among adults in tehran: Results from a large population-based cross-sectional study (Urban Heart-2)","volume":"39","author":"Asadi-Lari","year":"2016","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1662","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3008","article-title":"Socio-economic status and hbA(1c) in type 2 diabetes: A systematic review and meta-analysis","volume":"34","author":"Bijlsma-Rutte","year":"2018","journal-title":"Diabetes Metab Res Rev."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1663","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12902-018-0279-6","article-title":"Socioeconomic status and time in glucose target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC study","volume":"18","author":"Tan","year":"2018","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1664","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/dme.13519","article-title":"Inequalities in glycaemic control, hypoglycaemia and diabetic ketoacidosis according to socio-economic status and area-level deprivation in type 1 diabetes mellitus: A systematic review","volume":"35","author":"Lindner","year":"2018","journal-title":"Diabet. Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1665","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18020792","article-title":"The association between social determinants of health and self-reported diabetic retinopathy: An exploratory analysis","volume":"18","author":"Silverberg","year":"2021","journal-title":"Int J Environ Res Public Health."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1666","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dci20-0053","article-title":"Social determinants of health and diabetes: A scientific review","volume":"44","author":"Hill-Briggs","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1667","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3945\/jn.116.231365","article-title":"Psychological distress mediates the association between food insecurity and suboptimal sleep quality in Latinos with type 2 diabetes mellitus","volume":"146","author":"Berm\u00fadez-Mill\u00e1n","year":"2016","journal-title":"J Nutr."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1668","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1090198116639289","article-title":"Emotional and behavioral aspects of diabetes in american indians\/alaska natives","volume":"44","author":"Scarton","year":"2017","journal-title":"American Indians\/Alaska Natives. Health Educ Behav."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1669","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/1090198119868232","article-title":"Outcomes of a weight loss intervention to prevent diabetes among low-income residents of East Harlem, New York","volume":"46","author":"Mayer","year":"2019","journal-title":"Health Educ Behav"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1670","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.amepre.2017.01.032","article-title":"Multiple risk behavior interventions: Meta-analyses of RCTs","volume":"53","author":"Meader","year":"2017","journal-title":"Am J Prevent Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1671","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018826","article-title":"Do quality improvement initiatives for diabetes care address social inequities? Secondary analysis of a systematic review","volume":"8","author":"Lu","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1672","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/1753-0407.12889","article-title":"Systematic review of sociodemographic representation and cultural responsiveness in psychosocial and behavioral interventions with adolescents with type 1 diabetes","volume":"11","author":"Morone","year":"2019","journal-title":"J Diabetes."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1673","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1357633X17704346","article-title":"Telemedicine consultation for patients with diabetes mellitus: A cluster randomised controlled trial","volume":"24","author":"Sood","year":"2018","journal-title":"J\u00a0Telemed Telecare."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1674","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00592-017-1084-9","article-title":"Teleconsultation in type 1 diabetes mellitus (TELEDIABE)","volume":"55","author":"Bertuzzi","year":"2018","journal-title":"Acta Diabetol."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1675","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00592-019-01300-1","article-title":"A\u00a0randomized controlled trial comparing a telemedicine therapeutic intervention with routine care in adults with type 1 diabetes mellitus treated by insulin pumps","volume":"56","author":"Yaron","year":"2019","journal-title":"Acta Diabetol."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1676","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/dc19-0739","article-title":"Randomized study to evaluate the impact of telemedicine care in patients with type 1 diabetes with multiple doses of insulin and suboptimal HbA(1c) in Andalusia (Spain): PLATEDIAN study","volume":"43","author":"Ruiz de Adana","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1677","article-title":"Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1678","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/1357633X15608984","article-title":"Telemedicine compared with standard care in type 2 diabetes mellitus: A randomized trial in an outpatient clinic","volume":"22","author":"Rasmussen","year":"2016","journal-title":"J Telemed Telecare"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1679","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/tmj.2017.0203","article-title":"Smart care based on telemonitoring and telemedicine for type 2 diabetes care: Multi-center randomized controlled trial","volume":"24","author":"Jeong","year":"2018","journal-title":"Telemed J E Health."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1680","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12884-020-02892-1","article-title":"Effectiveness of telemedicine for pregnant women with gestational diabetes mellitus: An updated meta-analysis of 32 randomized controlled trials with trial sequential analysis","volume":"20","author":"Xie","year":"2020","journal-title":"BMC Pregnancy Childbirth."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1681","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/oby.22715","article-title":"Mobile application interventions and\u00a0weight loss in type 2 diabetes: A meta-analysis","volume":"28","author":"Cai","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1682","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1357633X18776823","article-title":"Effect of telemedicine intervention on hypoglycaemia in diabetes patients: A systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Hu","year":"2019","journal-title":"Telemed Telecare."},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1683","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/MLR.0000000000001387","article-title":"Racial differences in the effectiveness of a multifactorial telehealth intervention to slow diabetic kidney disease","volume":"58","author":"Kobe","year":"2020","journal-title":"Med Care."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1684","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1357633X18822575","article-title":"Pharmacist-led telehealth disease management program for patients with diabetes and depression","volume":"26","author":"Cohen","year":"2020","journal-title":"J Telemed Telecare."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1685","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004188","article-title":"Cluster-randomized trial to evaluate a centralized clinical pharmacy service in private family medicine offices","volume":"11","author":"Carter","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1686","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/dc17-0303","article-title":"Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: A randomized controlled trial","volume":"40","author":"Kempf","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1687","first-page":"162","article-title":"Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: A systematic review","author":"Rinaldi","year":"2020","journal-title":"Diabetes Res Clin Pract."},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1688","doi-asserted-by":"crossref","DOI":"10.2196\/16791","article-title":"Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: An umbrella review of systematic reviews and meta-analyses","volume":"22","author":"Timpel","year":"2020","journal-title":"J\u00a0Med Internet Res"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1689","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/1357633X16657500","article-title":"An internet-based health gateway device for interactive communication and automatic data uploading: Clinical efficacy for type 2 diabetes in a multi-centre trial","volume":"23","author":"Cho","year":"2017","journal-title":"J Telemed Telecare."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1690","doi-asserted-by":"crossref","DOI":"10.2196\/10321","article-title":"Mobile app for improved self-management of type 2 diabetes: Multicenter pragmatic randomized controlled trial","volume":"7","author":"Agarwal","year":"2019","journal-title":"JMIR Mhealth Uhealth."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1691","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/1357633X17723943","article-title":"Effects of telemonitoring on glycaemic control and healthcare costs in type 2 diabetes: A randomised controlled trial","volume":"24","author":"Warren","year":"2018","journal-title":"J Telemed Telecare"},{"key":"10.1016\/j.eprac.2022.08.002_bib1694","author":"Aviation Administration"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1696","first-page":"e112","article-title":"Anti-diabetic drug use and the risk of motor vehicle crash in the elderly","volume":"13","author":"Hemmelgarn","year":"2006","journal-title":"Can J Clin Pharmacol."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1697","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.22.2.220","article-title":"Diabetes and automobile crashes in the elderly. A population-based case-control study","volume":"22","author":"McGwin","year":"1999","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1698","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.1994.tb06526.x","article-title":"Medical conditions and motor\u00a0vehicle collision injuries in older adults","volume":"42","author":"Koepsell","year":"1994","journal-title":"J Am Geriatr Soc."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1699","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1463-1326.2012.01606.x","article-title":"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis","volume":"14","author":"Liu","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1700","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc20-0277","article-title":"An evaluation of the safety of pilots with insulin-treated diabetes in Europe flying commercial and noncommercial aircraft","volume":"43","author":"Garden","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1701","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dme.13515","article-title":"Could Freestyle Libre(\u2122) sensor glucose data support decisions for safe driving?","volume":"35","author":"Rayman","year":"2018","journal-title":"Diabetic Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1702","series-title":"Chapter 16 - digital health technologies, diabetes, and driving (meet your new backseat driver)","first-page":"219","author":"Drincic","year":"2020"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1703","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/ijcp.12832","article-title":"Diabetes and collision risk. A meta-analysis and meta-regression","volume":"70","author":"Hostiuc","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1704","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/dc16-0995","article-title":"Predicting and reducing driving mishaps among drivers with type 1 diabetes","volume":"40","author":"Cox","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1705","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40292-019-00324-6","article-title":"The effects of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Akbari","year":"2019","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1706","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12944-020-1198-x","article-title":"The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Akbari","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1707","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40199-019-00302-2","article-title":"Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"27","author":"Ardeshirlarijani","year":"2019","journal-title":"Daru."},{"issue":"51","key":"10.1016\/j.eprac.2022.08.002_bib1708","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009166","article-title":"Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTS","volume":"96","author":"He","year":"2017","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1709","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.medcli.2016.11.036","article-title":"Effects of probiotics supplement in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"148","author":"Hu","year":"2017","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.eprac.2022.08.002_bib1710","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.diabres.2016.06.014","article-title":"Probiotics for the management of\u00a0type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"118","author":"Samah","year":"2016","journal-title":"Diabetes Res Clin Pract."},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1711","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1017\/S0007114516000076","article-title":"Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: A meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sun","year":"2016","journal-title":"Br J Nutr."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1712","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1515\/jpem-2016-0230","article-title":"Multiple effects of probiotics on different types of diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"30","author":"Wang","year":"2017","journal-title":"J Pediatr Endocrinol Metab."},{"key":"10.1016\/j.eprac.2022.08.002_bib1713","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.12659\/MSM.902600","article-title":"Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: A meta-analysis of 12 randomized controlled trials","volume":"23","author":"Yao","year":"2017","journal-title":"Med Sci Monit."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1714","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.medici.2015.11.008","article-title":"Effect of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"52","author":"Zhang","year":"2016","journal-title":"Medicina (Kaunas)."},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1715","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3945\/ajcn.115.106989","article-title":"Psyllium fiber improves glycemic control proportional to loss of glycemic control: A meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus","volume":"102","author":"Gibb","year":"2015","journal-title":"Am J Clin Nutr."},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1716","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1753-0407.12621","article-title":"Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial","volume":"10","author":"Ranasinghe","year":"2018","journal-title":"J Diabetes."},{"key":"10.1016\/j.eprac.2022.08.002_bib1717","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","article-title":"Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial","volume":"111","author":"Bo","year":"2016","journal-title":"Pharmacol Res."},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1718","first-page":"Cd011919","article-title":"Resveratrol for adults with type 2 diabetes mellitus","volume":"1","author":"Jeyaraman","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.eprac.2022.08.002_bib1719","article-title":"The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis","author":"Abdelhaleem","year":"2021","journal-title":"Med Clin (Barc)."},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1720","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10654-018-0422-8","article-title":"Selenium exposure and the risk of type 2 diabetes: A systematic review and meta-analysis","volume":"33","author":"Vinceti","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1721","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000613","article-title":"Selenium supplementation and insulin resistance in a randomized, clinical trial","volume":"7","author":"Jacobs","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1722","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/nu11081894","article-title":"Effects of vitamin D supplementation on body composition and metabolic risk factors in men: A randomized controlled trial","volume":"11","author":"Lerchbaum","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1723","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/nu10030375","article-title":"The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2018","journal-title":"Nutrients"},{"issue":"Pt A","key":"10.1016\/j.eprac.2022.08.002_bib1724","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pnpbp.2018.02.007","article-title":"The effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial","volume":"84","author":"Raygan","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1725","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/cncr.26420","article-title":"The impact of type 2 diabetes mellitus on cancer-specific survival: A follow-up study in sweden","volume":"118","author":"Liu","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.eprac.2022.08.002_bib1726","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults","volume":"348","author":"Calle","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1727","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/dc12-0002","article-title":"Diabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults","volume":"35","author":"Campbell","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1728","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: A systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1729","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/bjc.2017.106","article-title":"Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: Meta-analysis of individual participant data of seven prospective cohorts in europe","volume":"116","author":"Freisling","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1730","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CEJ.0000000000000231","article-title":"Body mass index and the risk of cancer in women compared with men: A meta-analysis of prospective cohort studies","volume":"26","author":"Xue","year":"2017","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1731","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/s41598-021-81671-0","article-title":"Body mass index and cancer risk in patients with type 2 diabetes: A dose-response meta-analysis of cohort studies","volume":"11","author":"Soltani","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1732","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ijc.30824","article-title":"Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting","volume":"141","author":"Drake","year":"2017","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1733","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1055-9965.EPI-17-0495","article-title":"Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women","volume":"26","author":"Kabat","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1734","first-page":"607","article-title":"Body weight gain and risk of colorectal cancer: A systematic review and meta-analysis of observational studies","volume":"16","author":"Schlesinger","year":"2015","journal-title":"Obes\u00a0Rev"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1735","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaoncol.2015.0513","article-title":"Difference in association of obesity with prostate cancer risk between us african american and non-hispanic white men in the selenium and vitamin e cancer prevention trial (SELECT)","volume":"1","author":"Barrington","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1736","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128891","article-title":"Metabolic syndrome and breast cancer risk: A case-cohort study nested in a multicentre italian cohort","volume":"10","author":"Agnoli","year":"2015","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1737","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10552-015-0709-y","article-title":"Comparison of anthropometric measurements of adiposity in relation to cancer risk: A systematic review of prospective studies","volume":"27","author":"De Ridder","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1738","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10654-016-0169-z","article-title":"Overweight duration in older adults and cancer risk: A study of cohorts in europe and the united states","volume":"31","author":"Arnold","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1739","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","article-title":"Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the women's health initiative randomized clinical trials","volume":"1","author":"Neuhouser","year":"2015","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1740","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/annonc\/mdv142","article-title":"Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies","volume":"26","author":"Aune","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1741","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejca.2006.11.010","article-title":"Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis","volume":"43","author":"Olsen","year":"2007","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1742","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/ijc.29207","article-title":"Anthropometric factors and ovarian cancer risk: A systematic review and nonlinear dose-response meta-analysis of prospective studies","volume":"136","author":"Aune","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1743","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/2053369117709225","article-title":"Obesity and ovarian cancer risk: A systematic review","volume":"23","author":"Foong","year":"2017","journal-title":"Post reproductive health"},{"issue":"28","key":"10.1016\/j.eprac.2022.08.002_bib1744","doi-asserted-by":"crossref","first-page":"43669","DOI":"10.18632\/oncotarget.9664","article-title":"The association between BMI and gallbladder cancer risk: A meta-analysis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1745","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160474","article-title":"Abdominal obesity and gastroesophageal cancer risk: Systematic review and meta-analysis of prospective studies","volume":"37","author":"Du","year":"2017","journal-title":"Biosci Rep"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1746","doi-asserted-by":"crossref","first-page":"340.e341","DOI":"10.1016\/j.urolonc.2018.04.011","article-title":"Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial","volume":"36","author":"Gelfond","year":"2018","journal-title":"Urol Oncol"},{"issue":"44","key":"10.1016\/j.eprac.2022.08.002_bib1747","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012860","article-title":"The association between BMI and kidney cancer risk: An updated dose-response meta-analysis in accordance with PRISMA guideline","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1748","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/obr.12321","article-title":"Adiposity and risk of thyroid cancer: A systematic review and meta-analysis","volume":"16","author":"Schmid","year":"2015","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1749","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ijc.31100","article-title":"Body fatness at an early age and risk of colorectal cancer","volume":"142","author":"Hidayat","year":"2018","journal-title":"International journal of cancer"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119313","article-title":"Obesity and risk of bladder cancer: A dose-response meta-analysis of 15 cohort studies","volume":"10","author":"Sun","year":"2015","journal-title":"PloS One"},{"issue":"20","key":"10.1016\/j.eprac.2022.08.002_bib1751","doi-asserted-by":"crossref","first-page":"33990","DOI":"10.18632\/oncotarget.16722","article-title":"Association of body mass index with bladder cancer risk: A dose-response meta-analysis of prospective cohort studies","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1752","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/annonc\/mdv355","article-title":"Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies","volume":"26","author":"Genkinger","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1753","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18278-x","article-title":"Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1754","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.32109","article-title":"Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies","volume":"145","author":"Psaltopoulou","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1755","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-018-4543-y","article-title":"Body mass index and lung cancer risk in never smokers: A meta-analysis","volume":"18","author":"Zhu","year":"2018","journal-title":"BMC cancer"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1756","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3390\/nu8120810","article-title":"Abdominal obesity and lung cancer\u00a0risk: Systematic review and meta-analysis of prospective studies","volume":"8","author":"Hidayat","year":"2016","journal-title":"Nutrients"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib1757","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/djg009","article-title":"Body mass index and risk of prostate cancer in U.S. health professionals","volume":"95","author":"Giovannucci","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1758","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3892\/ol.2014.2841","article-title":"Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"issue":"9612","key":"10.1016\/j.eprac.2022.08.002_bib1759","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1760","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jnci\/djq526","article-title":"Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies","volume":"103","author":"Yang","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1761","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1762","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cphy.c170008","article-title":"Contribution of adipose tissue to development of cancer","volume":"8","author":"Cozzo","year":"2017","journal-title":"Compr Physiol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1763","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-016-3884-9","article-title":"Cancer incidence in persons with type 1 diabetes: A five-country study of 9,000 cancers in type 1 diabetic individuals","volume":"59","author":"Carstensen","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1764","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00125-019-04995-7","article-title":"Breast, cervical and colorectal cancer screening in adults with diabetes: A systematic review and meta-analysis","volume":"63","author":"Bhatia","year":"2020","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1765","first-page":"369","article-title":"The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin\u00a0Gastroenterol Hepatol"},{"issue":"46","key":"10.1016\/j.eprac.2022.08.002_bib1766","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008588","article-title":"Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1767","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","article-title":"Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies","volume":"92","author":"Huxley","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1768","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jss.2014.06.046","article-title":"High-risk population in sporadic pancreatic adenocarcinoma: Guidelines for screening","volume":"194","author":"Bruenderman","year":"2015","journal-title":"J Surg Res"},{"key":"10.1016\/j.eprac.2022.08.002_bib1769","doi-asserted-by":"crossref","DOI":"10.1038\/srep17591","article-title":"A\u00a0linear dose-response relationship between fasting plasma glucose and colorectal cancer risk: Systematic review and meta-analysis","volume":"5","author":"Shi","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1770","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12885-019-5748-4","article-title":"The effect of diabetes on the risk of endometrial cancer: An updated a systematic review and meta-analysis","volume":"19","author":"Saed","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1771","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/bjc.2012.414","article-title":"Diabetes and breast cancer risk: A meta-analysis","volume":"107","author":"Boyle","year":"2012","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1772","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00125-018-4664-5","article-title":"Sex differences in the association between diabetes and cancer: A systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events","volume":"61","author":"Ohkuma","year":"2018","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib1773","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.3748\/wjg.v21.i19.6026","article-title":"Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review","volume":"21","author":"Guraya","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1774","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","article-title":"A\u00a0meta-analysis of diabetes mellitus and the risk of prostate cancer","volume":"15","author":"Kasper","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1775","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41416-018-0055-4","article-title":"Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish randomized study of screening for prostate cancer","volume":"118","author":"Murtola","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1776","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41391-018-0123-0","article-title":"Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish randomized study of screening for prostate cancer","volume":"22","author":"Murtola","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1777","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/dmrr.2582","article-title":"Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: A meta-analysis of 11 cohort studies","volume":"31","author":"Cai","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1778","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4239\/wjd.v11.i6.227","article-title":"Diabetes and cancer: Epidemiological and biological links","volume":"11","author":"Wang","year":"2020","journal-title":"World Jo Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1779","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1186\/s12885-019-6279-8","article-title":"Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: Two randomised controlled feasibility trials","volume":"19","author":"Harvie","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1780","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/oby.22936","article-title":"Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: Analysis of the look ahead randomized clinical trial","volume":"28","author":"Yeh","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eprac.2022.08.002_bib1781","article-title":"Pharmacologic therapy of diabetes and overall cancer risk and mortality: A meta-analysis of 265 studies","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2022.08.002_bib1782","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res Rev"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1783","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ije\/dyx046","article-title":"Metformin and cancer in type 2 diabetes: A systematic review and comprehensive bias evaluation","volume":"46","author":"Farmer","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1784","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.18632\/oncotarget.13633","article-title":"Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis","volume":"8","author":"Hou","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1785","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/jgh.13639","article-title":"Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis","volume":"32","author":"Jung","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1786","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.18632\/oncotarget.13762","article-title":"Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eprac.2022.08.002_bib1787","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2016.05.027","article-title":"Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis","volume":"33","author":"Rokkas","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.eprac.2022.08.002_bib1788","article-title":"Metformin improves overall survival of colorectal cancer patients with diabetes: A meta-analysis","volume":"2017","author":"Meng","year":"2017","journal-title":"J\u00a0Diabetes Res"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1789","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002749","article-title":"Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: A meta-analysis","volume":"95","author":"He","year":"2016","journal-title":"Medicine"},{"issue":"16","key":"10.1016\/j.eprac.2022.08.002_bib1790","doi-asserted-by":"crossref","first-page":"26448","DOI":"10.18632\/oncotarget.14688","article-title":"Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1791","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1158\/1055-9965.EPI-17-0936","article-title":"Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: A grade-assessed systematic review and meta-analysis","volume":"27","author":"Tang","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1792","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ijgc-2018-000060","article-title":"Association of metformin use with ovarian cancer incidence and prognosis: A systematic review and meta-analysis","volume":"29","author":"Shi","year":"2019","journal-title":"Int Journal Gynecol Cancer"},{"key":"10.1016\/j.eprac.2022.08.002_bib1793","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2017.04.001","article-title":"Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus","volume":"101","author":"Perez-Lopez","year":"2017","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1794","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12885-018-4334-5","article-title":"Effect of metformin use on the risk and prognosis of endometrial cancer: A systematic review and meta-analysis","volume":"18","author":"Chu","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1795","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10552-015-0687-0","article-title":"Metformin and prostate cancer mortality: A meta-analysis","volume":"27","author":"Stopsack","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1796","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010035","article-title":"Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis","volume":"97","author":"Xin","year":"2018","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1797","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s11255-017-1548-4","article-title":"The impact of metformin use on survival in kidney cancer patients with diabetes: A meta-analysis","volume":"49","author":"Li","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"19","key":"10.1016\/j.eprac.2022.08.002_bib1798","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006888","article-title":"Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine"},{"issue":"37","key":"10.1016\/j.eprac.2022.08.002_bib1799","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021687","article-title":"Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis","volume":"99","author":"Shi","year":"2020","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1800","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1159\/000493214","article-title":"Survival benefit of metformin adjuvant treatment for pancreatic cancer patients: A systematic review and aeta-analysis","volume":"49","author":"Wan","year":"2018","journal-title":"Int J Exp Cell Physiol Biochem Pharmacol"},{"issue":"30","key":"10.1016\/j.eprac.2022.08.002_bib1801","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011596","article-title":"Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis","volume":"97","author":"Hu","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.eprac.2022.08.002_bib1802","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: Population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1803","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dom.13049","article-title":"Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes","volume":"20","author":"Garry","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1804","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/dom.12608","article-title":"Ten-year observational follow-up of proactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes","volume":"18","author":"Erdmann","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1805","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1806","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1807","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1808","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1810","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and c-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1811","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2337\/dc17-1956","article-title":"No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial","volume":"41","author":"Heged\u00fcs","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1812","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1813","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3004","article-title":"Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis","volume":"34","author":"Overbeek","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1817","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2022.08.002_bib1818","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1819","first-page":"482","article-title":"Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review","volume":"9","author":"Chen","year":"2017","journal-title":"J\u00a0Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2022.08.002_bib1820","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study","volume":"52","author":"Hemkens","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1821","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1822","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12672-012-0112-z","article-title":"Systematic review and meta-analysis of insulin therapy and risk of cancer","volume":"3","author":"Janghorbani","year":"2012","journal-title":"Hormones Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1824","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.23.1.95","article-title":"Use of influenza and pneumococcal vaccines in people with diabetes","volume":"23","author":"Smith","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1825","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00125-013-3158-8","article-title":"Working-age adults with diabetes experience greater susceptibility to seasonal influenza: A population-based cohort study","volume":"57","author":"Lau","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1826","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcrc.2013.08.019","article-title":"Diabetes mellitus and community-acquired bloodstream infections in the critically ill","volume":"29","author":"McKane","year":"2014","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.eprac.2022.08.002_bib1827","article-title":"Diabetes and hemoglobin a1c as risk factors for nosocomial infections in critically ill patients","volume":"2013","author":"Tsakiridou","year":"2013","journal-title":"Crit Care Res Pract"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1828","first-page":"534","article-title":"Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia","volume":"68","author":"Adamuz","year":"2014","journal-title":"J\u00a0Infection"},{"issue":"6","key":"10.1016\/j.eprac.2022.08.002_bib1829","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pcd.2016.05.005","article-title":"Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics","volume":"10","author":"Casanova","year":"2016","journal-title":"Primary Care Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1830","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/21645515.2018.1446719","article-title":"Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review","volume":"14","author":"Dos Santos","year":"2018","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.eprac.2022.08.002_bib1831","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12916-015-0295-6","article-title":"Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis","volume":"13","author":"Remschmidt","year":"2015","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1832","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/CVI.00288-15","article-title":"Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes","volume":"22","author":"Seo","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1833","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","article-title":"Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 influenza season","volume":"69","author":"Grohskopf","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1835","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: Updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.eprac.2022.08.002_bib1836","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/21645515.2016.1164362","article-title":"Prospective clinical trial of hepatitis b vaccination in adults with and without type-2 diabetes mellitus","volume":"12","author":"Van Der Meeren","year":"2016","journal-title":"Human Vaccines Immunother"},{"issue":"5","key":"10.1016\/j.eprac.2022.08.002_bib1837","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis b vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.eprac.2022.08.002_bib1838","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2014.12.060","article-title":"Immunogenicity and safety of an investigational hepatitis b vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis b vaccine in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1839","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2337\/dc20-2260","article-title":"HBsAg-19 severity is tripled in the diabetes community: A prospective analysis of the pandemic's impact in type 1 and type 2 diabetes","volume":"44","author":"Gregory","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1840","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1932296820924469","article-title":"Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the united states","volume":"14","author":"Bode","year":"2020","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.eprac.2022.08.002_bib1842","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656362","article-title":"How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: An expert opinion by IMIDS study group","volume":"12","author":"Ferretti","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1843","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: Updated recommendations of the Advisory Committee on Immunization Practices - United States, 2019","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1844","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000336","article-title":"The association between diabetes mellitus and incident infections: A systematic review and meta-analysis of observational studies","volume":"5","author":"Abu-Ashour","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.08.002_bib1845","first-page":"365","article-title":"Tetanus surveillance \u2014 United States, 2001-2008","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.eprac.2022.08.002_bib1846","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Reports"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1847","first-page":"CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"2019","author":"Gagliardi","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1848","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/21645515.2016.1232787","article-title":"Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged \u226550 years\u00a0when administered subcutaneously vs. intramuscularly","volume":"13","author":"Vink","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"29","key":"10.1016\/j.eprac.2022.08.002_bib1849","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550 years of age: A randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1850","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12879-019-3719-7","article-title":"Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: A prospective cohort study","volume":"19","author":"Ohfuji","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.eprac.2022.08.002_bib1851","first-page":"651","article-title":"Using the 4 pillars to increase vaccination among high-risk adults: Who benefits?","volume":"23","author":"Nowalk","year":"2017","journal-title":"Am J Manag Care"},{"issue":"46","key":"10.1016\/j.eprac.2022.08.002_bib1852","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","volume":"35","author":"Ofori-Anyinam","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.eprac.2022.08.002_bib1853","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jdiacomp.2018.11.003","volume":"33","author":"Hata","year":"2019","journal-title":"J\u00a0Diabetes Complicat"},{"issue":"4","key":"10.1016\/j.eprac.2022.08.002_bib1854","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2021.1903880","article-title":"Letter to the editor to: Verger P and Dub\u00e9 E. Restoring confidence in vaccines in the COVID-19 era, expert review of vaccines, 2020; 19(11):991-3","volume":"20","author":"Ridda","year":"2021","journal-title":"Exp Rev Vaccines"},{"issue":"1","key":"10.1016\/j.eprac.2022.08.002_bib1855","article-title":"Patient reminder and recall interventions to improve immunization rates","volume":"1","author":"Jacobson Vann","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"updated-by":[{"DOI":"10.1016\/j.eprac.2022.12.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000}}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:03:16Z","timestamp":1700902996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22005766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":1831,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1530891X22005766"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan\u20142022 Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}